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Ribonucleotide reductase catalyzes the rate-limiting step in de novo deoxyribonucleoside 
triphosphate (dNTPs) biosynthesis and is essential for providing balanced dNTP pools for 
nuclear and mitochondrial genome maintenance. RNR contains two components R1 and R2. R2 
generates free radicals that are transferred to R1 and used for catalysis. RNR is tightly regulated 
through several mechanisms, including the control of R2 expression levels. Broad 
overexpression of R2 in transgenic mice causes lung neoplasms through a mutagenic 
mechanism. Because R2 produces free radicals, I hypothesized that R2 deregulation results in 
mutagenic perturbations of cellular redox status which could contribute to R2-induced 
tumorigenesis. This dissertation aims to (A) elucidate the effect of RNR deregulation on redox 
homeostasis and dissect the molecular mechanism of RNR-induced mutagenesis and 
tumorigenesis, and (B) use RNR mice as a lung tumor model in imaging studies to assess lung 
tumor growth patterns. 
For the first aim, we generated cells that overexpress R2 and showed that this 
overexpression leads to increased reactive oxygen species (ROS) production. By generating a 
series of R2 mutants, we subsequently identified the source of R2-induced ROS production. In 
addition, some R2 mutants showed dominant negative effects by interfering with endogenous 
RNR, leading to mitochondrial DNA depletion and mitochondrial redox imbalance. These 
findings indicate the importance of RNR regulation in maintaining cellular ROS levels and 
suggest the possibility that R2-induced ROS may play a role in mutagenesis. 
 For the second aim, we adapted an automated algorithm for the measurement of 
pulmonary nodules on human chest CT scans and used it to measure mouse lung tumors. 
Euthanized mice were first imaged to optimize scan parameters and refine computational 
algorithms for tumor volume measurement. Lung tumor-bearing mice were then scanned 
sequentially for tumor growth rate determination. Findings from this study establish new 
automated algorithms to measure lung tumor volume in mice and confirm an exponential growth 
model for murine lung neoplasms.  
Together, these studies demonstrate the importance of RNR regulation in maintaining 
cellular redox homeostasis and genome integrity, and that RNR mice serve as an authentic model 
of human lung cancer in translational studies.  
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 1 
CHAPTER 1 Literature Review 
1.1 Importance of deoxyribonucleoside triphosphates (dNTPs) 
Accurate DNA replication and repair is essential for the maintenance and growth of an 
organism. There are many factors that coordinate together to ensure the fidelity of DNA 
replication and repair. Among these, one important factor is the production of balanced pools of 
the four deoxyribonucleoside triphosphates (dNTPs), which are building blocks of DNA. All 
eukaryotes have two genomes, the nuclear and the mitochondrial genomes, both of which need to 
maintain balanced dNTP pools for genomic integrity (Figure 1.1). The nuclear genome replicates 
during S phase and requires control of dNTP pool throughout the cell cycle, where the pool 
expands in S phase and is kept low outside of S phase. On the other hand, the mitochondrial 
genome replicates independent of the cell cycle and needs continuous supply of dNTPs. All these 
processes are tightly regulated in cells to fit the purpose of each genome replication (Mathews 
2006).  
Disturbances in dNTP pools can lead to genomic instability. Usually low dNTP levels 
can result in impaired DNA replication and repair while high dNTP levels can cause mutagenesis 
(Figure 1.1). Imbalance in dNTP pools has been linked to multiple human diseases such as 
cancer, mitochondrial and infectious diseases. dNTP accumulation can lead to  increased 
mutation rate during DNA replication, which can contribute to oncogenesis (Wheeler, Rajagopal 
et al. 2005). In addition, uncoordinated cell proliferation in cancer development can lead to 
insufficient nucleotides that cause replication stress and promote genomic instability (Bester, 
Roniger et al. 2011). Genetic mutations that lead to mitochondrial dNTP alterations can cause 
mitochondrial diseases characterized by severely depleted mitochondrial DNA (Bester, Roniger 
et al. 2011). Furthermore, during viral infection, reverse transcriptase lacks a proofreading  
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Figure 1.1 Importance of the four dNTPs in genome maintenance. A balanced dNTP pool is 
essential for both mitochondrial and nuclear genome integrity. Low dNTP levels can lead to 
growth defects and high dNTP levels are often mutagenic.  
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activity, and it has been shown that imbalance in dNTPs can lead to increased retroviral mutation 
rate, leading to viral variants that are drug resistant (Martinez, Vartanian et al. 1994; Vartanian, 
Meyerhans et al. 1994; Julias and Pathak 1998; Mathews 2006). Recently, it has been shown that 
SAMHD1, a host protein that restricts HIV infection in myeloid and resting T cells, is a dNTPase 
that removes the triphosphate from dNTPs, resulting in substrate depletion for viral DNA 
synthesis and blockage of HIV infection (Baldauf, Pan et al. 2012; Lahouassa, Daddacha et al. 
2012). All these examples emphasize the importance of dNTP balance in cells.  
1.1.1 dNTP biosynthesis pathways 
There are two biosynthetic pathways to synthesize dNTPs: the de novo pathway and the 
salvage pathway. In the de novo pathway, ribonucleoside diphosphates (NDPs, Figure1.2) are 
reduced to corresponding deoxyribonucleoside diphosphates (dNDPs, Figure1.2) by 
ribonucleotide reductase (RNR). Subsequently, the dNDPs are phosphorylated by nucleoside 
diphosphate kinases to produce deoxyribonucleoside triphosphates (dNTPs) for DNA replication 
and repair (Kunz and Kohalmi 1991). This is true for all dNTPs except dTTP. dTTP synthesis 
uses dUMP as precursor, which is converted to dTMP by dTMP synthase. dTMP is first 
phosphorylated by dTMP kinase and then nucleoside diphosphate kinase to generate dTTP 
(Kunz and Kohalmi 1991) (Figure 1.2). In the salvage pathway, deoxyribonucleosides 
(deoxyribose sugar + nitrogenous base, no phosphate group) are phosphorylated by 
deoxyribonucleoside kinases to generated corresponding dNTPs (Reichard 1988). Mammalian 
cells contain four principal salvage enzymes, namely deoxycytidine kinase (dCK), thymidine 
kinase 1 (TK1), thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) (Arner and 
Eriksson 1995). TK1 and dCK localize to the cytosol and are responsible for making dNTPs for  
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Figure 1.2 RNR and the de novo dNTP synthesis. As a single enzyme, RNR is involved in 
synthesizing all four dNTPs. It catalyzes the reduction of NDP to dNDP, where the 2’-OH is 
reduced to H. Figure modified from Hofer, Crona et al. 2012.  
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nuclear DNA synthesis. TK1 acts on deoxyuridine and thymidine to make dTTP while dCK 
primarily works on deoxycytidine, but also deoxyadenosine and deoxyguanosine to make dCTP, 
dATP and dGTP (Reichard 1988; Arner and Eriksson 1995). dGK and TK2 localize to the 
mitochondria and responsible for making dNTPs for mitochondrial DNA synthesis. dGK is. 
involved in making dATP and dGTP while TK2 is involved in making dCTP and dTTP (Arner 
and Eriksson 1995). 
1.1.2 dNTP imbalance and genomic instability 
dNTP pool sizes are precisely regulated in cells to maintain genome integrity. During S 
phase and DNA damage responses, dNTP levels are elevated to facilitate DNA replication and 
repair. In mammalian cells, the total cellular pool sizes are in the range of 10-100pmoles of each 
dNTP/million cells in S phase (Rampazzo, Miazzi et al. 2010). Outside of S phase and in non-
proliferating cells, dNTP levels are maintained at low levels (about 10-fold lower) for DNA 
repair and mitochondrial DNA (mtDNA) synthesis (Mathews 2006; Rampazzo, Miazzi et al. 
2010).  
Loss of normal control of dNTP regulating mechanisms can lead to imbalanced dNTP 
pools that can cause detrimental effects to cells. Depletion of dNTP pools by inhibition or 
mutation leads to DNA breaks, mutagenesis and cell death (Reichard 1988). On the other hand, 
elevated dNTP pools, including balanced expansion of all four dNTPs and unbalanced expansion 
of a subset of dNTPs, all contribute to increased mutagenesis (Wheeler, Rajagopal et al. 2005; 
Mathews 2006). Besides the effects on nuclear genome, dNTP alterations can also lead to 
accumulation of deletions and point mutations in mtDNA and severe mtDNA depletion 
(Mathews 2006).  
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In vitro DNA replication studies showed that imbalanced dNTP pools cause enhanced 
mutagenesis mainly by DNA misinsertion and the next-nucleotide effect (Reichard 1988; 
Wheeler, Rajagopal et al. 2005). DNA misinsertion can result from competition between dNTPs 
correctly and incorrectly paired with a template base and increased misincorporation of a 
nucleotide present in excess is often observed. Next-nucleotide effect refers to the observation 
that the 3’ to 5’ proofreading exonuclease activity of DNA polymerase is inhibited by 
accumulation of a particular dNTP. As a result, DNA chain extension from a mismatch site 
proceeds before the mismatched nucleotide can be removed (Petruska, Goodman et al. 1988; 
Perrino and Loeb 1989; Mendelman, Petruska et al. 1990). In addition, it has been shown in vitro 
that dNTP imbalances can stimulate frameshift mutations by correct base-pairing at a slipped 
structure or misalignment after incorporation of a mismatched nucleotide (Bebenek, Roberts et 
al. 1992).   
In vivo studies also provide evidence on the importance of dNTP pool regulation. dNTP 
pool bias caused by addition or depletion of deoxyribonucleosides resulted in increased mutation 
rates of cultured cells (Bradley and Sharkey 1978; Kaufman and Davidson 1979). Furthermore, 
constitutively high dNTP concentration in yeast arrests cell cycle progression in late G1 phase, 
affected activation of origins of replication and inhibits the DNA damage checkpoint (Chabes 
and Stillman 2007).    
1.2 Ribonucleotide Reductase 
Ribunocleotide Reductase (RNR) is involved in the rate-limiting step of the de novo 
biosynthesis of all four dNTPs. It catalyzes the substitution of the 2’ hydroxyl group of a 
ribonucleoside diphosphate (NDP) with hydrogen, resulting in a deoxyribonucleoside 
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diphosphate (dNDP). The catalytic mechanism of RNR requires protein radicals. It is an essential 
enzyme in DNA synthesis and therefore is indispensable for the survival of all living organisms.  
1.2.1 RNR enzyme 
1.2.1.1 RNR classification 
RNR can be grouped into three classes depending on their interaction with oxygen and 
the way they generate free radicals. Class I RNRs have two non-identical dimeric subunits (R1 
and R2). They require oxygen and Fe cofactor for the generation of a stable tyrosyl radical in the 
R2 subunit. Class II RNRs are isolated as monomers or dimers (R1). They don’t have an R2 
subunit for radical generation. Rather, they generate radicals directly on R1 by cleaving the 
cofactor adenosylcobalamin. Class II RNRs don’t require oxygen for their function. Class III 
RNRs contain dimeric R1 subunits and produce glycyl radicals on R1 when a radical SAM 
protein cleaves S-adenosylmethionine. Class III RNRs are anaerobic enzymes that are 
inactivated by oxygen. Nevertheless, in all three classes, the radical produced is channeled to a 
cysteine residue in the catalytic site of the R1 subunit and used for catalysis (Eklund, Uhlin et al. 
2001; Nordlund and Reichard 2006; Logan 2011). 
1.2.1.2 Overall structure of RNR 
Eukaryotes, E. coli and DNA viruses have Class I RNR.  Class I RNR enzymes have 
long been believed to have the structure α2β2. However, recent studies proposed that an α6β2 
complex may be more physiologically relevant (Rofougaran, Vodnala et al. 2006; Fairman, 
Wijerathna et al. 2011). The α2 dimer, called protein R1, has the catalytic size and allosteric 
regulation sites. The β2 dimer, called protein R2, harbors di-nuclear iron center that produces a 
stable tyrosyl radical, which is essential for RNR enzymatic activity (Figure 1.3).  
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Figure 1.3 Class Ia RNR crystal structures and important sites. (A) Human R1 structure with 
the activity site (A site, purple, ATP bound), catalytic site (C site, orange, GDP bound) and 
specificity site (S site, green, TTP bound) shown. Figure from Fairman, Wijerathna et al. 2011. 
(B) Mouse R2 structure with iron atoms shown as dark sphere and the radical harboring tyrosine 
shown in ball and stick representation. Figure modified from Eklund, Uhlin et al. 2001. (C) 
Model of E. coli RNR holoenzyme with R1 dimer positioned on top of the R2 dimer. Figure 
modified from Eklund, Uhlin et al. 2001. (D) Schematic representation of mouse RNR.  
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Most of the structure and function studies on Class I RNRs have been performed on the 
E. coli enzyme. The crystal structures of the R1 and R2 subunits of E. coli have been determined  
separately (Nordlund, Sjoberg et al. 1990; Uhlin and Eklund 1994). In E. coli, the R1 protein 
dimer has a relative molecular weight of 171Kd (2 x 761 residues). The R1 subunit can be 
divided into two large domains: the N-terminal domain (~220 residues) and the α/β barrel 
domain (~480 residues). The catalytic site is located in the center of a deep cleft across the 
subunit between the N-terminal and barrel domains. Dimerization of R1 are formed by two 
helices of the α/β barrel from each subunit. The R1 dimer structure is not very stable and both 
subunits and domains can move with respect to each other, which may form a structural basis for 
allosteric regulation and catalysis in the subunit (Uhlin and Eklund 1994). 
The R2 protein dimer has a relative molecular weight of 87K (2 x 375 residues) in E. 
coli. It is heart shaped and mainly composed of helices (70%). The dinuclear iron center and the 
tyrosyl radical site are located in the interior of the protein. The R2 dimer is formed mainly by 
homologous interactions between the helices of each subunit (Nordlund, Sjoberg et al. 1990). C 
terminus of R2 is important in mediating interactions with R1. Truncated forms of R2 without 
the last 7 or 30 C-terminal residues cannot bind R1 (Climent, Sjoberg et al. 1992; (Lycksell, 
Ingemarson et al. 1994).  
The only crystal structure of the R1-R2 holoenzyme complex available is from the 
bacteria Salmonella typhimurium (Uppsten, Farnegardh et al. 2006). Instead modeling has been 
used to generate E. coli R1-R2 complexes based on separate structures of the two subunits. R1 
dimers are suggested to sit on top of the heart-shaped R2 dimers since the shape of R1 is 
complementary to this part of the R2 (Uhlin and Eklund 1994). Due to the importance of the R2 
 10 
C terminus in binding to R1, crystal structures of R1 with the carboxyl end of R2 is also solved. 
R2 C terminal peptide is shown to bind in a hydrophobic cleft of R1 (Uhlin and Eklund 1994).  
Mammalian R1 and R2 dimer structures are very similar to those of E. coli (Kauppi, Nielsen et 
al. 1996; Fairman, Wijerathna et al. 2011). As mentioned before, in recent years, it is suggested 
that eukaryotic R1 forms a hexamer upon dATP or ATP binding and an α6β2 holoenzyme is the 
functional unit of RNR (Rofougaran, Vodnala et al. 2006; Fairman, Wijerathna et al. 2011).   
1.2.1.3 RNR catalytic mechanism 
Reduction of NDP to dNDP takes place in the catalytic site of R1 with the involvement of 
cysteine residues. In the first step of the catalytic cycle, a thiyl radical (C439) is generated by a 
long-range radical transfer from the tyrosyl radical in R2 (Figure 1.4A; also see 1.2.1.4 for 
details). This thiyl radical (C439) removes the 3’-H from the ribose ring of the substrate and 
generates a substrate radical. The substrate radical makes the 2’-OH on the ribose ring less 
stable, which is protonated by C225 and leaves as H2O. The resulting radical on the 2’ position 
of the ribose ring is reduced by two cysteine residues, C225 and C462. The excess radical is then 
transferred to the 3’ position of the ribose ring and extracts a hydrogen from C439, generating 
dNDP and a thiyl radical on C439 (Kolberg, Strand et al. 2004). For a complete turnover, the 
disulfide bond between C225 and C462 in the active site needs to be reduced. NADPH 
ultimately provides the reducing power of the catalytic reaction (Kolberg, Strand et al. 2004).  
1.2.1.4 RNR iron center and tyrosyl radical formation 
Crystal structures of R2 dimer show that each subunit contains an equivalent iron center. 
The iron atoms are coordinated by 6 charged residues from four helices (two histidines, three 
glutamic acids and one aspartic acid) (Nordlund, Sjoberg et al. 1990). However, little is known 
about the incorporation of iron into the R2 subunit, as well as the oxygen activation of the  
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Figure 1.4 RNR catalytic site and di-nuclear iron center chemistry. (A) RNR catalytic 
mechanism at the catalytic site in R1. Figure from Eklund, Uhlin et al. 2001. (B) RNR di-nuclear 
iron center oxidation and tyrosyl free radical production in R2. Two important intermediates P 
and X are shown. Figure modified from Mitic, Clay et al. 2007. (Amino acid numbers are based 
on E. coli RNR protein and mammalian RNR acts the same way; the equivalent of Y122 in 
mouse is Y177).  
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dinuclear iron center in vivo. Reconstitution reaction with purified E. coli R2 provided some 
insights into the possible mechanisms. Formation of active R2 starts with the reduced form of R2 
where it is bound to two ferrous ions (Fe2+). The reduced form of R2 can initially be formed 
when two ferrous ions bind to the apo protein or when the active form of R2 is reduced. In the 
first step of active R2 formation, the ferrous ions are oxidized by molecular oxygen to yield an 
azide complex. The reaction then goes through a peroxide intermediate P and a µ-oxo/µ-hydroxo 
[FeIII(µ-O)(µ-OH)FeIV] intermediate X. Finally, intermediate X oxidizes a nearby tyrosine 
residue (Y122 in E. coli and Y177 in mouse) to a stable tyrosyl radical by extracting a hydrogen 
atom from the phenol oxygen (Figure 1.4B)(Mitic, Clay et al. 2007). The diferrous iron site is 
oxidized to the diferric form (Fe3+), providing electrons to reduce oxygen to H2O (Eklund, Uhlin 
et al. 2001; Kolberg, Strand et al. 2004).  
1.2.1.5 Mouse R2 iron/radical site 
Although E. coli R2 serves as a good model in many ways for RNR in higher organisms, 
a number of significant differences have been observed between E. coli and mouse R2s. One 
striking difference is the stability of the iron center. E. coli iron center and tyrosyl radicals are 
stable at physiological conditions and can perform multiple turnovers of the substrate in vitro. 
However, the iron center in mouse R2 is labile and a continuous supply of Fe2+ and oxygen is 
needed to keep the enzyme fully active (Kolberg, Strand et al. 2004; Strand, Karlsen et al. 2004). 
Another striking difference is the accessibility of the iron/radical center. Crystal structure 
comparison shows that the iron/radical site in mouse R2 is accessible to solvent via a narrow 
hydrophobic channel, while this channel is blocked by an aromatic amino acid (Y209) in E. coli. 
The more open structure around the iron/radical site in mouse R2 explains the higher sensitivity 
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of this protein towards radical scavengers and inhibitors (Kauppi, Nielsen et al. 1996; Eklund, 
Uhlin et al. 2001; Kolberg, Strand et al. 2004).  
In order to study whether another amino acid may take over the role and enzymatic 
function of the important tyrosine 177 residue, a series of mouse R2-Y177X mutants have been 
generated by site-directed mutagenesis, with X representing tryptophan (W), phenylalanine (F), 
cysteine (C), or histidine (H). R2-Y177W mutant can generate a transient tryptophan radical at 
the desired position, but does not have catalytic activity. On the other hand, R2-Y177F, R2-
Y177C and R2-Y177H mutants can neither generate a radical at the desired site, nor have 
catalytic activity (Potsch, Lendzian et al. 1999). This suggests strongly that the tyrosyl radical 
177 is essential and cannot be replaced by other amino acids.  
1.2.1.6 Tyrosyl radical transfer 
One striking feature of Class I RNR is its long radical transfer chain. This radical transfer 
chain connects the essential tyrosyl radical in R2 to the active site thiyl radical in R1. It is 
proposed that the radical gets to the active site through a coupled electron/proton transfer along a 
conserved hydrogen-bonded chain, which is about 15 angstrom long (Rova, Adrait et al. 1999). 
In mouse RNR, the conserved residues His173, Asp266, Trp103 in the R2 subunit and Tyr738, 
Tyr737, Cys429 in the R1 subunit contribute to the formation of this radical transfer pathway 
(Rova, Adrait et al. 1999). It has been shown that the tyrosine residue 370 (Y370) in the mouse 
R2 subunit connects the radical transfer pathway in R2 with the radical transfer pathway in R1. 
Mutating this tyrosine to phenylalanine (Y370F) renders the RNR enzyme completely inactive 
(Rova, Adrait et al. 1999).  
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1.2.2 RNR gene 
1.2.2.1 Mouse RNR gene 
In eukaryotes, the genes for R1 and R2 are located on separate chromosomes. In mouse, 
the large subunit R1 is encoded by the gene Rrm1, which consists of 19 exons and spans 26kb on 
chromosome 7. The small subunit R2 is encoded by either the Rrm2 gene or the p53R2 gene. The 
Rrm2 gene consists of 10 exons and spans 5.9kb on chromosome 12 while the p53R2 gene 
consists of 9 exons and spans 37kb on chromosome 15 (Johansson, Hjortsberg et al. 1998; 
Jordan and Reichard 1998; Tanaka, Arakawa et al. 2000). An enzyme complex of Rrm1 and 
Rrm2 provides dNTPs for S phase DNA replication and repair in proliferating cells while the 
Rrm1 and p53R2 complex provides dNTPs for DNA repair in quiescent cells and for 
mitochondrial DNA replication and repair (Guittet, Hakansson et al. 2001; Pontarin, Ferraro et 
al. 2007; Pontarin, Ferraro et al. 2012). The p53R2 gene was originally identified as a p53-
inducible gene following DNA damage (Tanaka, Arakawa et al. 2000). At the protein level, 
mouse p53R2 is 81% identical to mouse Rrm2. Most of the important domains in Rrm2 are 
conserved in p53R2, including the iron center, the tyrosine radical site and the radical transfer 
pathway. The major structure difference between Rrm2 and p53R2 is that p53R2 lacks 33 
amino-terminal residues including a KEN box that is required for degradation of Rrm2 during 
mitosis (Nordlund and Reichard 2006). In terms of enzyme activity, it has been shown that 
mouse p53R2 was about 43% of the specific activity of the mouse Rrm2 when assayed in vitro 
with an excess of mouse Rrm1 protein (Guittet, Hakansson et al. 2001). Human p53R2 is shown 
to have about 40-70% kinetic activity of that of human Rrm2 in vitro (Shao, Zhou et al. 2004; 
Qiu, Zhou et al. 2006).  
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1.2.2.2 Yeast RNR gene 
In budding yeast, two genes, RNR1 and RNR3, encode separate versions of the R1 
subunit, Rnr1 and Rnr3, respectively. Two genes, RNR2 and RNR4, encode two R2-like proteins, 
Rnr2 and Rnr4, respectively (Nordlund and Reichard 2006). RNR1 and RNR3 shard 80% amino 
acid sequence identity and both proteins contain the essential catalytic and allosteric regulation 
sites. The different roles of Rnr1 and Rnr3 are still not very clear. It is believed that all dimeric 
combinations of the two subunits, Rnr1/Rnr1, Rnr1/Rnr3, and Rnr3/Rnr3 exist. Expression of 
Rnr1 is essential for cell growth while Rnr3 is not. Under normal conditions, the expression level 
of Rnr3 is very low; however, Rnr3 expression level is largely induced upon DNA damage 
(Kolberg, Strand et al. 2004). Rnr2 and Rnr4 form a heterodimer to provide a functional RNR 
with the large subunit. They only share 47% amino acid sequence identity. Rnr4 lacks essential 
residues that are involved in iron binding and is therefore not enzymatically active. Rnr4 is 
demonstrated to have a structural function, where it stabilized the Rnr2 subunit and facilitates 
iron assembly in Rnr2 (Kolberg, Strand et al. 2004; Nordlund and Reichard 2006; Zhang, Liu et 
al. 2011).  
1.2.3 RNR regulation 
The regulation of RNR is complex and multi-faceted, because imbalances in dNTP pools 
are mutagenic and can interfere with many other aspects of metabolism. There are several 
important regulatory mechanisms of RNR in cells: allosteric regulation, cell cycle regulation, 
subcellular localization regulation, small inhibitory protein regulation and iron availability 
regulation.  
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1.2.3.1 Allosteric regulation of RNR 
Allosteric regulation of RNR allows the enzyme to provide a balanced supply of all four 
dNTPs and to adapt rapidly to changes in the requirements for dNTPs. Allosteric regulation of 
RNR involves the binding of effectors to two separate sites in the R1 subunit: the specificity site 
that regulates substrate specificity and the activity site that regulates the general activity of RNR 
(Nordlund and Reichard 2006).  
The specificity for each of the four substrates is determined by the binding of an 
allosteric effector to the specificity site: binding of dATP (or ATP) at the specificity site 
promotes the binding and reduction of the pyrimidines CDP and UDP; binding of dTTP inhibits 
reduction of CDP and UDP and stimulates reduction of GDP; binding of dGTP inhibits reduction 
of GDP and stimulates reduction of ADP. Binding of dCTP has no or only a minor effect 
(Kolberg, Strand et al. 2004). Recently, a collection of yeast strains expressing several single 
amino acid mutants of the specificity site was generated. These mutants showed imbalanced 
dNTP pools and increased mutation rates. Depletion of one or a few dNTPs activated the S phase 
checkpoint; however, when none of the dNTPs was limiting for DNA replication, even extreme 
and mutagenic dNTP pool imbalances did not activate the S phase checkpoint (Kumar, Viberg et 
al. 2010).  
The overall activity of RNR is controlled by the binding of dATP or ATP to the activity 
site: ATP binding activates RNR activity while dATP binding inhibits enzyme activity. As a 
result, dATP has both a stimulatory effect and an inhibitory effect. However, since dATP has a 
much higher affinity to the specificity site, the inhibitory effect of dATP is only significant at 
high concentrations of dATP (Kolberg, Strand et al. 2004). It has been reported that mutating the 
Aspartic acid (D) to asparagine (N) in the activity site, the so-called D57N mutation, resulted in 
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an RNR enzyme that does not respond to dATP-mediated inhibition. Mammalian lymphoma 
cells expressing this mutant RNR had around 3- to 10- fold increase in dNTP pools and about 
40-fold increase in mutation rate (Weinberg, Ullman et al. 1981; Caras and Martin 1988). When 
this mutant was expressed in yeast, it resulted in a 1.6-2 fold increase in dNTP pools under 
normal growth conditions and an 11- to 17-fold increase in dNTP pools during DNA damage. 
This disruption in dNTP pools also led to a 2- to 3-fold increase in mutation rates (Chabes, 
Georgieva et al. 2003).  
Previous studies have suggested that at physiologically nucleotide concentrations, both 
active and inactive RNR complexes consists of an R1 hexamer and an R2 dimer (R16-R22) 
(Rofougaran, Vodnala et al. 2006). Recently, crystal structures of the yeast enzyme with the 
dATP-induced R1 hexamer has been solved. Site-directed mutagenesis and functional assays 
showed that hexamerization of R1 is a prerequisite for inhibition by dATP, indicating that dATP-
induced R1 oligomerization acts as a mechanism for regulating RNR activity (Fairman, 
Wijerathna et al. 2011). The same study also showed that ATP binding induces R1 
hexamerization and activates RNR activity, suggesting a possible functional R16-R22 oligomer at 
physiologically conditions (Fairman, Wijerathna et al. 2011). Since both ATP and dATP can 
induce R1 hexamer formation, it is still not clear how dATP acts as an inhibitor while ATP is an 
activator. This maybe because that ATP and dATP hexamers have different packing 
arrangements and the conformational changes accompanying dATP hexamerization may lead to 
the disruption of free-radical transfer to the active site (Fairman, Wijerathna et al. 2011). 
1.2.3.2 Cell cycle regulation of RNR 
In mammals, RNR activity is highly induced during S phase. R1 and R2 are regulated 
differently. R1 gene expression during the cell cycle is mainly regulated at the transcriptional 
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level, with the transcription of Rrm1 negligible in G0/G1 phase and reaches maximum in S phase. 
The TATA-less promoter of Rrm1 is recognized by cell cycle specific transcription factors 
(Johansson, Hjortsberg et al. 1998). However, even if R1 mRNA level fluctuates during the cell 
cycle, R1 protein shows a constant level throughout the cell cycle due to its long half life (about 
15 hours) (Engstrom, Eriksson et al. 1985).  
R2 is regulated both transcriptionally and by protein degradation. R2 promoter contains a 
TATA-box, an upstream activating region and a proximal repressive element that binds E2F4. 
Similar to R1 regulation, the transcription of Rrm2 is undetectable in G0/G1 phase and peaks in S 
phase (Chabes, Bjorklund et al. 2004). In contrast to R1 protein, R2 protein correlates with its 
mRNA level well and has a short half-life of 3 hours (Engstrom, Eriksson et al. 1985). Therefore, 
R2 level is the rate limiting factor for RNR enzyme activity.  
After synthesizing dNTPs for S phase DNA replication and repair, R2 protein is degraded 
through two ubiquitin ligases that have central roles in cell cycle regulation: the Skip1/Cullin/F-
box (SCF) complex and the anaphase-promoting complex (APC) (Chabes, Pfleger et al. 2003; 
D'Angiolella, Donato et al. 2012). During G2 phase, R2 protein is recognized by cyclin F, an 
SCF ubiquitin ligase F-box protein and targeted for degradation. This is achieved by CDK-
mediated phosphorylation of R2 on Thr33, which exposes an Rxl motif to cyclin F. After DNA 
damage, cyclin F is down-regulated in an ATR-dependent manner to allow accumulation of R2 
(D'Angiolella, Donato et al. 2012). During mitosis/G1 phase, R2 is degraded by the Cdh1-APC 
complex that recognizes a KEN box motif at the N-terminus of R2. Mutating the KEN box motif 
stabilized R2 during mitosis/G1 in R2-overexpressing cells (Chabes, Pfleger et al. 2003).  
p53R2, the p53 inducible small subunit of RNR, on the other hand, is not cell cycle 
regulated. It has basal level expression through out the cell cycle and lacks the N-terminal KEN 
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box required for degradation during mitosis. After DNA damage, p53R2 is induced in a p53-
dependent manner. It can substitute for R2 and form an active RNR, providing dNTPs for DNA 
repair (Tanaka, Arakawa et al. 2000; Guittet, Hakansson et al. 2001; Nordlund and Reichard 
2006).   
1.2.3.3 Subcellular localization regulation of RNR 
RNR subcellular localization is an additional layer of control. In yeast, it is well 
established that Rnr1 and Rnr3 localize to the cytoplasm while Rnr2 and Rnr4 are in the nucleus. 
In response to S-phase or DNA damage, Rnr2-Rnr4 complex enters the cytoplasm to bind to 
Rnr1, forming an active complex. Rnr2 and Rnr4 are anchored in the nucleus by a protein Wtm1. 
After DNA damage and under replication stress, Wtm1 dissociates from Rnr2 and Rnr4, 
releasing the subunits to the cytoplasm (Lee and Elledge 2006; Zhang, An et al. 2006). The 
cytoplasmic Rnr2 and Rnr4 are actively imported to the nucleus by a protein Dif1, which binds 
directly to the Rnr2-Rnr4 complex. Dif1 is both cell cycle and DNA damage regulated (Lee, 
Wang et al. 2008; Wu and Huang 2008). Therefore, the nuclear localization of Rnr2 and Rnr4 is 
achieved by a dynamic balance of Wtm1-mediated nuclear retention and Dif1-mediated nuclear 
import.   
In mammal, the localization of RNR subunits is still controversial. It is largely believed 
that Rrm1 and Rrm2 localize to the cytoplasm during S phase and synthesized dNTPs are 
diffused to the nucleus for DNA replication (Engstrom and Rozell 1988; Pontarin, Fijolek et al. 
2008). p53R2 was reported to translocate to the nucleus upon DNA damage to facilitate dNTP 
synthesis at the site of DNA damage (Nakano, Balint et al. 2000; Tanaka, Arakawa et al. 2000). 
However, a study from a few years ago showed that R1, R2 and p53R2 all localize to the 
cytoplasm during cell proliferation and after DNA damage (Pontarin, Fijolek et al. 2008). In 
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recent years, there is increasing evidence showing that R1 and R2 accumulate at the DNA 
damage site in the nucleus. This accumulation is dependent on the interaction between R1 and 
the DNA damage response protein Tip60 (Niida, Katsuno et al. 2010; Hu, Yeh et al. 2012). In 
addition, R2 has been reported to enter the nucleus in G2 phase to interact with cyclin F and get 
degraded (D'Angiolella, Donato et al. 2012).   
1.2.3.4 Small inhibitory protein regulation of RNR 
In yeast, RNR activity is also regulated by the binding of small inhibitory proteins. In S. 
cerevisiae, Sml1, a 104-amino-acid protein, binds to the C terminus of Rnr1 and inhibits its 
activity (Zhao, Muller et al. 1998; Zhao, Georgieva et al. 2000). Sml1 is regulated by the cell 
cycle checkpoint proteins Mec1 (homolog of ATM), Rad53 (homolog of CHK2) and Dun1. 
During S phase and after DNA damage, Mec1 and Rad53 activate Dun1, which directly 
phosphorylate Sml1, leading to its degradation. At the same time, Dun1 activates the 
transcriptional induction of RNR genes. The dual function of Dun1 ensures synthesis of 
sufficient amounts of dNTPs for DNA replication and repair (Zhao and Rothstein 2002). In S. 
pombe, Spd1 binds to Cdc22p (R1 subunit in S. Pombe) and inhibits RNR activity (Hakansson, 
Dahl et al. 2006). So far, no Sml1 homolog or any kind of inhibitory protein of RNR has been 
identified in mammals.  
1.2.3.5 Iron availability regulation of RNR 
Iron is an essential cofactor in the class Ia RNRs. A recent study looked at the 
mechanisms that control RNR function upon Fe deficiency. The authors showed that in budding 
yeast, during Fe starvation, the R2 subunit is redistributed from the nucleus to the cytoplasm in a 
manner that is independent of the checkpoint kinases Mec1 and Rad53. Instead, the iron-
regulated Cth1/Cth2 mRNA-binding proteins specifically interact with and degrade the mRNA 
 22 
of an R2 nuclear-anchor protein Wtm1. The decrease in Wtm1 protein levels results in the 
redistribution of R2 subunit to the cytoplasm, where it assembles with R1 to form active 
complexes. In addition, Cth1/Cth2 induce downregulation of R2 mRNA levels, leading to a 
multilayered control of RNR that optimized RNR function to allow DNA synthesis and repair 
when iron is limited (Sanvisens, Bano et al. 2011).  
1.2.4 RNR and DNA damage response 
1.2.4.1 RNR and DNA damage response in yeast 
All organisms respond to DNA damage in two ways: by cell cycle arrest and by induction 
of DNA damage repair genes. In yeast, the most abundant DNA damage-inducible genes are 
those involved in DNA replication, including genes coding for DNA polymerases and subunits 
of RNR. When DNA synthesis is blocked by agents such as hydroxyurea (HU), or when DNA is 
damaged by agents such as UV light, transcription of yeast RNR genes, RNR1, RNR2 and RNR3 
are induced. RNR1 mRNA level shows ~5 fold increase, RNR2 mRNA shows ~25 fold increase 
and RNR3 mRNA is increased about 500 fold (Elledge, Zhou et al. 1993). Later it has been 
demonstrated that activation of yeast RNR genes in response to DNA damage is through the 
canonical Mec1/Rad53 DNA damage response pathway, where a downstream kinase Dun1 is 
activated. Activation of Dun1 has three roles in promoting RNR activity: by activating 
transcription of RNR genes, by phosphorylating and degrading the RNR inhibitory protein Sml1 
and by facilitating cytosolic localization of RNR (Elledge, Zhou et al. 1993; Zhao and Rothstein 
2002; Lee and Elledge 2006; Zhang, An et al. 2006). The end result of increased RNR activity is 
a 6 to 8 fold increase in dNTP levels, which improves organismal survival after DNA damage. In 
recent years, there is increasing evidence showing that in E. coli and yeast, increased dNTP 
levels after DNA damage allow more efficient translesion synthesis to bypass certain DNA 
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lesions (Sabouri, Viberg et al. 2008; Gon, Napolitano et al. 2011). It is worth noting that this 
increase in dNTP pool also leads to higher mutation rates, which may result from reduced 
fidelity of replicative polymerases and/or activation of error-prone translesion DNA synthesis at 
elevated dNTP levels (Chabes, Georgieva et al. 2003; Lis, O'Neill et al. 2008; Gon, Napolitano 
et al. 2011). In addition, it has been proposed that the same mechanisms also result in reduced 
recombinogenic lesions in yeast strains with increased dNTP levels (Fasullo, Tsaponina et al. 
2010).  
1.2.4.2 RNR and DNA damage response in mammals 
Similar as in yeast, DNA damage in mammals activates the canonical ATM/ATR DNA 
damage response pathway. Activation of ATM and ATR has two outcomes: recruitment of DNA 
damage repair proteins including 53BP1 and Brca1 to the site of DNA damage and activation of 
downstream CHK2/p53 and CHK1 kinases to halt the cell cycle progression. It has long been 
shown that DNA damage activates mammalian RRM1 and RRM2. Upon treatment of DNA 
damaging agents such as chlorambucil, RRM1 mRNA level is induced 9 fold while RRM2 
mRNA level is induced 13 fold (Hurta and Wright 1992). In addition, upon UV damage, RRM1 
promoter is induced up to 3 fold and RRM2 promoter is induced up to 10 fold (Filatov, 
Bjorklund et al. 1996). It has also been demonstrated that there is S phase/DNA damage-specific 
stabilization of the R2 protein (Chabes and Thelander 2000).  
Recently, it has been shown that RNR activity after DNA damage affects repair pathway 
choice both in yeast and mammals (Burkhalter, Roberts et al. 2009; Moss, Tinline-Purvis et al. 
2010). It is demonstrated that upon ionizing radiation, inhibition of RNR activity in mammalian 
cells favors non-homologous end joining (NHEJ) while promotion of RNR activity favors 
homologous recombination (HR) (Burkhalter, Roberts et al. 2009). This is because HR requires 
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more than 10,000 dNTPs in order to synthesize DNA strand during the pair process (Robert, 
Vanoli et al. 2011).  
The discovery of p53R2, a p53-induced R2 subunit, makes direct connection between 
DNA damage response and RNR activity, and solves the mystery of DNA damage repair in 
quiescent cells where the level of Rrm2 is not detectable. In mammals, upon DNA damage, 
ATM/ATR is activated, which then activates its downstream factor p53. p53 binds directly to the 
first intron of the p53R2 gene, activates p53R2 transcription and expression (Nakano, Balint et 
al. 2000; Tanaka, Arakawa et al. 2000). p53R2 protein interacts with Rrm1 and forms an active 
RNR complex to provide dNTPs for DNA damage repair (Guittet, Hakansson et al. 2001; 
Hakansson, Hofer et al. 2006). Recently, it has also been demonstrated that ATM can directly 
phosphorylate p53R2 in response to genotoxic stress. This phosphorylation leads to stabilization 
of p53R2 protein against hyperubiquitination and degradation by the ubiquitin ligase MDM2 and 
confers resistance to DNA damage (Chang, Zhou et al. 2008). Inhibition of endogenous p53R2 
expression in cells that have intact p53-dependent DNA damage checkpoint reduced RNR 
activity, DNA repair and cell survival after exposure to various genotoxins (Tanaka, Arakawa et 
al. 2000). Furthermore, cancer cell lines that have p53R2 mutation, which resulted in loss of 
RNR activity, showed enhanced DNA damage-induced apoptosis (Yamaguchi, Matsuda et al. 
2001). p53R2 knout-out mice die by the age of 14 weeks due to severe renal failure. Kidneys 
from p53R2 null mice showed increased number of apoptotic cells and higher rates of 
spontaneous mutation. p53R2 null MEFs had severely attenuated dNTP pools under oxidative 
stress (Kimura, Takeda et al. 2003). When the role of p53R2 in mitochondrial DNA synthesis 
was detected later (see section 1.2.5), measurement of mitochondrial DNA content in tissues 
(muscle, kidney and liver) from p53R2 null mice revealed severe mitochondrial DNA depletion 
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(Bourdon, Minai et al. 2007). All of these results suggest that p53R2 has a pivotal role in 
maintaining dNTP levels for repair of DNA damage. 
Unlike in yeast, even if there is increased RNR activity after DNA damage in mammals, 
it is still not clear what effects DNA damage has on dNTP pools in mammals (Kunz and 
Kohalmi 1991). A recent report showed that in non-proliferating cells, there is a slow, 4-fold 
increase in p53R2 protein expression after DNA damage, which results in a less than 2-fold 
increase in dNTP pools. This 2-fold increased dNTP pool is only about 5% of the size of the 
pools in S-phase cells. Moreover, logarithmically growing mammalian cells do not show any 
major increase in their dNTP pools when p53R2 is activated upon DNA damage (Hakansson, 
Hofer et al. 2006). This may be due to the possibility that RNR activity and dNTP pools are more 
strictly regulated in mammals and some undiscovered mechanisms might act on dNTP pools 
after DNA damage. In addition, in mammals dNTP biosynthesis may also be compartmentalized 
close to the damage sites during the DNA damage response (Niida, Katsuno et al. 2010) and 
measurement of total cellular dNTP changes may not be sensitive enough to reflect the local 
changes. 
1.2.5 RNR and mitochondrial DNA synthesis 
Mitochondrial DNA (mtDNA) synthesis is not cell cycle regulated. In proliferating cell, 
there is no difficulty obtaining dNTPs for mitochondrial DNA synthesis since levels of dNTPs 
are about 20 times higher in S-phase cells than in resting cells (Hakansson, Hofer et al. 2006). 
dNTPs can be actively transported from the cytoplasm into mitochondria in these growing cells 
(Mathews and Song 2007). In resting cells, dNTPs for mitochondrial DNA synthesis can come 
from salvage of deoxyribonucleosides by the salvage pathway enzymes dGK and TK2 that 
localize in the mitochondria (Mandel, Szargel et al. 2001; Saada, Shaag et al. 2001). Recently, it 
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has been demonstrated that beside the salvage pathway, p53R2-catalyzed ribonucleotide 
reduction is required for proper mitochondrial DNA synthesis and DNA repair in resting cells 
(Bourdon, Minai et al. 2007; Thelander 2007; Pontarin, Ferraro et al. 2012). Over-expression of 
p53R2 in mice leads to mtDNA depletion in skeletal muscles (Ylikallio, Page et al. 2010). 
Moreover, mutations in p53R2 have been associated with multiple human mitochondrial diseases 
that are characterized by severe mtDNA depletion and accumulation of deletions and point 
mutations in mitochondrial genome (Bourdon, Minai et al. 2007; Kollberg, Darin et al. 2009; 
Shaibani, Shchelochkov et al. 2009; Tyynismaa, Ylikallio et al. 2009) (more details in section 
1.3.3).  
1.3 RNR deregulation and genomic instability 
Balanced dNTP pools are essential for genomic integrity and organismal survival. As the 
enzyme that catalyzes the rate-limiting step of de novo dNTP synthesis, RNR is tightly regulated 
to ensure the fidelity of genome maintenance. It is not surprising to find out that RNR 
deregulation leads to genomic instability and causes detrimental effects in organisms. For 
example, RNR deregulation has been shown to be mutagenic in both yeast and mammalian cells 
(Caras and Martin 1988; Chabes, Georgieva et al. 2003). RNR deregulation can lead to genomic 
instability through at least two different mechanisms: altered enzyme activity that may result in 
dNTP pool disruptions and elevated free radical production that may contribute to oxidative 
stress.  
1.3.1 Genomic instability induced by altered enzyme activity 
It is not surprising that deregulation of enzymes involved in dNTP biosynthesis often 
leads to mutagenesis. For example, mutations of two enzymes that are important for dTTP 
synthesis, TK1 and TMPK, lead to over stabilization of the enzymes and subsequent dTTP 
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accumulation, which then result in increased spontaneous mutation rates and genomic instability 
(Ke, Kuo et al. 2005). As a key enzyme in dNTP synthesis, RNR enzyme activity alterations are 
also mutagenic. Exposure of E. coli to UV light increases the expression of RNR, leading to a 
1.8- to 3.7-fold increase in all four dNTPs. This increase in dNTP pool is accompanied by 
increased spontaneous mutagenesis (Gon, Napolitano et al. 2011).  
Yeast RNR requires at least 5-10 times higher dATP concentration than mammalian RNR 
in vitro to have feedback inhibition at the activity site (a property called “relaxed dATP feedback 
inhibition”) (Reichard, Eliasson et al. 2000; Domkin, Thelander et al. 2002). Due to this 
property, in yeast upon DNA damage, there is a 6 to 8 fold increase in dNTP pools. This increase 
in dNTP pools dramatically improves cell survival, but also leads to increased mutations rates, 
indicating that altered RNR enzyme activity leads to altered dNTP pool and causes mutagenesis 
(Chabes, Georgieva et al. 2003). The same paper also showed that an RNR1 mutant, RNR1-
D57N, which has a D57N mutation in the allosteric activity site in RNR1 and completely loses 
dATP feedback inhibition, resulted in an 11- to 17- fold increase in dNTP pools during DNA 
damage. This disruption in dNTP pool also causes increased mutation rates (Chabes, Georgieva 
et al. 2003). A recent study created yeast strains with single amino acid substitution in a region 
of RNR1 that is highly conserved from yeast to humans and is important for the connection 
between the specificity site and the catalytic site. Yeast stains that express these RNR1 mutants 
have dNTP pool imbalances, which also correlate with elevated mutation rates. The mutations 
can be explained by imbalanced dNTP-induced increase in misinsertion, strand misalignment 
and mismatch extension at the expense of proofreading (Kumar, Abdulovic et al. 2011).  
Unlike in yeast, where the connection between RNR enzyme activity alteration and 
increased mutagenesis is relatively clear, how RNR deregulation leads to mutagenesis in 
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mammals is not fully understood. A mouse T-lymphosarcoma cell line (S49) was selected by 
deoxyguanosine and a resistant mutant clone (dGuo-200-1) was identified to have the D57N 
mutation in the large subunit Rrm1. Same as in yeast, this mutation causes complete loss of 
dATP feedback inhibition. It has been shown that this cell line has a 2- to 9-fold increase in 
dNTP pools and over 100-fold increase in spontaneous mutation rates (Ullman, Clift et al. 1980; 
Weinberg, Ullman et al. 1981; Caras and Martin 1988). A later study cloned the cDNA of Rrm1-
D57N and transfected the DNA into Chinese Hamster Ovary (CHO) cells. CHO cells expressing 
this mutant Rrm1-D57N protein showed around a 15- to 25- fold increase in the frequency of 
spontaneous mutation; however, no dNTP pool changes was discovered in these cells (Caras and 
Martin 1988). Another cell line with RNR enzyme activity alterations is a hydroxyurea-resistant, 
protein Rrm2-overexpressing mouse cell line. These cells have 3-15 times higher RNR enzyme 
activity than the parent cells. However, the dNTP pools are close to normal (Akerblom, 
Ehrenberg et al. 1981). In addition, the hydroxyurea-resistant, Rrm2-overexpressing mouse 
mammary tumor TA 3 cell line had around 40-fold increase in Rrm2 protein level compared to 
the parent cells, yet didn’t show dNTP pool changes compared to the parent cells (Eriksson, 
Graslund et al. 1984; Chabes and Thelander 2000). Therefore, it is not very clear whether the 
elevated mutagenesis associated with RNR activity alterations is resulted from dNTP pool 
perturbations. Failure to detect dNTP pool changes in cells with altered RNR activity could be 
due to relatively small changes in dNTP pools, which is difficult to measure. Alternatively, a 
specific interaction of RNR with the machinery of DNA replication or repair may be involved.  
The effect of RNR activity alterations in whole organisms such as mice has also been 
investigated. Simultaneous over-expression of Rrm1 and Rrm2 (or p53R2) subunits in mice 
leads to imbalanced dNTP pools, where expansion in dATP and dCTP pools and reduction in 
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dTTP pool were observed. In addition, this over-expression also leads to progressive 
mitochondrial DNA (mtDNA) depletion in the mouse skeletal muscle (Ylikallio, Page et al. 
2010). When the mutant Rrm1-D57N that loses dATP feedback inhibition is simultaneously 
over-expressed in mice together with either Rrm2 or p53R2, embryonic and postnatal lethality 
was observed. Skeletal muscles from these mice show dNTP pool perturbations, with 3- to 40-
fold increase in dCTP, dTTP and dGTP and 4- to more than 300-fold increase in dATP (J. Page 
and R. Weiss, unpublished data). This implies that RNR activity alterations in organismal level 
also cause dNTP pool disturbances, which can have detrimental effects in organisms. The 
mechanism of how dNTP pool alterations leads to lethality in these mice is still under 
investigation.  
1.3.2 Genomic instability induced by elevated free radical production 
The small subunit of RNR, Rrm2, produces free radicals during the catalytic cycle 
(Kolberg, Strand et al. 2004). Free radicals in cells can interact with critical macromolecules 
including DNA, proteins and lipids, leading to cell death, mutation and other toxicities (Martin 
and Barrett 2002). Mouse Rrm2 has a relatively open structure around the free radical producing 
di-nuclear iron center (Kolberg, Strand et al. 2004). It is possible that the free radicals produced 
by Rrm2 can interfere with other molecules in cells. It has been shown that recombinant human 
Rrm2 protein produces excessive reactive oxygen species (ROS) in vitro (Xue, Zhou et al. 2006; 
Liu, Xue et al. 2008). Controversially, in the same paper, p53R2 has been shown to act as an 
antioxidant in vitro (Liu, Xue et al. 2008). However, critical assay conditions including the 
activity and stability of the two subunits were not provided in the paper, making it hard to 
compare and conclude the redox properties of these subunits in vitro. 
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Excessive ROS production can cause increased oxidative stress, which leads to DNA 
damage such as base modifications and DNA strand alterations. Oxygen radicals produce more 
than 30 different DNA adducts with each potentially mutagenic and contributing to the etiology 
of cancer (Feig, Reid et al. 1994). Furthermore, Rrm2 has been shown to cooperate with 
oncogenes including Ras to determine transformation and malignant potential. This activity is 
independent of ribonucleotide reduction and involves activation of Ras downstream proteins Raf 
and Rac (Fan, Villegas et al. 1996). Since ROS can activate Ras signaling pathways in cancer, 
the cooperativity of Rrm2 and Ras could be through ROS production and activation of 
downstream pathways (Fan, Villegas et al. 1996). Rrm2 and p53R2 overexpressing transgenic 
mice develop lung neoplasms with frequent G to T transversion mutations in growth regulatory 
genes. G to T transversions are a signature of oxidative DNA damage, suggesting that R2-
induced mutagenesis and tumorigenesis is associated with increased oxidative stress (Xu, Page et 
al. 2008).  
1.3.3 Mitochondrial genome instability induced by p53R2 deregulation 
Consistent with a role of Rrm1 and p53R2 in providing dNTPs for DNA repair and 
mitochondrial DNA synthesis in resting cells, p53R2 knockout mice die at around 14 weeks of 
age due to severe renal failure (Kimura, Takeda et al. 2003). In addition, multiple tissues in these 
p53R2 knockout mice showed mitochondrial DNA (mtDNA) depletion (Bourdon, Minai et al. 
2007). In humans, nonsense, missense and splice-site mutations and in-frame deletions of the 
p53R2 gene have been shown to result in mitochondrial DNA depletion syndrome (MDS), where 
the patients only had 1-4% residual mtDNA in muscle and are not viable (Bourdon, Minai et al. 
2007; Kollberg, Darin et al. 2009). Mitochondrial neurogastrointestinal encephalopathy 
(MNGIE) is a progressive neurodegenerative disorder. Patients with this disease often have 
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around 12% residual mtDNA and two missense mutations in p53R2 that affects p53R2 and Rrm1 
interaction and enzyme activity have been identified to contribute to this disease (Shaibani, 
Shchelochkov et al. 2009). Another mitochondrial disorder called autosomal-dominant 
progressive external ophthalmoplegia (adPEO) is characterized by accumulation of multiple 
mtDNA deletions in postmitotic tissues. A group of patients with this disease have a nonsense 
mutation in p53R2 that results in a protein with truncation of the C-terminus essential for the 
interaction with Rrm1 (Tyynismaa, Ylikallio et al. 2009). All these findings suggest that the de 
novo dNTP synthesis pathway mediated by RNR is essential to maintain not nuclear, but also 
mitochondrial genome integrity. 
1.4 RNR and cancer 
Tumor cells are fast proliferating and thus require large amount of dNTPs. Early evidence 
in the 1970s already showed that in a series of slow and fast growing rat hepatomas, RNR 
activity correlated well with tumor growth rate. Differences of 200-fold in enzyme activity were 
observed between the very fast and the slow growing tumors (Elford, Freese et al. 1970). The 
importance of RNR in DNA synthesis and repair has made it an important target for anticancer 
and antivirus agents a long time ago. For example, in the 1980s, marked increase in dNTP pools 
was identified in cancer cells and anticancer chemotherapy targeting nucleotide metabolism was 
investigated (Weber 1980). However, the role RNR plays in tumorigenesis is still not very well 
understood.  
1.4.1 Rrm1 suppresses tumorigenesis in early stage tumor development 
It is generally believed that the large subunit of RNR, Rrm1, acts as a tumor suppressor. 
It has been shown that Rrm1 over-expression in RAS-transformed mouse cells led to reduced 
transforming activity and marked suppression of tumorigenicity and lung metastases in vivo 
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(Fan, Huang et al. 1997). In addition, Rrm1 over-expression in human and mouse lung cancer 
cell lines induced PTEN expression, suppressed migration, invasion, metastasis formation, and 
increased survival in a mouse model (Gautam, Li et al. 2003). Rrm1 transgenic mice showed 
significantly suppressed lung tumor formation induced by the carcinogen urethane and it is 
proposed that this tumor suppressor activity is mediated through efficient DNA damage repair 
(Gautam and Bepler 2006). In contrast, Rrm1 transgenic mice from a different group showed 
comparable spontaneously lung tumor incidence as wild type control (Xu, Page et al. 2008). In 
human patients with non-small cell lung cancer (NSCLC) and treated with surgery already, high 
levels of Rrm1 expression are associated with longer life span and later disease recurrence than 
patients with low levels (Bepler, Sharma et al. 2004). It has been demonstrated that Rrm1 protein 
in NSCLC is nuclear and highly correlates with expression of a nuclear excision repair protein 
ERCC1. Co-expression of these two proteins is significantly associated with disease-free and 
overall survival, especially in a group of patients who underwent lung cancer surgery at early 
stages (Zheng, Chen et al. 2007).  
1.4.2 R2 promotes tumorigenesis  
Rrm2 has been shown to play a direct role in determining malignant potential through 
cooperating with oncogenes. Expression of Rrm2 in mouse cells leads to increased focus 
formation and anchorage-independent growth in cooperation with a variety of oncogenes 
including ras, myc and src (Fan, Villegas et al. 1996; Fan, Villegas et al. 1998). Human 
carcinoma cells that have higher Rrm2 expression level demonstrated higher invasive potential in 
vitro (Zhou, Tsai et al. 1998). These cells also showed decreased thrombspondin-1 and increased 
VEGF production, suggesting a role of Rrm2 in tumor angiogenesis (Zhang, Hu et al. 2009). In 
vivo study with Rrm2 over-expressing transgenic mice showed significantly increased lung 
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tumorigenesis, with the tumors histopathologically resemble human papillary adenocarcinomas 
and often have mutations in the K-ras proto-oncogene. When combined with defects in DNA 
mismatch repair pathway, these Rrm2 over-expressing mice showed synergistically increased 
mutagenesis and carcinogenesis, providing strong evidence for Rrm2 as a tumor promoter 
through a mutagenic mechanism (Xu, Page et al. 2008).  
In humans, Rrm2 expression level is associated with breast tumor grade, suggesting a 
role of RNR in supporting rapid cell division of high-grade tumors (Ma, Salunga et al. 2003). 
Overexpression of Rrm2 has also been observed in patients with gastric cancer, ovarian cancer, 
bladder cancer and colorectal cancer (Morikawa, Hino et al. 2010; Morikawa, Maeda et al. 2010; 
Liu, Zhang et al. 2012; Lu, Feng et al. 2012; Wang, Lu et al. 2012). There is evidence showing 
that up-regulated Rrm2 expression in colorectal cancer cell lines is mediated by the oncogene 
KRAS (Yoshida, Tsunoda et al. 2011). In addition, Rrm2 overexpression induces cellular 
invasiveness in a pancreatic cancer cell line in a NF-κB-dependent manner (Fan, Villegas et al. 
1996).  
The role of p53R2 in mutagenesis and tumorigenesis is controversial. Based on the p53-
induced nature of p53R2 expression and its role in DNA damage repair, it is proposed that 
p53R2 has tumor suppressor activity (Tanaka, Arakawa et al. 2000). p53R2 has been shown to 
have antioxidant activity in vitro (Xue, Zhou et al. 2006). Under genotoxic stress, p53R2 can 
facilitate p21 accumulation and G1 arrest, which may help with DNA damage repair and 
prevention of mutation accumulation (Xue, Zhou et al. 2007). In human, p53R2 is negatively 
related to metastasis of colon adenocarcinoma samples (Liu, Zhou et al. 2006). Higher levels of 
p53R2 expression suppress invasiveness of cancer cells and are correlated with markedly better 
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survival in colorectal cancer patients (Liu, Lai et al. 2011). Tumor suppressor activity of p53R2 
may be due to its role in DNA repair and regulation of the redox state in cells.  
On the other hand, there are several reports on p53R2 as a tumor promoter. p53R2 
overexpressing cells have increased mutation frequency and p53R2 overexpression in mice 
induced lung tumor development (Xu, Page et al. 2008). In humans, p53R2 expression is 
correlated with melanoma malignancy, oral carcinogenesis, esophageal squamous cell carcinoma 
and non-small cell lung cancer (Yanamoto, Kawasaki et al. 2003; Okumura, Natsugoe et al. 
2006; Uramoto, Sugio et al. 2006; Yanamoto, Kawasaki et al. 2009; Matsushita, Ikeda et al. 
2012). In addition, a couple of polymorphisms in the gene encoding p53R2, RRM2B, have been 
identified and associated with cancer-susceptibility (Smeds, Kumar et al. 2001; Deng, Xie et al. 
2005). 
Both Rrm2 and p53R2 subunits require oxygen to generate tyrosyl radicals for proper 
RNR function. As a result, cellular oxygen levels can affect free radical production and RNR 
activity, where hypoxia leads to decreased free radicals and reoxygenation leads to increased free 
radicals (Reichard and Ehrenberg 1983; Probst, Schiffer et al. 1989). It has been shown that upon 
re-oxygenation after exposure to moderate hypoxia, cancer cells with higher levels of R2 resume 
DNA replication and S phase progression faster than cells with normal levels of R2 (Graff, 
Amellem et al. 2002). As a result, cells are given less time for DNA damage recognition and 
repair, which could contribute to mutagenesis. Since cancer cells undergo cycles of hypoxia and 
reoxygenation (Bristow and Hill 2008), this may provide a possible explanation of the 
correlation between R2 levels and tumor malignancy (Fan, Villegas et al. 1996; Fan, Villegas et 
al. 1998).  
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1.4.3 RNR expression in human cancer studies 
Recent advances in molecular biology, including genomics and proteomics, have 
provided a fantastic opportunity for researchers to look at human cancer samples at a molecular 
level (Rhodes, Yu et al. 2004). RNR gene expression in human cancers has been studied using 
the ONCOMINE database and summarized in Figure 1.5. RRM2 is among the top 10% highly 
expressed genes in 73 out of 168 cancer vs. normal sample analyses. These include bladder 
cancer, brain and CNS cancer, breast cancer, colorectal cancer, liver cancer, lung cancer and 
sarcoma. RRM1 is among the top 10% highly expressed genes in 30 out of 170 studies. Cancer 
types include brain and CNS cancer, lung cancer and sarcoma. RRM2B (the gene enconding 
p53R2 in humans) is only found in 5 out of 90 studies with top 10% over-expression. In addition, 
both RRM2 and RRM1 are also shown to have reduced expression in a few cancers.  
RNR gene copy number changes are also analyzed using the TCGA database (Figure 
1.6). RRM2 showed amplifications in a few cancer types including breast, ovarian, prostate and 
uterine. This is consistent with the ONCOMINE data where RRM2 gene expression is increased 
in breast, ovarian and prostate cancers. Increased copy number and gene expression of RRM2 
correlate well with Rrm2 protein as a tumor promoter. RRM1 showed copy number changes in 
small percentages across a few cancer types. It is amplified in sarcoma samples, which is 
consistent with increased RRM1 gene expression in sarcoma samples based on ONCOMINE 
data. On the other hand, it is lost in a small percentage of glioblastoma cases, which disagrees 
with its increased expression in brain cancer based on ONCOMINE data. This reflects the 
complex role Rrm1 plays in tumorigenesis. It can act as a tumor suppressor initially, but later 
may become important for tumor maintenance. RRM2B amplification is associated with more  
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Figure 1.5 Bar graph showing RNR expression in human cancers. In general, RNR gene 
overexpression is associated with different cancer types. RRM2 is among the top 10% highly 
expressed genes in 73 out of 168 analyses, RRM1 is among the top 10% in 30 out of 170 studies 
and RRM2B (encoding p53R2) is among the top 10% in 5 out of 96 cases. In addition, RRM2 is 
among the top 10% under expressed genes in 7 out of 168 studies and RRM1 is among the top 
10% in 6 out of 170 studies. The expression level of the c-Myc proto-oncogene is shown as a 
comparison. c-Myc is among the top 10% highly expressed genes in 40 out of 174 analyses and 
among the top 10% under expressed genes in 17 out of 174 studies. Data are retrieved from the 
ONCOMINE cancer gene expression database (version 4.4.3, search done on 12/5/12). 
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Figure 1.6 Bar graph showing RNR copy number variations in human cancers. In general, 
RNR copy number variations are associated with different cancer types. RRM2 is amplified in a 
small percentage of sarcoma, breast, ovarian and uterine cancers. RRM1 is amplified in a small 
percentage of sarcoma and uterine cancer. Its copy number is decreased in glioblastoma and lung 
cancer. p53R2 is amplified in a wide range of cancers including breast, colon, glioblastoma, 
kidney, lung, ovarian, prostate, sarcoma and uterine cancers. However, most of these 
amplifications are together with c-Myc amplification. Data are retrieved from the TCGA 
database (search done on 12/5/12). 
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cancer types and occurs at higher percentages for each cancer type. This is partially because 
RRM2B (8q22.3) is located close to the oncogene c-myc (8q24) on the chromosome and majority 
of RRM2B amplification is accompanied with c-myc amplification in these cancers. Further 
analysis reveals that RRM2B amplification is observed in breast cancer, colon cancer, 
glioblastoma, ovarian cancer, prostate cancer and uterine cancer at small percentages 
independent of c-myc amplification. This correlates well with its increased expression in breast 
and prostate cancers in ONCOMINE data and supports p53R2 protein as a tumor promoter. 
1.4.4 RNR and cancer therapy 
The key role of RNR in DNA synthesis and cell growth has made it an important target 
for anticancer therapy. Increased RNR expression has been associated with malignant 
transformation and tumor cell growth (Shao, Zhou et al. 2006). Efforts for new RNR inhibitors 
have been made in basic and translational research. RNR inhibitors can be divided into different 
categories based on different criteria. 
1.4.4.1 Rrm1 inhibition 
Rrm1 can be inhibited at the protein level or RNA level. The general concept of Rrm1 
protein inhibition is inactivating Rrm1 protein by interfering with the active site or inducing 
allosteric malfunction by nucleoside analogs (Shao, Zhou et al. 2006). Gemcitabine (2’, 2’-
dfluoro-2’-deoxycytidine, dFdC) is a well known deoxycytidine analog with antitumor activity 
against a wide variety of cancers. It is approved as the single treatment for advanced pancreatic 
cancer and for combination therapy against non-small cell lung cancer, breast cancer and ovarian 
cancer (Wong, Soo et al. 2009; Bennett, Tomlinson et al. 2012). Gemcitabine is metabolized 
intracellularly by deoxycytidine kinase (dCK) and other enzymes to produce gemcitabine 
diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) (Bouffard, Laliberte et al. 1993; 
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Shao, Zhou et al. 2006). dFdCDP inhibits RNR by interacting with the active site and results in 
loss of RNR catalytic activity (Heinemann, Xu et al. 1990). Clofarabine (CIF) is another 
commonly used Rrm1 protein inhibitor and has been used to treat leukemia (Shao, Zhou et al. 
2006). It is a deoxyadenosine analog and binds to the activity site of Rrm1 at a higher affinity 
than the allosteric inhibitor dATP, thus giving a powerful RNR allosteric inhibition (Xie and 
Plunkett 1995; Xie and Plunkett 1996). Recently, it has been shown that CIF binds to the activity 
site of Rrm1 and targets human RNR by converting the large Rrm1 subunit into persistent 
hexamers in vitro and in vivo, providing the first evidence that an external ligand can perturb 
Rrm1 function by interfering with its oligomeric state (Aye and Stubbe 2011; Aye, Brignole et 
al. 2012) 
In the last decade, Rrm1 has been identified as the key molecule in determining the 
efficacy of gemcitabine. Overexpression of Rrm1 has been reported in gemcitabine-resistant 
cancer cells both in vitro and in vivo (Davidson, Ma et al. 2004; Bergman, Eijk et al. 2005; 
Jordheim, Guittet et al. 2005; Bepler, Kusmartseva et al. 2006). In human cancer patients, high 
level of Rrm1 expression has been correlated with poor response to gemcitabine (Ceppi, Volante 
et al. 2006; Nakahira, Nakamori et al. 2007; Ohtaka, Kohya et al. 2008; Akita, Zheng et al. 2009; 
Reynolds, Obasaju et al. 2009; Jordheim, Seve et al. 2011; Rodriguez, Boni et al. 2011; Gong, 
Zhang et al. 2012). As a result, efforts have been made on individualized chemotherapy based on 
Rrm1 gene expression level in patients with advanced NSCLC (Simon, Sharma et al. 2007).  In 
addition, Rrm1-specific small interfering RNA (siRNA) has been explored as a way to 
downregulate the expression of Rrm1 protein in tumor cells to overcome gemcitabine resistance 
(Wonganan, Chung et al. 2012). 
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1.4.4.2 R2 inhibition 
R2 inhibitors target the small subunits Rrm2 and p53R2 by interfering with the iron 
center and tyrosyl radical production (Shao, Zhou et al. 2006). Hydroxyurea, a radical scavenger 
that inactivates RNR by directly quenching the tyrosyl radical in R2, has been used for cancer 
therapy for decades (Lassmann, Thelander et al. 1992). The limitation of hydroxyurea is the 
development of resistance. Overexpression of R2 and mutations in R2 have been shown to 
confer resistance to hydroxyurea (Zhou, Hsu et al. 1995; Jiang, Zhang et al. 2004; Sneeden and 
Loeb 2004).  
Iron is a well-known growth factor and also an essential co-factor for RNR function. 
Therefore, iron chelators can be used to inhibit RNR activity and in the treatment of cancer 
(Buss, Greene et al. 2004). Triapine (3-AP) is an iron chelator and RNR inhibitor that is 
currently in phase II clinical trials for cancer chemotherapy (Nutting, van Herpen et al. 2009; 
Traynor, Lee et al. 2010; Ocean, Christos et al. 2011). It is demonstrated that Triapine forms 
complexes with iron and the Triapine-Fe(II) complex is a potent reductant that rapidly quenches 
the tyrosal radical in R2, rendering RNR inactive (Aye, Long et al. 2012).  
Recently, there are also advances in targeting R2 by RNA interference. Delivery of 
siRNA against R2 by nanoparticles or by retroviruses has been shown to suppress tumor growth 
in head and neck cancer and pancreatic cancer (Duxbury, Ito et al. 2004; Rahman, Amin et al. 
2012).  
1.5 Summary 
RNR’s critical role in dNTP biosynthesis has made it an essential enzyme for organismal 
survival. It is well known that dNTP pool perturbation can cause detrimental effects in cells 
including DNA replication inhibition, growth impairment, genomic instability, mutagenesis and 
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tumorigenesis. Therefore, RNR activity is tightly regulated in cells to ensure a balance in dNTP 
pools. Over the past few decades, RNR has been actively studied by many groups to understand 
its structure, mechanisms of function, regulation, disease association and drug targeting 
potential. Several aspects of RNR including its regulation, role in DNA damage response and 
mutagenesis is relatively well understood in yeast. In mammals, there are still quite a few 
unanswered questions regarding RNR. Important questions we are asking are:  what are the 
cellular and physiological consequences when RNR is deregulated? Does disabling different 
regulatory mechanisms of RNR lead to different outcomes? What are the underlying mechanisms 
for these different outcomes?  
Previous research in the lab has shown that disabling RNR cell cycle regulation by over-
expressing R2 in cells leads to increased mutagenesis and in mice leads to lung tumor 
development. The first part of this dissertation investigated the molecular mechanism of R2-
induced tumorigenesis. The effect of R2 over-expression on cellular redox homeostasis and 
mitochondrial function has been studied. A possible role of reactive oxygen species (ROS) in 
R2-induced mutagenesis and tumorigenesis is suggested. The second part of this dissertation 
used R2 overexpressing mice as a lung tumor model and developed micro-computed tomography 
(micro-CT) techniques to measure lung tumor growth rates. Exponential lung tumor growth in 
mice has been revealed by this study using automated tumor measurement algorithm.  
Although R2 over-expression leads to tumorigenesis, over-expression of the large R1 
subunit or a mutant form of R1 that abolishes the allosteric feedback inhibition of RNR (R1-
D57N), does not lead to pathological phenotypes in mice. However, combining overexpression 
of R1-D57N and R2 in mice leads to synthetic lethality. The supplementary part of this 
dissertation characterized the stage of lethality and examined the underlying mechanism of the 
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cause of death. Simultaneous deregulation of the R1 and R2 subunits leads to dramatic changes 
in dNTP pools and results in embryonic and postnatal lethality.  
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CHAPTER 2 Ribonucleotide Reductase Deregulation Leads to Increased Reactive Oxygen 
Species Production and Mitochondrial Dysfunction 
2.1 Abstract 
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in de novo nucleotide 
biosynthesis and is essential for maintaining genome integrity. RNR deregulation has been 
shown to cause dNTP pool imbalances, which can be mutagenic. However, as an enzyme that 
produces and utilizes free radicals for its function, the effect of RNR deregulation on redox 
homeostasis in cells is not fully understood. In this study, we show that overexpression of the 
free radical producing R2 subunit of RNR leads to increased levels of cellular reactive oxygen 
species (ROS). This increased ROS requires the di-nuclear iron center of R2 and is not affected 
by the disruption of the free radical transfer pathway, which transfers the free radicals in R2 to 
the R1 subunit of RNR for catalysis. Instead, R2 mutants with defective free radical transfer are 
shown to interfere with endogenous RNR function, leading to mitochondrial DNA depletion and 
disruption of mitochondrial ROS homeostasis. These results demonstrate the importance of RNR 
regulation in maintaining mitochondrial genome integrity, as well as cellular and mitochondrial 
redox balance. Importantly, this study suggests a potential role for R2-induced ROS production 
in mutagenesis and tumorigenesis.  
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2.2 Introduction 
Ribonucleotide reductase (RNR) is a key enzyme in de novo deoxyribonucleotide 
triphosphate (dNTP) synthesis, where ribonucleoside diphosphate (NDP) is reduced to 
deoxyribonucleoside diphosphate (dNDP), which is further phosphorylated to dNTP and used in 
DNA synthesis (Eklund, Uhlin et al. 2001). Eukaryotic RNR enzyme belongs to the class Ia 
family, where it is composed of two nonidentical dimeric subunits R1 and R2. The large R1 
subunit harbors the catalytic site and two allosteric regulation sites. It is encoded by the gene 
RRM1 in mammals. The small R2 subunit contains the di-nuclear iron center where free radicals 
are generated and transferred to the catalytic site and used for catalysis. R2 can be encoded by 
the gene RRM2 or RRM2B in mammals (Nordlund and Reichard 2006). Rrm1 and Rrm2 
complex is responsible for making dNTPs in proliferating cells. p53R2 can substitute Rrm2 and 
form an active enzyme with Rrm1. It is initially identified as the downstream target of the tumor 
suppressor p53 whose expression is highly induced upon DNA damage (Nakano, Balint et al. 
2000; Tanaka, Arakawa et al. 2000; Guittet, Hakansson et al. 2001; Hakansson, Hofer et al. 
2006). In recent years, p53R2 is shown to be expressed at low levels independent of the cell 
cycle and provide dNTPs for mitochondrial genome maintenance (Pontarin, Ferraro et al. 2007; 
Pontarin, Ferraro et al. 2012).  
Since a balanced dNTP pool is essential for genome integrity, RNR activity is highly 
regulated in cells (Mathews 2006; Nordlund and Reichard 2006). One primary regulation of 
RNR is through the cell cycle where the transcription of Rrm1 and Rrm2 is not detectable in G0-
G1 phase, but peaks in S-phase cells (Eriksson, Graslund et al. 1984; Mann, Musgrove et al. 
1988; Bjorklund, Skog et al. 1990). Due to the long half-life of Rrm1, its protein level remains 
constant throughout the cell cycle while Rrm2 protein correlates well with its mRNA level. 
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Rrm2 protein peaks in S phase and is degraded in G2 and late mitosis by the ubiquitin ligases 
Skp1-Cul1-F-box (SCF) and anaphase promoting complex (APC), respectively (Eriksson, 
Graslund et al. 1984; Chabes and Thelander 2000; Chabes, Pfleger et al. 2003; D'Angiolella, 
Donato et al. 2012). As a result, RNR enzyme activity is partially regulated by the availability of 
Rrm2. Disruption of RNR cell cycle regulation by constitutively over-expressing Rrm2 in cells 
leads to increased mutation frequency and in mice leads to lung tumorigenesis. These lung 
tumors resemble human papillary adenocarcinoma and often have mutations in the K-ras proto-
oncogene (Xu, Page et al. 2008). Rrm2 promotes tumorigenesis through a mutagenic mechanism, 
which could be due to increased RNR activity and dNTP alterations, or increased free radical 
production and oxidative stress. Since the lung tumors in Rrm2 overexpressing mice have 
mutations that are characteristic of oxidative DNA damage, this suggests a potential role of 
oxidative stress in Rrm2 induced mutagenesis and tumorigenesis (Xu, Page et al. 2008).  
RNR catalytic cycle starts with free radical production in R2. The di-ferrous iron center 
(Fe(II)Fe(II)) in R2 is oxidized by O2 and through a series of intermediate stages, a di-ferric iron 
center (Fe(III)Fe(III)) and a stable tyrosyl radical (Y177) are produced. The di-nuclear iron 
center is located within a four-helix bundle (Nordlund and Eklund 1995) and is coordinated by 
side chains from six charged residues (Glu/Asp/His) from the four helices (Nordlund, Sjoberg et 
al. 1990; Strand, Karlsen et al. 2004). Y177 radical is transferred to the catalytic site in R1 
through a long-range radical transfer pathway consisting of amino acids that can form hydrogen 
bonds. Tyrosine 370 (Y370) is an essential residue in this pathway where it connects the radical 
transfer in R2 with that in R1 (Rova, Adrait et al. 1999; Eklund, Uhlin et al. 2001; Kolberg, 
Strand et al. 2004). It is located on the C-terminus of R2, which is essential for interacting with 
R1 (Climent, Sjoberg et al. 1992; Lycksell, Ingemarson et al. 1994). Mutating these two tyrosine 
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residues to non-hydrolysable phenylalanine in recombinant R2 proteins renders RNR 
enzymatically inactive in vitro, indicating the importance of free radicals in RNR function 
(Potsch, Lendzian et al. 1999; Rova, Adrait et al. 1999).  
When studying the role of RNR in genome integrity, a major focus is on the relationship 
between RNR-induced dNTP pool alterations and mutagenesis. Due to the free radical producing 
nature of R2, deregulation of this protein could also result in perturbations of cellular redox 
homeostasis. However, the effect of R2 deregulation on the redox status in cells is not well 
characterized. Reactive oxygen species (ROS) in cells can lead to oxidative stress with elevated 
levels of oxidative DNA lesions (8-oxoG), resulting in mutagenesis and tumorigenesis (Valko, 
Rhodes et al. 2006). Liu et al. showed that human recombinant R2 protein leads to increased 
ROS production in vitro while p53R2 acts as an antioxidant (Liu, Xue et al. 2008). Moreover, 
mutation signature in R2-induced lung tumors is indicative of oxidative DNA damage (G to T 
transversions due to 8-oxoG incorporation into DNA), suggesting an association between R2-
induced tumorigenesis and elevated ROS, which could potentially result from R2 deregulation.  
Furthermore, RNR is important in mitochondrial DNA (mtDNA) synthesis. Mutations in 
p53R2 has been linked to mtDNA depletion in human diseases ((Bourdon, Minai et al. 2007; 
Kollberg, Darin et al. 2009; Shaibani, Shchelochkov et al. 2009; Tyynismaa, Ylikallio et al. 
2009). Rrm2 over-expression has also been shown to cause mtDNA depletion in mouse skeletal 
muscles (Ylikallio, Page et al. 2010). As a major source of ROS production in cells, 
mitochondria function is tightly related to its redox status (Murphy 2009). Therefore, it is worth 
investigating whether mtDNA depletion under these conditions can lead to disruption of 
mitochondrial ROS homeostasis.  
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In this study, we looked closely at the effect of R2 deregulation on cellular and 
mitochondrial redox homeostasis. We showed that R2 overexpression leads to increased ROS 
production in cells and that di-nuclear iron center is the source of R2-induced ROS. Two R2 
mutants that are defective for free radical transfer had dominant negative effect in cells by 
interfering with endogenous Rrm1, leading to mtDNA depletion and mild increase in 
mitochondrial ROS. Our results provide insights into the effect of RNR on redox homeostasis, 
emphasize the importance of RNR regulation in cellular function and suggest a potential role of 
ROS production in R2-induced mutagenesis.  
2.3 Materials and methods 
2.3.1 Plasmids 
Mammalian expression plasmids encoding RRM1, RRM2 and RRM2B (p53R2) were 
previously constructed in the pCaggs expression vector (Xu, Page et al. 2008). All primers used 
for making Rrm2 mutants in this study are listed in Table 2.1. pCaggs-Rrm2-Fe6 was made 
using a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) using 
primers (A), (B), (C) and (D). pCaggs-Rrm2-Y177F and pCaggs-Rrm2-Y370F were made using 
overlap extension PCR (Ho, Hunt et al. 1989). The two universal primers used are primers (I) 
and (J). The primers harboring corresponding mutations were  (E) and (F) for Y177F and (G) 
and (H) for Y370F.  
pCaggs-Rrm2-Δ7 and pCaggs-Rrm2-Y370F-Δ7 were made using primers (K) and (L) 
and pCaggs-Rrm2-Δ20 was made using primers (K) and (M). pCaggs-Rrm2-Y177F-Δ7 and -Δ20 
were generated by subcloning. pCaggs-Rrm2-Y177F, pCaggs-Rrm2-Δ7 and pCaggs-Rrm2-Δ20 
plasmids were digested with ClaI and XbaI. The smaller insert piece from Rrm2-Y177F was  
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ligated to the larger backbone pieces from Rrm2-Δ7 and Rrm2-Δ20. 
pCaggs-Rrm2-T33A was made using a QuikChange Lightning Site-Directed 
Mutagenesis Kit with primer (O). pCaggs-Rrm2-T33A-Y177F, pCaggs-Rrm2-T33A-Y370F and 
pCagss-Rrm2-T33A-Fe6 were generated by subcloning. pCaggs-Rrm2-T33A plasmid was 
digested by XbaI and EcoRV to release the insert with T33A mutation, which was ligated to the 
backbones from pCaggs-Rrm2-T33A-Y177F, pCaggs-Rrm2-T33A-Y370F and pCagss-Rrm2-
T33A-Fe6 upon XbaI and EcoRV digestion.  
All mutant constructs were confirmed by DNA sequencing.  
Bacterial expression plasmids encoding Rrm2, Rrm2-Fe6, Rrm2-Y177F, Rrm2-Y370F, 
Rrm2-Δ7 and Rrm2-Δ20 were constructed in the pGEX-6P-2 GST-fusion protein expression 
vector (Kaelin, Krek et al. 1992). pCaggs plasmids encoding Rrm2, Rrm2-Fe6, Rrm2-Y177F, 
Rrm2-Y370F, Rrm2-Δ7 and Rrm2-Δ20 were digested by Xho1 to generate the desired Rrm2 
wild type and mutant inserts, which were then cloned into Xho1 digested pGEX-6P-2 backbone.  
2.3.2 RNR overexpressing cell lines 
Mouse 3T3 fibroblast cells expressing empty pCaggs vector, pCagss-Rrm1, pCaggs-
Rrm2 and pCaggs-p53R2 were generated previously (Xu, Page et al. 2008). 3T3 cells expressing 
Rrm2-Y177F, Rrm2-Y370F, Rrm2-Fe6, Rrm2-Δ7, Rrm2-Δ20, Rrm2-Y177F-Δ7, Rrm2-Y177F-
Δ20 and Rrm2-Y370F-Δ7 were generated by transfecting corresponding plasmids together with 
PGK-puro plasmid into 3T3 cells using FuGENE6 transfection reagent (Roche Diagnostics Co., 
Mannheim, Germany).  Transfected 3T3 cells were cultured in standard culture media 
(Dulbeco’s Modification of Eagles Medium supplemented with 10% bovine calf serum, 1.0mM 
L-glutamine, 0.1mM MEM non-essential amino acids, 100µg/ml streptomycin sulfate, 100U/ml 
penicillin). 48 hours after transfection, standard media was replaced by selection media 
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containing 1.25µg/ml puromycin, which was changed every 2 days. After 10-14 days, 
puromycin-resistant colonies were pooled together and expanded for further analysis and 
experiments. Puromycin-resistant cells were always kept in selection media.  
2.3.3 Bacterial culture and lysates 
pGEX-Rrm2, Rrm2-Fe6, Rrm2-Y177F, Rrm2-Y370F, Rrm2-Δ7 and Rrm2-Δ20 plasmids 
were transformed into XA90 competent cells and colonies were picked for bacterial culture (LB 
and Amp). Expression of GST-fused Rrm2 wild type and mutant proteins were induced by IPTG. 
Bacteria were collected and resuspended in lysis buffer (50mM Tris-HCl pH 8.0, 120mM NaCl, 
50mM EDTA, 1% Triton X-100 and 3mg/ml lysozyme) supplemented with 1x proteinase 
inhibitor (2µg/ml leupeptin, 2µg/ml apropinin and 20µg/ml PMSF). Cells were lysed in lysis 
buffer by two freeze and thaw cycles.  
2.3.4 Western blot and pull-down assay 
Rrm2 overexpressing 3T3 and U2OS cells were collected and lysed in RIPA buffer 
(50mM Tris-HCl pH 8.0, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 150mM sodium chloride, 50mM sodium fluoride) supplemented with 1x proteinase 
inhibitor (2µg/ml leupeptin, 2µg/ml apropinin and 20µg/ml PMSF) and 1x phosphatase inhibitor 
(400µM sodium orthovanadate). Protein lysates were separated on 10% polyacrylamide gel and 
transferred to PVDF membrane. Antibodies used were goat anti-R2 (sc-115, Santa Cruz 
Biotechnology) and mouse anti-α-tubulin (Sigma). 
In pull-down assay, bacterial lysates expressing Rrm2 wild type and mutants were 
incubated with Glutathione Sepharose beads (Amersham Biosciences) for 2-4hrs. Human 
embryonic kidney 293 cell lysates were added to GST-protein bound beads and incubated for 2-
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4hrs. Beads were washed with NETN buffer (20mM Tris-HCl pH 8.0, 10mM NaCl, 1mM EDTA 
and 0.5% NP-40) and loaded on 10% polyacrylamide gel. Proteins were transferred to PVDF 
membrane and detected by mouse anti-R1 (AD203, Bio Med Tek).   
2.3.5 ROS measurement 
Total cellular ROS was measured by dihydroethidium (DHE) staining (Life 
Technologies).  Cells were grown on glass coverslips at a density of 105 cells/3ml for 24hrs and 
stained with 5µM DHE in standard culture media at 37°C for 20min. Cells were then subjected 
to confocal imaging using a Zeiss LSM 510 Meta confocal microscope (excitation 405nm and 
emission 530nm). Fluorescence intensity of cells was quantified by Image J.  
Mitochondrial ROS was measured by MitoSox Red staining (Life Technologies). Cells 
were grown on glass coverslips at a density of 105 cells/3ml for 24hrs and stained with 5µM 
MitoSox Red in standard culture media at 37°C for 20min. MitoSox Red containing media was 
replaced by normal standard media after 20min and cells were incubated in standard media for 
another 20min. Cells were then subjected to confocal imaging using a Zeiss LSM 510 Meta 
confocal microscope (excitation 514nm and emission 575nm). Fluorescence intensity of cells 
was quantified by Image J.  
All Statistics was performed by JMP. 
2.3.6 Genomic DNA extraction and qPCR 
Rrm2 expressing 3T3 cells were collected in cold PBS and digested overnight at 50°C in 
digestion buffer (100mM NaCl, 10mM Tris-HCl pH 8.0, 25mM EDTA pH 8.0, 0.5% SDS and 
freshly added 0.1mg/ml proteinase K). 50µg/ml of RNase A was added to the digestion mixture 
the next day and incubated at 50°C for 1hr.  The mixture was then subjected to phenol 
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chloroform extraction and ethanol precipitation. DNA was resuspended in nanopure water and 
concentration was measured by NanoDrop.   
5ng of genomic DNA was used in qPCR assay. Mitochondrial encoded cytochrome C 
oxidase I (mt-COI) was amplified by the following primers: 
Forward: 5’TGCTAGCCGCAGGCATTACT3’ 
Reverse: 5’CGGGATCAAAGAAAGTTGTGTTT3’ 
Nuclear encoded GAPDH was amplified by the following primers: 
Forward: 5’GCCTTCCGTGTTCCTACC3’ 
Reverse: 5’CCTCAGTGTAGCCCAAGATG3’ 
qPCR reactions were performed using Applied Biosystems 7500 Fast Real-Time PCR 
thermocycler under the following conditions: 50°C for 2min, 95°C for 10min, 95°C for 15sec 
(40x) and 60°C for 1min.  
2.3.7 Total cellular dNTP measurement 
RNR expressing 3T3 cells (106 total) were cultured on 10cm tissue culture dish and 5 x 
105 cells were collected 24hr after. Total cellular dNTPs were extracted and measured as 
previously described (Sherman and Fyfe 1989; Ferraro, Franzolin et al. 2010). Briefly, cells were 
resuspended in 100µl of cold 0.4N perchloric acid and incubated on ice for 20min. After 
centrifugation at 14,000g for 1min, the supernatant was collected and neutralized with 100µl of 
0.5N trioctylamine (Sigma) in 1,1,2-fluorotrichloromethane (Sigma). Samples were votexed 
briefly and centrifuged at 14,000g for 2min and the upper aqueous phase was snap-frozen in 
liquid N2 and stored at -80°C until dNTP measurements were performed.    
Ribonucleoside levels in samples were first measured as described (Kochanowski, 
Blanchard et al. 2006; Ylikallio, Page et al. 2010) to assess dNTP extraction quality using a 
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Shimadzu HPLC system. Samples were separated on a Supelco LC-18T column in 30mM 
KH2PO4 and 10mM tetrabutylammonium hydrogen sulfate, pH 6.5 mixed with methanol (buffer 
A= 91.7% salt solution and 8.3% methanol; buffer B=71.6% salt solution and 28.4% methanol) 
over a 40min time period. The elution gradient was as follows: 0-100%B for 0-24min, 1min at 
100%B and 100-0%B for 25-30min at a flow rate of 1ml/min. Samples with >80% ATP were 
used for subsequent dNTP measurements as reported (Ferraro, Franzolin et al. 2010; Ylikallio, 
Page et al. 2010). Briefly, 50µl reaction mixtures were prepared and incubated for 1hr. The 50µl 
reaction mixture contains 10µl cellular dNTP extract to be measured together with 40mM Tris-
HCl, pH7.4, 10mM MgCl2, 5mM dithiothreitol, 0.25µM oligonucleotide, 1.5µg RNase A, 
0.25µM labeled dATP (or labeled dTTP for the dATP assay) and DNA polymerase. For dATP 
and dTTP assays, 0.02 units and 0.025 units of Klenow enzyme (Fermentas) were used 
respectively and incubated at 37°C. For dGTP and dTTP assays, 0.2µl homemade Tag were used 
and incubated at 48°C. After 1hr incubation, 30µl reaction mixture was removed and spotted 
onto Whatman DE81 paper discs. Discs were washed three times in 5% Na2HPO4 and once each 
in dH2O and 95% EtOH. Discs were dried and counted on a Beckman Coulter LS6500 
scintillation counter. Standard curves were prepared using concentrated stocks of pure individual 
dNTPs (Fermentas).  
2.3.8 Electron Paramagnetic Resonance (EPR) assay and free tyrosyl radical 
measurement 
Rrm2 expressing 3T3 cells were cultured, collected in EPR buffer (50mM Hepes pH7.6 
and 5% glycerol) and transferred to a 3.8mm thin wall quartz EPR tube (Wilmad-LabGlass). The 
tube was spun down at 500xg for 5min at 4°C. Supernatant was removed and the remaining 
~200µl of packed cells were rapidly (<5s) frozen stepwise: first in methanol that had been pre-
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chilled over dry ice at ~ -70°C, followed by liquid N2. EPR instrument settings were as 
following: sweep time, 61 second; time constant, 0.163 seconds; modulation frequency 100kHz, 
modulation amplitude 1.0G; microwave power, 25dB (0.6325mW). Spectra data were acquired 
at 50K for 70 scans. 
2.3.9 RNR enzyme activity assay 
Rrm2 expressing 3T3 cells were cultured and collected in ice-cold activity assay buffer 
(50mM Hepes pH7.6 and 15mM MgCl2). Cells were subjected to 3 cycles of rapid freeze/thaw 
subsequent to the addition of EDTA-free protease inhibitor cocktails at the final concentration of 
2 tablets/ml (Roche) and the debris was removed by centrifugation at 13,000xrpm, 4°C for 
10min. The supernatant was used in subsequent CDP reductase activity assay. A typical assay 
mixture in a final volume of 135 µl contains, in final concentrations, 50mM Hepes pH7.6, 15mM 
MgCl2, 3mM ATP, 10mM NaF, 0.5mM [5-3H]-CDP, 2mM NADPH, 100µM E. coli Trx, 1µM E. 
coli TrxR, 6µM of human recombinant His6-Rrm1 and freshly prepared lysate. The assay 
mixture was preincubated at 37°C for 1min, and the reaction was initiated by the addition of 
lysate. Four 30µl aliquots were removed and quenched with 30µl 2% HClO4 at the designated 
time points over 3.5min, followed by immediate neutralization with 0.4M 30µl KOH (Aye, 
Brignole et al. 2012). dCDP production was analyzed as described (Steeper and Steuart 1970). 
Briefly, the neutralized aliquots were treated with calf alkaline phosphatase according to 
manufacturer’s protocol (Roche), and incubated for 2h at 37°C. Subsequent to the addition of 
1mM dC as carrier, the dephosphorylated samples were applied to a borate column to separate 
ribonucleosides ([5-3H]-Cyt) and deoxyribonucleosides ([5-3H]-dC). Water was applied to the 
column to elute the [5-3H]-dC product. The effluent was collected and [5-3H]-dC was quantified 
by determining the radioactivity with liquid scintillation counter. 
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2.3.10 HPRT mutagenesis assay 
Human osteosarcoma U2OS cells were pre-cleansed for existing HPRT mutation before 
the assay. U2OS cells were maintained in HAT media (standard culture media supplemented 
with 0.2mM sodium hypoxanthine, 0.4µM aminopterin, 0.02µM thymindine (GIBCO)) for two 
weeks. Cells were then recovered in HT media (standard culture media supplemented with 
0.1mM sodium hypoxanthine, 0.016µM thymidine (GIBCO)) for one week. After that, cells 
were transfected with vector, Rrm2, Rrm2-Y177F, Rrm2-Y370F, Rrm2-Fe6, Rrm2-T33A, 
Rrm2-T33A-Y177F, Rrm2-T33A-Y370F and Rrm2-T33A-Fe6 plasmids using polyethylenimine 
(PEI) transfection reagent together with PGK-puro plasmid (Ehrhardt, Schmolke et al. 2006). 
Transfected U2OS cells were cultured in standard culture media as 3T3 cells in 2.3.2. 48 hours 
after transfection, standard media was replaced by selection media containing 2.0µg/ml 
puromycin, which was changed every 2 days. After 8 days, puromycin-resistant colonies were 
pooled together and expanded for HPRT mutagenesis assay as described (Xu, Page et al. 2008; 
D'Angiolella, Donato et al. 2012).  
Basically, Rrm2 over-expressing U2OS cells were seeded at a density of 5 x 105 per 
10cm culture dish with 10 dishes total for each cell line. Cells were kept in HPRT media 
(selection media supplemented with 5µg/ml 6-thioguanine (Sigma)) for two weeks. 6-
thioguanian resistant colonies were stained by crystal violet and counted. Plating efficiency was 
determined by plating 100 cells per 10cm culture dish with 3 dishes total in selection media. 
After two weeks, colonies were stained by crystal violet and counted.  
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2.4 Results 
2.4.1 Overexpression of R2 in cells leads to increased production of reactive oxygen 
species (ROS) 
The small subunit R2 harbors di-nuclear iron centers that generate free radicals upon 
oxygen binding. To test whether elevated levels of R2 in cells affect their redox status, we 
measured superoxide levels as an indication of reactive oxygen species (ROS) production. 
Mouse 3T3 fibroblast cells overexpressing empty vector, Rrm1, Rrm2 and p53R2 were 
generated previously (Xu, Page et al. 2008) (see also Figure 2.1A). These cells were incubated 
with dihydroethidium (DHE) and imaged using confocal microscopy. Representative images of 
cells with red fluorescence are shown in Figure 2.1B. Fluorescence intensity was quantified by 
Image J and summarized in Figure 2.1C. As Figure 2.1 illustrated, overexpression of either small 
subunit, Rrm2 or p53R2, led to increased superoxide production in cells while overexpression of 
vector and the large subunit Rrm1 had no effect on cellular superoxide production.  
2.4.2 Di-nuclear iron center of Rrm2 contributes to increased ROS in cells 
To investigate the role of the di-nuclear iron center and the radical transfer pathway in 
Rrm2-induced ROS production in cells, a panel of Rrm2 mutants were generated and stably 
expressed in cells (Figure 2.2A). In Rrm2-Fe6 mutant, all six charged residues that coordinate 
the iron atom at the di-nuclear iron center were mutated to alanine (Strand, Karlsen et al. 2004). 
Rrm2-Y177F and Rrm2-Y370F had mutations in two essential tyrosine residues in the radical 
transfer pathway and could not produce free radicals at the corresponding tyrosine sites as shown 
in vitro with recombinant proteins (Potsch, Lendzian et al. 1999; Rova, Adrait et al. 1999). It is 
also shown in vitro that the Y370F mutation had no effect on free radical production at Y177 site  
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Figure 2.1 Overexpression of small subunit R2 leads to elevated levels of superoxide 
production in mouse fibroblasts. (A) Western blot showing the expression levels of RNR 
proteins in vector, Rrm1, Rrm2 and p53R2 transfected mouse cell lines. (Figure from Xu, Page 
et al. 2008). (B) Representative pictures showing red fluorescence of dihydroethidium (DHE) 
stained vector, Rrm1, Rrm2 and p53R2 expressing cells. Images were taken at 20x with 405nm 
excitation and 530nm emission. Corresponding bright field images were also shown. (C) Bar 
graph showing the fold change of superoxide levels in Rrm1, Rrm2 and p53R2 expressing cells 
as compared to the vector control. 175 cells for each cell line from 4 independent experiments 
were quantified and fluorescence levels were normalized against the vector control (*** 
P<0.001, two way ANOVA, error bars indicate standard deviation).  
 
 
 
 
Vector Rrm1 Rrm2 p53R2
DH
E
Br
ig
ht
 F
ie
ld
A
B
C
vec
tor
Rrm
1
Rrm
2
p5
3R
2
0.0
0.5
1.0
1.5
2.0
2.5
Fo
ld
 ch
an
ge
 o
f R
OS
 le
ve
l
***"
#175"cell"counts""from""
4"independent"experiments"
#Two"way"ANOVA,"P<0.0001"
***"
 59 
 
 
 
 
  
Figure 2.2 Enzymatic activity and EPR spectra in Rrm2 wild type and mutant expressing 
cells. (A) Western blot showing the expression levels of Rrm2-Y177F, Rrm2-Y370F and Rrm2-
Fe6 in transfected mouse 3T3 cells. (B) EPR spectra of the Y177 site in Rrm2 wild type and 
mutant expressing 3T3 cells. Free radical production at Y177 site was detected in Rrm2 wild 
type and Rrm2-Y370F proteins while Rrm2-Y177F and Rrm2-Fe6 proteins were defective for 
free radical production. (C) Rrm2 wild type overexpressing 3T3 cells showed higher enzymatic 
activity than the vector control while Rrm2-Y177F, Rrm2-Y370F and Rrm2-Fe6 were all 
enzymatically inactive.  
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(Rova, Adrait et al. 1999). Due to the inability to transfer free radicals, recombinant Rrm2-
Y177F and Rrm2-Y370F were shown to be enzymatically inactive in vitro (Potsch, Lendzian et 
al. 1999; Rova, Adrait et al. 1999).  
Before we looked at ROS production in these mutants, we wanted to test whether the 
observations on radical production and enzyme activity in Rrm2-Y177F and Rrm2-Y370F held 
true in our in vivo cell culture system. We also wanted to investigate the effects of complete di-
nuclear iron center disruption in Rrm2-Fe6 on radical production and RNR enzyme activity. 
Electron paramagnetic resonance (EPR) was used to track free radical production at the Y177 
site in these mutants. As shown by Figure 2.2B, 3T3 cells overexpressing wild-type Rrm2 and 
Rrm2-Y370F had free radical production at Y177 site while cells overexpressing either Rrm2-
Y177F or Rrm2-Fe6 had no free radical at Y177 site. These results correlated well with 
previously published in vitro data of Rrm2-Y177F and Rrm2-Y370F, and also demonstrated the 
importance of the di-nuclear iron center in free radical production in Rrm2.  
Next, we measured RNR enzyme activity in cells expressing Rrm2-Y177F, Rrm2-Y370F 
and Rrm2-Fe6. As shown in Figure 2.2C, cells overexpressing wild-type Rrm2 showed increased 
RNR enzyme activity compared to cells with endogenous RNR expression. In contrast, cells 
overexpressing Rrm2-Y177F, Rrm2-Y370F and Rrm2-Fe6 showed minimal RNR enzyme 
activity. This result confirmed the in vitro observation of loss of enzyme activity in Rrm2-Y177F 
and Rrm2-Y370F. It also provided evidence on loss of activity in Rrm2-Fe6 mutant, indicating 
that free radical production and transfer are essential for RNR enzyme activity. 
With the mutants behaving as expected in terms of Y177 radical production and enzyme 
activity, we then examined the levels of superoxide in cells over-expressing these mutants by 
DHE staining. Representative images in Figure 2.3A and 2.3B showed that increased superoxide  
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Figure 2.3 The effect of Rrm2 mutant overexpression in cells on superoxide production. (A) 
Representative pictures showing red fluorescence of DHE stained Rrm2-Y177F and Rrm2-
Y370F expressing cells. Corresponding bright field images were also shown. Images were taken 
at 20x with 405nm excitation and 530nm emission. (B) Representative pictures showing red 
fluorescence of DHE stained Rrm2-Fe6 expressing cells. Corresponding bright field images were 
also shown. Images were taken at 40x with 405nm excitation and 530nm emission. (C) Bar 
graph showing the fold change of superoxide levels in Rrm2 wild type and mutant expressing 
cells as compared to the vector control. For staining with Rrm2-Y177F and Rrm2-Y370F, 285 
cells for each cell line from 7 independent experiments were quantified; for staining with Rrm2-
Fe6, 200 cells from 3 independent experiments were quantified. All fluorescence levels were 
normalized to the vector control (***P<0.001, two way ANOVA).  
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was observed in Rrm2-Y177F and Rrm2-Y370F expressing cells while Rrm2-Fe6 expressing 
cells had basal level superoxide production. Image J quantification of red fluorescence further 
confirmed this observation (Figure 2.3C). Taken together, these results demonstrated that 
complete disruption of the di-nuclear iron center in Rrm2-Fe6 mutant resulted in loss of free 
radical production and rendered the levels of superoxide comparable to control cells, suggesting 
that increased superoxide in Rrm2 over-expressing cells resulted from free radical production at 
the di-nuclear iron center and was not affected by the status of the free radical transfer pathway. 
2.4.3 Y177F and Y370F expressing cells have mild mitochondrial genome instability and 
mitochondrial redox imbalance  
Although p53R2 is responsible for mitochondrial DNA (mtDNA) synthesis in resting 
cells, Rrm2 provides dNTPs for nuclear DNA and mtDNA synthesis in proliferating cells 
(Hakansson, Hofer et al. 2006; Pontarin, Ferraro et al. 2012). We were interested in whether 
introducing the Rrm2 mutants (Rrm2-Y177F, Rrm2-Y370F and Rrm2-Fe6) into cells would 
have dominant negative effects that may affect nuclear and mitochondrial DNA synthesis. Since 
mitochondria are a major source of cellular ROS (Kirkinezos and Moraes 2001), we were 
particularly interested in the effect of Rrm2 mutants on mitochondrial function and 
mitochondrial redox status. In order to examine this, we looked at the levels of mitochondrial 
DNA in Rrm2 mutant overexpressing cells. As shown in Figure 2.4A, Rrm2-Y177F and Rrm2-
Y370F expressing cells showed about 50% depletion of mtDNA as compared to the vector 
control. In contrast, Rrm2-Fe6 had minimal effects on the levels of mtDNA in cells. In addition, 
there was a consistently slight, but not significant decrease of mtDNA in cells overexpressing 
wild type Rrm2. 
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Figure 2.4 Rrm2-Y177F and Rrm2-Y370F expression in cells leads to mitochondrial DNA 
depletion and excessive mitochondrial ROS production. (A) Mitochondrial DNA (mtDNA) 
levels in 3T3 cells transfected with vector, Rrm2, Rrm2-Y177F, Rrm2-Y370F and Rrm2-Fe6. 
Total DNAs from these cells were extracted and analyzed by qPCR. The level of cytochrome c 
oxidase subunit 1 (CO1) gene was used to assess the level of mtDNA and the level of GAPDH 
gene was used as the internal nuclear control. mtDNA levels from 4 independent experiments 
were analyzed (***P<0.001, **P<0.01, one way ANOVA). (B) Representative pictures showing 
red fluorescence of MitoSox Red stained Rrm2-Y177F and Rrm2-Y370F expressing cells. 
Corresponding bright field images were also shown. Images were taken at 40x with 514nm 
excitation and 575nm emission. (C) Bar graph showing the fold change of mitochondrial ROS 
levels in Rrm2 wild type, Rrm2-Y177F and Rrm2-Y370F expressing cells as compared to the 
vector control. 200 cells for each cell line from 4 independent experiments were quantified and 
all fluorescence levels were normalized to the vector control (***P<0.001, two way ANOVA).  
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Next, we looked at the consequence of mtDNA depletion in Rrm2-Y177F and Rrm2-
Y370F expressing cells.  Previous studies have shown that mtDNA mutations and depletions 
led to altered mitochondrial redox homeostasis (Chomyn and Attardi 2003; Ishikawa, Takenaga 
et al. 2008; Lebedeva, Eaton et al. 2009). We then measured the levels of superoxide in 
mitochondria by staining Rrm2-Y177F and Rrm2-Y370F expressing cells with a mitochondria 
specific superoxide indicator MitoSox Red. As shown in Figure 2.4B and 2.4C, Rrm2-Y177F 
and Rrm2-Y370F expressing cells showed significant increase in mitochondrial superoxide 
production. In addition, there was a slight, but significant increase of mitochondrial superoxide 
in cells that overexpress wild type Rrm2. In conclusion, these data indicated that Rrm2-Y177F 
and Rrm2-Y370F mutants interfered with mitochondrial DNA synthesis in cells. Overexpression 
of these mutants led to mtDNA depletion and excessive superoxide production in cells. 
2.4.4 Y177F and Y370F mutants lead to mitochondrial dysfunction by interfering with 
endogenous Rrm1 
Y177F and Y370F over-expressing cells showed decreased mtDNA level and increased 
mitochondrial superoxide production. We hypothesized that these two mutants had dominant 
negative effects in cells by interfering with the endogenous Rrm1 large subunit. It was possible 
that Y177F and Y370F mutants bind to endogenous Rrm1 subunit and formed inactive RNR 
complex. As a consequence, the level of endogenous Rrm1 available for making wild type RNR 
was decreased, which could result in decreased levels of functional RNR, limited dNTP 
synthesis and compromised mtDNA replication. In order to test this hypothesis, we first 
generated Rrm2 mutants that could not bind to Rrm1. Rrm2 C terminus (either the last 7 or the 
last 20 C-terminal residues) had been shown to mediate the binding between Rrm1 and Rrm2 
(Climent, Sjoberg et al. 1992; Lycksell, Ingemarson et al. 1994). We generated Rrm2Δ7, 
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Rrm2Δ20, Rm2-Y177FΔ7, Rrm2-Y177FΔ20 and Rrm2-Y370FΔ7 mutants by truncating the last 
7 or the last 20 residues of the C-terminus.  
In order to examine the interaction between Rrm2 C terminal truncation mutants and 
Rrm1, we made GST tagged proteins, GST-Rrm2, GST-Rrm2Δ7 and GST-Rrm2Δ20. After 
purification by glutathione beads, GST tagged Rrm2 proteins were incubated with 293 cell 
lysates and the binding to endogenous Rrm1 was assayed by western blot. As indicated by Figure 
2.5A (left panel, while GST-Rrm2 successfully pulled down endogenous Rrm1, GST-Rrm2Δ7 
and GST-Rrm2Δ20 were not able to interact with endogenous Rrm1. Since GST-Rrm2-Y177F 
and GST-Rrm2-Y370F were able to interact with endogenous Rrm1 (Figure2.5A right panel), 
this suggested that Y177F and Y370F mutations had no effect on Rrm2 and Rrm1 binding. 
Therefore, we expected that Rrm2-Y177FΔ7, Rrm2-Y177FΔ20 and Rrm2-Y370FΔ7 mutants 
were not able to bind endogenous Rrm1 as well. In addition, we were curious to see whether 
disruption of the di-nuclear iron center would change the overall structure of Rrm2 and affect 
binding to Rrm1. As shown in Figure 2.5A (right panel), complete disruption of the di-nuclear 
iron center in Rrm2-Fe6 had no effect on Rrm2 and Rrm1 binding.  
After confirmation of loss of interaction between Rrm2 C-terminal truncation mutants 
and Rrm1, we generated 3T3 cells over-expressing these C-terminal truncation mutants (Figure 
2.5B). When mtDNA and mitochondrial superoxide levels were studied, we observed normal 
mtDNA and mitochondrial superoxide levels in these cells (Figure 2.5E and 2.5F). These results  
suggested that in cells expressing Rrm2 C-terminal truncation mutants that could not interact 
with endogenous Rrm1, the dominant negative effect was disrupted, which brought the mtDNA 
and mitochondrial superoxide levels back to normal. We also examined the cellular superoxide 
levels in these Rrm2 C-terminal truncation mutants using DHE staining. As shown in Figure  
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Figure 2.5 Rrm2-Y177F and Rrm2-Y370F mutants cause mitochondrial dysfunction by 
interfering with endogenous Rrm1. (A) Left panel: pull-down assay showing the disruption of 
Rrm1 and Rrm2 interaction in Rrm2-Δ7 and Rrm2-Δ20. Right panel: pull-down assay showing 
normal interaction between Rrm2-Y177F, Rrm2-Y370F, Rrm2-Fe6 and Rrm1. GST tagged 
Rrm2 wild type and mutant proteins were bound to glutathione beads, incubated with 293 cell 
lysates and western blotted to detect the association with Rrm1. (B) Western blot showing the 
expression levels of Rrm2 C terminal truncation mutants, Rrm2-Δ7, Rrm2-Δ20, Rrm2-Y177F-
Δ7, Rrm2-Y177F-Δ20 and Rrm2-Y370F-Δ7 in transfected mouse 3T3 cells. (C) Representative 
pictures showing red fluorescence of DHE stained Rrm2-Δ7, Rrm2-Δ20, Rrm2-Y177F-Δ7, 
Rrm2-Y177F-Δ20 and Rrm2-Y370F-Δ7 expressing cells. Corresponding bright field images 
were also shown. Images were taken at 20x with 405nm excitation and 530nm emission. (D) Bar 
graph showing the fold change of superoxide levels in Rrm2 wild type and mutant expressing 
cells as compared to the vector control. 150 cells for each cell line from 3 independent 
experiments were quantified. All fluorescence levels were normalized to the vector control 
(***P<0.001, two way ANOVA). (E) No changes in mtDNA levels were observed in 3T3 cells 
overexpressing Rrm2 C-terminal truncation mutants. mtDNA levels in these cell lines were 
measured using qPCR as in Figure 2.4A (3 independent experiments, one way ANOVA). (F) No 
change in mitochondrial superoxide levels were observed in 3T3 cells overexpressing Rrm2 C-
terminal truncation mutants. Mitochondrial superoxide levels in these cell lines were measured 
using MitoSox Red staining and quantified using Image J as in Figure 2.4B and 2.4C. 100 cells 
from 2 independent experiments were analyzed (***P<0.001, two way ANOVA). 
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2.5C and 2.5D, all Rrm2 C-terminal truncation mutants showed increased cellular superoxide 
levels. This further suggested that as long as the di-nuclear iron center was intact, there were 
increased cellular superoxide levels in Rrm2 and this superoxide production was not affected by 
the disruption of radical transfer and interaction between Rrm1 and Rrm2. 
2.4.5 The role of ROS production in Rrm2-induced mutagenesis and tumorigenesis 
It is shown that Rrm2 overexpression in 3T3 cells led to increased mutation frequency 
and Rrm2 overexpression in mice led to lung tumor development (Xu, Page et al. 2008). 
However, the molecular mechanism of R2-induced mutagenesis and tumorigenesis is not known. 
In this study, we showed that increased Rrm2 levels in cells led to increased RNR enzyme 
activity (Figure 2.3A) and increased ROS production (Figure 2.1B and 2.1C). Since preliminary 
dNTP measurement in Rrm2 overexpressing cells didn’t show significant changes (Figure 2.6), 
we were interested in whether Rrm2-induced ROS production had a direct role in Rrm2-induced 
mutagenesis and tumorigenesis independent of RNR enzyme activity.  
The panel of Rrm2 mutants generated in this study could be divided into two categories: 
one could not produce free radicals and had no enzyme activity such as Rrm2-Fe6; the other 
could produce free radicals but had no enzyme activity such as Rrm2-Y177F and Rrm2-Y370F. 
With these two types of Rrm2 mutants in hand, we were able to compare their effects on 
mutation frequency in cells and examine whether ROS production can lead to increased 
mutagenesis.  
In order to study this, we generated U2OS cells that overexpressed vector, Rrm2, Rrm2-
Fe6, Rrm2-Y177F and Rrm2-Y370F. HPRT assay was used to measure the mutation frequency 
in these cells. However, cells expressing wild type Rrm2 only showed slight increase in mutation 
frequency, making the comparison with mutation frequency in Rrm2 mutants hard (data not  
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Figure 2.6 Total cellular dNTP levels in (A) proliferating Rrm2 and p53R2 expressing 3T3 
cells and (B) RNR transgenic lung tissues. Total nucleotides were extracted from cells and 
each dNTP was measured by an indirect enzymatic assay. Each data point represents the mean of 
three independent experiments, with error bars representing the standard deviation. (Data 
collected and figure prepared by Dr. Xia Xu, 2008).  
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Figure 3.1  Intracellular dNTP pools in logarithmically growing RNR over-expressing 
3T3 cells or RNR transgenic lung tissues. Intracellular dNTPs were extracted and 
quantified from (A) logarithmically growing 3T3 cells overexpressing Rrm1, Rrm2, 
p53R2, or containing the empty plasmid vector and (B) RNR transgenic lung tissues, 
using an enzymatic assay as described in Materials and Methods. Each data point 
represents the mean of three independent experiments, with error bars representing the 
standard deviation.
 72 
shown). In order to circumvent the problem, we decided to perform HPRT assay in a sensitized 
background, where we introduced Y177F, Y370F and Fe6 mutations into Rrm2-T33A mutant 
background. Rrm2-T33A is a non-degradable Rrm2 mutant and has been shown to cause more 
than 20x increase in mutation frequency in U2OS cells compared to control cells (D'Angiolella, 
Donato et al. 2012). By combining our Rrm2 mutants with Rrm2-T33A, we expect to establish a 
condition where we can analyze and compare mutation frequency in different Rrm2 mutants. 
2.5 Discussion 
In this study, we investigated the effect of the small subunit Rrm2 deregulation on redox 
homeostasis and mitochondrial function in cells. 3T3 cells overexpressing Rrm2 wild type 
showed increased levels of RNR enzyme activity, Y177 tyrosyl radical production and increased 
superoxide generation. Complete disruption of the di-nuclear iron center of Rrm2 in Rrm2-Fe6 
mutant renders Rrm2 protein enzymatically inactive and Y177 radical production defective. As a 
consequence, Rrm2-Fe6 mutant has no effect on superoxide production in cells, indicating that 
functional di-nuclear iron center contributes to increase superoxide generation in Rrm2 wild type 
over-expressing cells. The discovery of Rrm2-induced superoxide production is consistent with 
published work where human recombinant Rrm2 showed increased hydrogen peroxide (H2O2) 
production in vitro (Liu, Xue et al. 2008). Since p53R2 has intact di-nuclear iron center as Rrm2, 
it is not surprising that p53R2 overexpressing cells also showed elevated superoxide levels in our 
study. However, this is opposite to published work. In the same paper that showed increased 
H2O2 production by Rrm2, human recombinant p53R2 was shown to have antioxidant activity in 
vitro (Liu, Xue et al. 2008). With inadequate information provided in the paper, we were not able 
to assess how much recombinant p53R2 and Rrm2 proteins were added to the assay system, 
whether these amounts reflected equal activity of the two subunits and how stable these subunits 
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were during the 30min assay period. Since Fe is required for R2 radical production, it is also not 
clear whether and how much Fe had been supplemented. 
Two Rrm2 mutants, Rrm2-Y177F and Rrm2-Y370F that have mutations in the radical 
transfer pathway of Rrm2, caused increased superoxide production in cells (about 1.7-fold 
increase). These mutants also lead to about 1.3-fold increase in mitochondrial superoxide 
production through their dominant negative effects, suggesting that there are two sources for the 
observed overall increase in superoxide levels: the intact di-nuclear iron center and the 
dysfunctional mitochondria. 
However, when the overall cellular superoxide levels were measured in cells with Rrm2 
C-terminal truncation mutants that do not have dominant negative effect, no corresponding 
decrease in overall superoxide levels were observed. Instead, the levels of superoxide in these 
cells were comparable to those of Rrm2-Y177F and Rrm2-Y370F expressing cells where about 
1.7-fold increase in overall superoxide was detected. This discrepancy could be due to the nature 
of the ROS indicator used. DHE is often used as an indicator of overall cellular superoxide 
levels. However, it only localizes in the cytosol and does not go to the mitochondria. It measures 
overall cellular superoxide because mitochondrial superoxide production can affect the cytosolic 
superoxide readout. As a result, the overall superoxide levels measured by DHE in the study may 
mainly reflect cytosolic superoxide changes. It is possible that the change in mitochondrial 
superoxide production is not strong enough to affect the cytosolic superoxide production and to 
be detected by DHE staining. This also suggests that increased mitochondrial superoxide 
production in Rrm2-Y177F and Rrm2-Y370F expressing cells only has minor contribution to the 
overall increased superoxide production observed in these cells.  
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Human p53R2 protein with truncation of the last 25 residues of the C-terminus leads to a 
disease called autosomal-dominant progressive external ophthalmoplegia (adPEO), which is a 
mitochondrial disorder that is characterized by accumulation of mtDNA deletions in postmitotic 
tissues. Because the mutant protein causes a dominant trait, it is hypothesized that this p53R2 
truncation mutant can compete with the wild-type p53R2 in forming the heterotetramer, resulting 
in a gain of function or a dominant negative effect of RNR in cells (Tyynismaa, Ylikallio et al. 
2009). Our Rrm2 C-terminal truncation mutants didn’t show dominant negative effect and had 
normal mtDNA levels. This could be due to the fact that in cells overexpressing Rrm2 C-
terminal truncation mutants, the p53R2 protein level is normal. Since the Rrm2 C-terminal 
truncation mutants cannot bind and interfere with endogenous Rrm1, there is enough Rrm1 
subunits to form an active RNR with p53R2, which is the primary complex that is responsible for 
providing dNTPs for mtDNA replication. It would be interesting to introduce the p53R2 C-
terminal truncation mutants into cells and investigate whether this will lead to mtDNA deletions 
as observed in human patients.  
The dominant negative effect suggested here proposed that Rrm2-Y177F and Rrm2-
Y370F mutants interfere with endogenous Rrm1 and decrease the level of functional RNR (both 
the Rrm1-Rrm2 and Rrm1-p53R2 form of RNR) in cells, resulting in limited dNTPs for mtDNA 
synthesis. dNTP pools in cells overexpressing Rrm2-Y177F and Rrm2-Y370F were assayed 
(Sherman and Fyfe 1989; Ferraro, Franzolin et al. 2010), but no depletion in dNTP pools was 
observed (Figure 2.7). Since these cells also didn’t show any growth defects (Figure 2.8), this 
suggests that dNTP pool changes are small and our assay system may not be sensitive enough to 
detect such small changes.  
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Figure 2.7 Total cellular dNTP levels in Rrm2-Y177F and Rrm2-Y370F overexpressing 
cells. Total nucleotides were extracted from cells and each dNTP was measured by an indirect 
enzymatic assay. Each data point represents the mean of two independent experiments, with 
error bars representing the standard deviation. 
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Figure 2.8 Proliferation of cells overexpressing Rrm2 WT and mutant proteins. Each cell 
line was cultured in standard culture media (see methods for details regarding the components of 
the media) and passed every 3 days with counting. Total population doublings were determined 
and plotted against time. 
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When mitochondrial superoxide levels were measured, besides the increased superoxide 
production in Rrm2-Y177F and Rrm2-Y370F cells, Rrm2 over-expressing cells also showed a 
slight, but significant increase in mitochondrial superoxide production. This could be due to the 
increased RNR activity and subsequent changes in dNTP pools in these cells. It has been shown 
that Rrm2 over-expressing transgenic mice had dNTP pool changes and progressive mtDNA 
depletion in skeletal muscle, supporting the idea that Rrm2 overexpression can lead to dNTP 
pool imbalance and affect mitochondria function (Ylikallio, Page et al. 2010). Again, our dNTP 
assay system may not be sensitive enough to detect such changes. 
We showed that about 50% mtDNA depletion is associated with about 1.3-fold increase 
in mitochondrial superoxide production. This same mtDNA depletion level has been shown to 
cause significant disruption of cellular ROS homeostasis in p53 null cells. These cells are 
characterized by reduced mitochondrial and cellular superoxide levels (50% reduction) and 
increased cellular hydrogen peroxide (1.8-fold increase) (Lebedeva, Eaton et al. 2009). The 
opposite changes in superoxide levels in our R2-expressing cells and the p53 null cells could be 
due to following reasons. In the Lebedeva study, the concentration of DHE used to measure 
overall superoxide production was 40x more than that used in our study (80µM vs. 5µM, with 
5µM commonly used). Too much loading of fluorescent dyes to cells can disrupt the redox status 
of cells in study as the probes can act as either antioxidants or prooxidants (Sen and Packer 
2002). Furthermore, the Lebedeva study used p53 null cells. Since p53 is a transcription factor 
that is involved in many cellular processes, decreased mitochondrial superoxide production in 
p53 null cells may not be directly associated with mtDNA depletion. It has been shown that p53 
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represses activity of manganese superoxide dismutase (MnSOD), the mitochondrial enzyme 
responsible for the conversion of superoxide to hydrogen peroxide, in human cells (Drane, 
Bravard et al. 2001). As a result, knocking-out p53 could lead to decreased superoxide and 
increased hydrogen peroxide production independent of mtDNA levels. 
Rrm2-Fe6 mutant binds to the large Rrm1 subunit, suggesting that disrupting the di-
nuclear iron center does not affect the subunit interaction. It is surprising that Rrm2-Fe6 didn’t 
show the same dominant negative effects as Rrm2-Y177F and Rrm2-Y370F. When culturing 
cells expressing Rrm2-Fe6, we noticed that these cells showed gradually decreased growth 
compared to Rrm2 wild type and other Rrm2 mutant cell lines (Figure 2.8). This observation 
suggests that Rrm2-Fe6 may have dominant negative effects in cells and may be selected against. 
This dominant negative effect could be the same as Rrm2-Y177F and Rrm2-Y370F where the 
mitochondrial function is affected. It could also be something different and more severe. For 
example, the dNTP pool balance may be more severely disrupted in Rrm2-Fe6 mutant, which 
affects not only the mitochondrial, but also the nuclear genome integrity. In the current study, all 
experiments performed on Rrm2-Fe6 mutant used early passage cells that grow normally and no 
defects in mtDNA synthesis was detected. It would be worth investigating the dNTP pools, 
mitochondrial and nuclear genome integrity and redox status in later slow-growing Rrm2-Fe6 
mutant.  
One important question we want to address is the downstream effect of R2-induced ROS 
production. Elevated ROS levels in cells have been shown to cause oxidative stress and promote 
mutagenesis and tumorigenesis (Droge 2002; Valko, Rhodes et al. 2006). Superoxide-generating 
proteins of the NADPH oxidase family have been shown in vitro to cause increased superoxide 
production and cell transformation when overexpressed alone or together with Ras (Irani, Xia et 
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al. 1997; Suh, Arnold et al. 1999; Mitsushita, Lambeth et al. 2004; Block and Gorin 2012). In 
addition, proteins that can sense oxidative stress and induce apoptosis help prevent ROS 
accumulation and thus their carcinogenic effects in cells (Dolado, Swat et al. 2007). We are 
currently investigating whether R2-induced ROS plays a direct role in mutagenesis and 
tumorigenesis. With the panel of Rrm2 mutants in hand, we are studying the mutagenic effect of 
Rrm2 mutants that can produce free radicals, but are enzymatically inactive (Rrm2-Y177F and 
Rrm2-Y370F), as well as Rrm2 mutant that is defective for both free radical production and 
enzyme activity (Rrm2-Fe6). If Rrm2-Y177F and Rrm2-Y370F show increased mutation 
frequency while Rrm2-Fe6 does not, this would suggest a role of R2-induced ROS in 
mutagenesis.   
In conclusion, we showed that overexpression of the small subunit of RNR, R2, leads to 
increased ROS production in cells. The di-nuclear iron center of R2 produces free radicals and 
contributes to this increase in ROS. When charged residues critical for iron coordination were 
mutated in Rrm2-Fe6, there is no elevated ROS production in cells. Moreover, when critical 
tyrosine residues in the radical transfer pathway were mutated to non-hydrolysable residues in 
Rrm2-Y177F and Rrm2-Y370F mutants, they lost RNR enzyme activity. However, because the 
di-nuclear iron center is still intact, these mutants lead to increased ROS in cells. On top of this, 
they also have dominant negative effect by interfering with endogenous large R1 subunit, leading 
to mild mtDNA depletion and increased mitochondrial ROS production, which has a minor 
contribution to the increased overall ROS in cells. This panel of Rrm2 mutants gives us a great 
opportunity to study the role of RNR in redox homeostasis, mitochondrial function and the role 
of R2-induced ROS in mutagenesis and tumorigenesis.   
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3.1 Abstract 
Computed tomography (CT) is among the non-invasive imaging modalities for monitoring lung 
tumor growth in humans. Manual or semi-automated methods are used to calculate the tumor 
size, and an exponential growth model is used to predict tumor growth. However, current 
measurement methodologies are often time-consuming and lack consistency. In addition, 
knowledge of in vivo lung tumor growth patterns in humans is limited. Treatment of lung cancers 
in humans often involves surgical resection of the primary tumor, and individual patients rarely 
are subjected to multiple sequential CT scans because of the associated radiation exposure. In 
this study, we monitored lung tumor growth rate in a mouse model of lung cancer by micro-CT 
and developed an automated algorithm to measure tumor size at an early stage. Transgenic mice 
over-expressing the enzyme ribonucleotide reductase (RNR) develop non-small cell lung cancers 
at approximately 12 months of age and in this study were scanned four to six times with at least a 
three-week time interval in between the scans. Six tumors from four mice was analyzed and all 
showed an exponential growth pattern in vivo. The average tumor doubling time was about 71 
days, while tumors of smaller initial size grew faster. These results establish automated 
algorithms to measure early stage lung tumor volume and confirm the exponential lung tumor 
growth model in humans. The improved computational methods developed here, as well as a 
better understanding of mouse lung tumor growth patterns, are expected to serve as a resource 
that will aid efforts to improve lung cancer diagnosis and the evaluation of therapeutic responses. 
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3.2 Introduction 
Lung cancer is the leading cause of cancer death among both men and women 
worldwide. The five-year survival rate for lung cancer is only 16%, as compared to 89% and 
100% for breast and prostate cancers, respectively. If lung cancers are detected and treated in 
their earliest stages, the survival rate can be improved to 92% (Jemal, Siegel et al. 2010). Not 
only is the detection of lung tumors critical, but measuring disease progression and treatment 
response is also important for improving patient care. Such clinical data can be collected using 
non-invasive imaging techniques, such as X-ray computed tomography (CT). CT images are 
generated based on X-ray attenuation by tissues, with the degree of attenuation proportional to 
the tissue density. CT instruments generate a series of 2D X-ray images, which are stacked 
together to produce a 3D image. Based on these images, clinicians can identify and measure 
potential lung neoplasms.  
Tumor size and growth rate are key criteria for cancer staging and can be used to evaluate 
the effectiveness of therapies. Measurement of these parameters must be highly accurate in order 
for CT scans to be useful for clinical purposes. Accurate quantification of tumor growth requires 
optimization of CT scan parameters and measurement software using extensive data sets with 
growing tumors. However, these data sets are not readily available for human patients because of 
the large number of repeated CT scans required and the associated X-ray dosage concerns. 
Furthermore, human patients are subjected to clinical interventions that include surgical resection 
or therapies that impair growth. As a result, much of the research on evaluating measurement 
methods has relied on the use of repeat “coffee break” scans, in which patients are scanned twice 
over a short period of time (Goodman, Gulsun et al. 2006; Gietema, Schaefer-Prokop et al. 2007; 
Zhao, James et al. 2009; Oxnard, Zhao et al. 2011); or the use of repeat scans obtained during 
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image-guided biopsy of pulmonary nodules (Reeves, Jirapatnakul et al. 2009). These studies 
have reported repeat scan variability of around 25% volume change. However, it is unclear 
whether these data can be extrapolated to the measurement of growing tumors.  
One approach to quantify tumor growth is to combine an empirical tumor volume 
measurement with a mathematical model for tumor growth rate. The two most commonly used 
growth models are the exponential growth model, where the growth rate is proportional to the 
current value and continues indefinitely, and the Gompertzian growth model, which resembles 
the exponential growth model initially but reduces the growth rate as time progresses. However, 
due to the reasons noted above, the in vivo growth of human lung tumors has not been 
extensively studied. Another complication for accurately measuring tumor growth is the variance 
in ground truth. Several studies have suggested that manual measurements of tumor size by 
radiologists are inconsistent (Marten, Auer et al. 2006; Reeves, Biancardi et al. 2007; Ross, 
Miller et al. 2007) and should not be relied upon to provide ground truth. In order to circumvent 
the limitations of human CT cans, we used a mouse model of lung cancer to develop automated 
methods for accurate tumor growth rate and growth pattern determination. Because we examined 
early lung tumor growth where the nutrients and space are not constrained for tumor cells, we 
hypothesized that an exponential growth pattern would be observed.  
Mouse models have great value for the study of lung cancer, and micro-CT has been used 
to detect and measure tumors (Cavanaugh, Cody et al. 2004; Veldhuizen, Ford et al. 2007). 
Investigation of disease progression and therapeutic responses are of particular interest in these 
animal models, and require accurate and consistent methods for tumor growth measurements. 
Currently, most tumor measurements on murine micro-CT scans are performed using basic tools. 
Haines et al. applied thresholds to CT images and separated lung parenchyma from soft tissue 
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structures by region growing and manual contouring. The change in soft tissue volume was used 
as a measure of tumor burden (Haines, Bettano et al. 2009). Fushiki et al. used a similar method 
with additional manual and semi-automated segmentation to select only neoplastic tissue 
(Fushiki, Kanoh-Azuma et al. 2009). A more advanced method applied a semi-automated tool 
which presented a preliminary automated tumor boundary. However, manual modification of the 
boundary was required to produce an acceptable segmentation (Cody, Nelson et al. 2005). All of 
these methods require extensive user interaction with the system, which is time-consuming and 
may result in measurement variability among different users. 
In this study, we utilized a mouse lung tumor model based on overexpression of the small 
subunit of the enzyme ribonucleotide reductase (RNR) (Xu, Page et al. 2008). RNR catalyzes the 
rate-limiting step in deoxyribonucleotide biosynthesis, and plays an essential role in the 
maintenance of genome integrity. RNR-overexpressing mice develop lung adenomas and 
adenocarcinomas that histopathologically resemble human papillary adenocarcinomas, the most 
common form of human non-small cell lung cancer. RNR-induced lung tumors arise via a 
mutagenic mechanism and frequently contain K-ras mutations, which also occur in 
approximately 30% of human lung adenocarcinomas (Reynolds and Anderson 1991; Reynolds, 
Wiest et al. 1992). In combination with deletion of the DNA mismatch repair gene Msh6, RNR 
overexpression results in lung neoplasms in 100% of mice by 6 months of age (Xu, Page et al. 
2008).  
Micro-CT images of RNR-induced murine lung neoplasms were measured using an 
automated algorithm adapted from tools for the measurement of pulmonary nodules on human 
chest CT scans. Initial imaging studies in mice were performed to optimize scan parameters and 
refine computational algorithms for tumor volume measurement. Four lung tumor-bearing mice 
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were then sequentially scanned for tumor growth rate determination by curve fitting. Our results 
indicate that the tumors demonstrated exponential growth, a finding that is consistent with 
modeling of growth patterns for human lung cancers. This study provided better tools for lung 
tumor measurements, as well as better insights into lung tumor growth, which can improve early 
detection and facilitate therapeutic evaluation of human lung cancers. 
3.3 Material and methods 
3.3.1 Animals, necropsy and histology analyses 
Rrm2 and p53R2 transgenic mice (Rrm2Tg and p53R2Tg) were described previously (Xu, 
Page et al. 2008). Msh6+/- mice (Edelmann, Yang et al. 1997) were obtained from the Mouse 
Models of Human Cancers Consortium and interbred with Rrm2Tg mice to generate Msh6-/-R2Tg 
experimental mice. All mice were maintained identically, following guidelines approved by the 
Cornell University Institutional Animal Care and Use Committee.  
After the final micro-CT scan, mice were euthanized by asphyxiation using carbon 
dioxide and necropsied. Lungs were imaged using a Canon digital camera and were inflated and 
fixed with 10% neutral-buffered formalin, embedded in paraffin, sectioned, and stained with 
hematoxylin and eosin (H&E). H&E sections of the lungs were scanned using the Aperio 
ScanScope and physical measurements of lung neoplasms were made using the Aperio software. 
Lung neoplasms were classified based on guidelines endorsed by the Mouse Models of Human 
Cancers Consortium (Nikitin, Alcaraz et al. 2004). 
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3.3.2 Micro-CT imaging 
3.3.2.1 Post-mortem imaging 
Preliminary scans of mice following euthanasia were used for initial development and 
verification of the algorithm. Nine mice were scanned after they were euthanized by carbon 
dioxide asphyxiation. These scans were acquired using a GE eXplore CT 120 micro-CT scanner. 
Scan parameters that varied in current, voltage, number of projections, number of frames to 
average, and reconstruction resolution were tested (Table 3.1). Three of the nine euthanized mice 
had visible tumors, which were used to test the automated tumor measurement methods.  
3.3.2.2 Live imaging 
In the live study scans, mice were first put in the induction chamber and anesthetized 
with a continuous flow of 4% isoflurane/oxygen mixture. When the animals stopped moving and 
their breathing slowed down, the isoflurane/oxygen mixture was reduced to 1-3% and 
maintained at this range during the duration of the micro-CT scan (Hung, Dodson et al. 2009). 
Scans of the thoracic region were acquired using the same micro-CT scanner with a current of 50 
mA and voltage of 100 kV. Each scan consisted of 720 projections in a single full rotation of the 
gantry. Two frames were acquired at each position of the gantry and averaged prior to being 
transferred to the workstation for reconstruction. Respiratory gating of the mice was achieved 
using the BioVet physiological monitoring and triggering system by m2m imaging corporation. 
A small external force by taping a piece of paper tower to the back of the mouse was applied in 
order for the mouse to activate the pressure sensor used for respiratory gating. Micro-CT images 
were reconstructed at 50 µm3 voxel dimensions. The final image volume varied according to the 
selected region of interest, but typically ranged from 400 x 400 x 500 slices to 800 x 550 x 1000  
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Table 3.1a. Different scanner acquisition parameters tested in this study. 
# Current 
(mA) 
Voltage 
(kVp) 
Exposure 
time (ms) 
# of 
Views/scan 
Frame 
averaging 
SD 
(HU) 
1 32 70 32 220 1 53.3 
2 50 70 32 220 1 80.4 
3 32 80 32 220 1 45.6 
4 50 80 32 220 1 41.1 
5 50 100 32 220 1 39.2 
6 50 100 20 360 2 30.5 
 
a The intensities of small regions within the lung parenchyma were sampled and used to compute 
the standard deviation (SD). Higher standard deviation values indicate higher noise. 
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slices. Half of the total live scans had calibration phantoms included. Scans were converted from 
the manufacturer's proprietary format to DICOM and then imported into research software. 
3.3.3 Automated volumetric analysis 
The volume of the murine lung tumors was computed from the segmentation result 
produced by an automated algorithm. The algorithm was adapted from previous work on 
automated segmentation of lung tumors in whole lung CT scans of humans (Kostis, Reeves et al. 
2003). An overview of the algorithm, which consists of several stages, is presented in Figure 3.1. 
The user initiates the algorithm by drawing a line across the nodule indicating the nodule's 
extent. The algorithm uses the provided information to extract a region of interest to analyze. 
After pre-processing the image, an adaptive threshold is applied, followed by filtering to remove 
attached pulmonary vessels. If the nodule is juxtapleural, an additional step is performed to 
separate the nodule from the chest wall. The final result is a binary image containing only those 
voxels belonging to the nodule. The steps of the algorithm are described in further detail in the 
following sections.  
3.3.3.1 Region of interest pre-processing 
The endpoints of the line drawn by the user are used to estimate the location and size of 
the nodule. A large region of interest (ROI) corresponding to 5x5x5 cm cube is extracted from 
the whole micro-CT scan around the estimated center of the nodule. This large region of interest 
is analyzed to determine if the nodule is juxtapleural. A threshold is applied to the image and the 
connected component that contains the estimated nodule is kept. A nodule is considered 
juxtapleural if this connected component occupies more than 15% of the ROI. Depending on the 
outcome, different parameters are used to separate attached structures and an additional step to 
separate the nodule from the chest wall is performed.  
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Figure 3.1. Flowchart showing the major steps of the automated segmentation algorithm. 
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The next pre-processing step is to further refine the estimated nodule location and size in 
order to ensure consistency if the manually specified points are altered slightly. By modeling a 
pulmonary nodule as a sphere, we can use a 3D Laplacian of Gaussian (LoG) template to 
localize the nodule and a 3D Gaussian template to estimate the size. A LoG template is used to 
locate the nodule to account for nodules with attached structures. An iterative process is used to 
optimize the location and size using the LoG and Gaussian templates respectively. A sample 
result from this step is shown in Figure 3.2. 
The estimated nodule location and size are used to establish a tight region of interest 
around the nodule, which is set to twice the estimated size of the nodule. In the case of scans 
obtained in a longitudinal study, the ROI size is fixed to the same value for all scans in the study. 
This tight ROI is then resampled to provide subvoxel accuracy to help reduce the effects of 
partial voxels (Kostis, Reeves et al. 2003; Reeves, Chan et al. 2006). At the end of the pre-
processing step, we have a refined estimation of the nodule size and location and a tight region of 
interest both before and after resampling. 
3.3.3.2 Adaptive thresholding 
The next step in the segmentation algorithm is to threshold the region of interest to 
separate the soft tissue from the lung parenchyma. While the use of an adaptive threshold does 
not provide much benefit for segmenting nodules from human CT scans compared to a fixed 
threshold (Reeves, Chan et al. 2006), the murine micro-CT scans exhibited significant variation 
in the intensity of the lung parenchyma from one scan to another. To compensate for this 
variation, an adaptive threshold was selected for each scan. A histogram of the small region of 
interest, prior to resampling, was generated. A threshold was established based on the 
assumption that the histogram would be bi-modal, with one peak corresponding to the lung  
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Figure 3.2. A representative image showing size and location estimation of a nodule by the 
automated algorithm. Micro-CT image of an RNR transgenic mouse lung (transverse view) is 
shown, with a nodule highlighted in yellow by the algorithm. The image was derived from a scan 
taken at 50µm with 720 projections. The size of this nodule was estimated by the automated 
algorithm to be 1.41 mm in diameter, 1.46 mm3 in volume.  
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parenchyma and another to the soft tissue. The threshold was selected to be the midpoint of the 
two peaks, as shown by the plot in Figure 3.3. After the adaptive threshold was determined, the 
threshold was applied to the resampled ROI image to generate a binary image, with all soft tissue 
structures labeled. 
3.3.3.3 Pulmonary vessel removal 
To separate the nodule from attached structures such as pulmonary vessels, iterative 
morphological filtering is performed. A morphological opening is performed using a large 
spherical kernel to remove the vessel attachments, followed by a series of dilation operations 
with increasingly larger spherical kernels to regrow some of the fine surface features. This 
process is described in further detail by Kostis et al (Kostis, Reeves et al. 2003). Figure 3.4A, 
3.4B and 3.4C illustrate the effect of this step on a 3D reconstruction of the nodule region, 
showing the region before and after applying the vessel removal step. 
3.3.3.4 Chest wall removal 
Finally, if the nodule is juxtapleural, a surface-fitting approach is used to estimate the 3D 
shape of the chest wall or pleural surface in order to remove it from the segmentation. The 
pleural surface has low curvature and few inflection points, which suggests a model using a 
second or third degree polynomial function. A more detailed description of the work can be 
found in Jirapatnakul, A.C. et al (Jirapatnakul, Mulman et al. 2011).  
The nodule and pleural surface points were first extracted from the image by a 
morphological erosion and binary exclusive-OR (XOR) operation. Given two binary images, the 
XOR operation produces a binary image showing where the two input images differed. The 
surface points are those points belonging to either the nodule or pleural surface but having a lung 
parenchyma voxel as a neighbor. The average normal was computed from these surface points  
 94 
 
 
Figure 3.3. Histogram showing voxel intensities of the lung parenchyma and soft tissue in a 
region of interest. Voxel intensities of a region of lung from an RNR transgenic mouse 
including a nodule were sampled and used to create the histogram. Bins were set at 10 HU. The 
peak on the left represents the lung parenchyma and the peak on the right represents the soft 
tissue. The line in the middle indicates the calculated adaptive threshold by the automated 
algorithm. The data shown were from a scan taken at 50µm with 720 projections.  
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Figure 3.4. 3D visualization of the lung showing the steps of removing vessels and the chest 
wall from the segmented nodule. (A) Micro-CT image of a whole lung (transverse view) from 
an RNR transgenic mouse with a zoom-in image showing a nodule (yellow circle outlined by 
automated algorithm). 3D visualization of the lung from the same mouse with a nodule was 
created from the segmentation after (B) adaptive thresholding, (C) vessel removal, and (D) 
removal of the chest wall by the automated algorithm. The final result in (D) shows a successful 
segmentation of the nodule free of vessels and the chest wall. The 3D visualization was created 
based on a scan taken at 50µm with 720 projections.  
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and used to orient a coordinate system to simplify the calculation of the error in the estimated 
surface. The surface points were then mapped into this coordinate system.  
To estimate the surface, a hill climbing optimization method was used to search for the 
best parameters of a third degree polynomial function with the goal of minimizing the error of 
the estimated surface to the actual surface points. However, one important task is to distinguish 
the points belonging to the pleural surface from the points belonging to the nodule surface or 
other nearby structures. This is accomplished by first using only those surface points located far 
from the nodule and iteratively evaluating larger subsets of surface points until there is a large 
change in the estimated surface. A 3D reconstruction of the nodule is shown after juxtapleural 
segmentation in Figure 3.4D. 
3.3.3.5 Volume computation 
The result of the segmentation algorithm is a binary image, with the voxels belonging to 
the nodule labeled as 1 and all other voxels labeled as 0. The volume is computed by summing 
the number of voxels in the nodule segmentation and multiplying by the voxel size. If the 
removal of the chest wall is not complete, which is the most common problem of a non-
satisfactory segmentation, several parameters can be adjusted to change the segmentation: size of 
the morphological filter used for attachment removal, size of the volume of interest, and whether 
the nodule is juxtapleural, for nodules where the algorithm fails to correctly detect that the 
nodule is juxtapleural.  
3.3.4 Manual tumor measurements 
The growth measured by the automated algorithm was compared to the growth measured 
by an observer. The observer measured each tumor by selecting the axial slice through the tumor 
with the largest cross-sectional area and marking the largest diameter. This diameter was 
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converted to a volume measurement, assuming a spherical model, and this volume was compared 
to the volume measured by the algorithm. This closely mirrors the measurement method used in 
RECIST (Eisenhauer, Therasse et al. 2009). 
3.3.5 Growth analysis 
In this study, each mouse was scanned several times. Tumors were identified and their 
volumes were measured for each scan. Tumor growth can be determined from the tumor volume 
and time interval between scans. Exponential growth can be modeled by the following equation:  
 
where V1 is the volume at time t1, V2 is the volume at time t2, and r is the growth rate. After 
taking the natural log and rearranging the equation, we obtain the linear expression: 
 
When we plotted ln (volume) versus time and obtained the best-fit line, the slope of the line 
equals r in the growth equation.  
We calculated the tumor doubling time (DT, defined as ln2/r), as well as the growth index (GI) 
of tumors observed in the scans. We define GI, the percent tumor growth per month, as follows: 
 
Rearranging this equation gives a GI value that can be calculated using the slope r of the best-fit 
line: 
GI = 100[e30.4375r-1] 
In contrast to DT where a lower value indicates faster growth, a higher GI represents faster 
growth. DT can be converted to GI by the following equation: 
GI = 100[230.4375 / DT-1] 
€ 
V2 =V1er⋅(t2 − t1 )
€ 
r = ln(V2 /V1)(t2 − t1)
€ 
GI =100 (V2 /V1)(30.4375 /( t2 − t1 ) −1[ ]
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3.4 Results 
In this study, we used micro-CT to monitor the progression of murine lung tumors in vivo. 
Prior to performing imaging of live animals, we first performed post-mortem imaging of nice 
mice, three of which had lung neoplasms, in order to optimize micro-CT methods, scan 
parameters, and measurement algorithms. Figure 3.5A shows the micro-CT image of the lung 
from a euthanized mouse scanned with 360 projections and the image was reconstructed at 50 
micron resolution. The neoplasm identified in the micro-CT scan was also identified on the 
histological slide of the corresponding lung lobe (Figure 3.5B). The neoplasm is an adenoma, 
with a clear border between the solid tumor mass and the surrounding lung parenchyma. Higher 
magnification images of the histological section clearly showed that the tumor region is much 
denser than the surrounding lung parenchyma, hence the different densities of these tissues 
observed in micro-CT. The diameter of this tumor was measured to be 2mm at necropsy. The 
automated algorithm was used to measure the volume of the same tumor. The region of interest 
including the tumor is illustrated in Figure 3.5C, with every third image from the tumor 
segmentation shown. A 3D visualization of this segmented tumor was then generated with axial, 
sagittal and coronal views shown in Figure 3.5D. Consistent with the physical measurement at 
necropsy, the diameter computed by the algorithm was 1.82mm. Physical and computed 
measurements for three additional tumors from two tumor-bearing mice were compared and also 
found to be highly similar with the difference in tumor diameter between the two methods ranges 
from 3.8% to 32% (Table 3.2). Together, these results validate our computational methods for 
automated lung tumor measurement from micro-CT images of mice. 
The GE eXplore CT 120 micro-CT scanner was a newly released scanner at the time of 
this study. Therefore we tested different scan parameters to optimize the tradeoffs between  
 99 
 
 
 
 
 
 
 
 
Figure 3.5. Micro-CT and histological analyses of an RNR transgenic mouse lung tumor. 
(A) Micro-CT image of lung (sagittal view) from an RNR transgenic mouse with a tumor (red 
circle generated manually). Image was derived from a scan taken at 50µm with 220 projections. 
(B) Hematoxylin and eosin stained lung tissue of the same mouse (scale bar 1000µm). Normal 
and tumor tissues are also shown at a higher magnification (scale bar 40µm). Diameter of the 
tumor was measured to be 2mm at necropsy. (C) Upper panel: Several slices (every 4th slice 
shown) through a small region of interest including the tumor in (A). Lower panel: The same 
tumor separated by the automated segmentation algorithm from other soft tissue structures such 
as blood vessels and the chest wall. The result is shown with the tumor in red and other soft 
tissue structures in green. (D) A 3D visualization of the segmented tumor in (C) showing axial, 
sagittal, and coronal views. The volume equivalent diameter of the tumor is calculated to be 1.82 
mm. 
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Table 3.2. Comparison of tumor sizes determined by physical measurement from 
histological slides or by automated analysis of post-mortem micro-CT scans 
Mouse  
(tumor) 
Diameter by physical 
measurement (mm) 
Diameter by 
automated 
algorithma (mm) 
Percent difference 
between two methods 
Mouse 1 (tumor A) 1.94 2.03 4.5% 
Mouse 1 (tumor B) 1.89 1.82 3.8% 
Mouse 2 2.60 3.02 14.9% 
Mouse 3 2.39 1.73 32% 
 
a The automated algorithm is not designed for diameter measurement. Rather, for ease of 
comparison, the volume measured by the algorithm was converted to an equivalent diameter 
assuming the tumor is a sphere. 
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speed, image quality, and radiation dosage of this particular scanner. In order to do this, one 
mouse was repeatedly scanned with six different sets of parameters. The noise of the scans was 
quantified by measuring the standard deviation of five local regions in the lung parenchyma 
(Table 3.1). The scan with the lowest noise was produced with the following parameters: 100 
kVp, 50 mA, 360 projections, and 2 frame averaging. To increase image quality and resolution, 
the parameters used for subsequent live imaging were 100 kVp, 50 mA, 720 projections and 2 
frame averaging with reconstruction at 50µm resolution. All live scans were acquired using these 
optimized parameters with the exception of two scans (Table 3.3). 
Live micro-CT scanning was performed on four lung tumor-bearing mice. These mice 
were scanned a minimum of four times, with at least three weeks between scans. Each scan was 
examined to identify potential nodules. For each mouse, at least one tumor was visible in every 
scan over the course of the study and could be tracked sequentially for growth rate analysis. The 
volume of each nodule was computed by the automated algorithm at each time point and 
recorded for growth analysis (Figure 3.6A and Figure 3.7). Two observers independently verified 
the segmentation of the tumors by the algorithm. 
Mice were euthanized following the last live scan, and necropsy and histological analyses 
were performed for further characterization of the tumors identified in micro-CT scans (Figure 
3.6B, 3.6C and Figure 3.7). The growth of each nodule over time is illustrated in Figure 3.6D. In 
this graph, natural log of the tumor volume was plotted against time and a line of best fit was 
used to model the tumor measurements for each mouse. The slopes of the straight lines were then 
converted to growth index (GI) and tumor doubling time (DT) to indicate the growth rates of the 
tumors (Table 3.4). The initial tumor volume for each tumor varied from 0.050mm3 to 
0.898mm3. Tumors that had smaller initial volumes tended to grow slightly faster, with the  
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Table 3.3. Scanner acquisition parameters used for live scans 
 Current 
(mA) 
Voltage 
(kVp) 
Exposure 
Time (ms) 
# of 
Views/scan 
Frame 
averaging 
All except 50 100 20 720 2 
Mouse 1 (time point 3) 50 100 20 720 1 
Mouse 2 (time point 1) 50 100 20 440 2 
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Figure 3.6. Sequential micro-CT scans over time to measure lung tumor growth rate in 
four RNR transgenic mice. (A) Micro-CT image of sequential scans of an RNR transgenic 
mouse (mouse #3 tumor A) (Manually generated red circle indicates the tumor). Images were 
acquired at 50µm with 720 projections. (B) Gross image of the lungs at necropsy showing the 
tumor (black arrow) after the last scan. (C) Hematoxylin and eosin stained section from lungs 
shown in (B) (scale bar 1000µm). Normal and tumor tissues are also shown at a higher 
magnification (scale bar 40µm). (D) Growth curves of lung tumors from four RNR transgenic 
mice. Natural log of the tumor volume was plotted against time from the first micro-CT scan. A 
straight line of best fit was used to model the growth of each tumor.   
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Figure 3.7. Analysis of lung tumor growth in RNR transgenic mice by sequential micro-CT 
scanning. Micro-CT imaging was performed on RNR transgenic mice and representative 2-D 
micro-CT images are shown for each imaging session (A) mouse #1; (B) mouse #2; (C) mouse 
#3 tumor B; (D) mouse #4 tumor A; (E) mouse #4 tumor B.  All images were acquired at 50µm 
with 720 projections. The time point of the scan and calculated tumor volume are indicated. 
Manually generated red outlines highlight the tumor analyzed in each image. H&E stained 
sections were generated for each sample following the final imaging session. Scale bar represents 
1000µm. 
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Table 3.4 Tumor volume doubling time and growth index of tumors detected in RNR 
transgenic mice by micro-CT. 
Mouse 
(Tumor)  
Age at 
first scan 
(month) 
Initial 
tumor 
volume 
(mm3) 
Growth 
curve 
slope 
Tumor volume 
doubling time  
(=ln2/slope) (days) 
Growth index  
[=100(e30.4375*slope-1)] 
(% increase per month) 
1 11 0.685 0.0053 130.8 17.51 
2 12 0.898 0.0151 45.90 58.35 
3 (A) 12 0.324 0.0111 62.44 40.19 
  (B)  0.052 0.0368 18.84 206.5 
4 (A) 11 0.190 0.0136 50.97 51.28 
  (B)  0.050 0.0237 29.25 105.7 
 
NOTE: mice were first micro-CT scanned at the indicated age and then subjected to a series of 
sequential scans to monitor tumor growth. The slope of the growth curve was converted to tumor 
doubling time and growth index to indicate the rate of tumor growth. 
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exception for the tumor in mouse 2 (Table 3.4). The GI values of the tumors ranged from 17.51 
to 105.7% per month.  
The growth curves of the tumors in Figure 3.6D followed an exponential growth pattern, 
although there was deviation from a perfect exponential model. The deviation could be due to 
several factors. To assess whether the deviation was caused by variation from the micro-CT 
scanner due to alterations in calibration from scan to scan, phantoms of known density were 
scanned together with the mice. The intensities of the voxels within the phantom were sampled 
and the mean and standard deviation of the distribution was computed. Histograms for the 
distribution of intensities for air, water, and bone phantoms were plotted for two scans of the 
same mouse (Figure 3.8A and 3.8B), with the mean and standard deviations reported in Table 
3.5. While the mean intensity of the air phantom did not vary much (4.2 HU difference), the 
means for the water and bone phantoms differed by 25.7 HU and 20.6 HU, respectively. The 
noise of the scans, which is quantified by the standard deviation of the distribution of pixel 
values in the phantoms, also differed from scan to scan. The greatest difference occurred with the 
air phantom, where there was a 30.9 HU difference. The difference decreased as the mean 
intensity increased, with the standard deviations for water and bone being 24.7 HU and 3.4 HU 
respectively. In addition to phantoms, we also measured the voxel intensities of the lung 
parenchyma and soft tissue from different scans to see whether they were consistent. Figure 3.8C 
and 3.8D shows the distribution of voxel intensities for the lung parenchyma and soft tissue from 
two different scans on the same mouse (mouse 4). The value that best separated the lung 
parenchyma from soft tissue varied by 35 HU from one scan to the other. These data show that 
alterations in calibration and tissue intensities from scan to scan can contribute to variations of 
the measurements and deviation from a perfect exponential growth curve. 
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Figure 3.8. Phantoms and tissues show variation in intensities across different scans. (A) 
Distribution of intensities of three phantoms, air, water, and bone (left to right peaks), with mean 
intensities -927.6HU, 92.2HU, and 2612.6HU, respectively, in one scan. (B) Distribution of 
intensities of the same phantoms as in (A) in a repeated scan six weeks later with mean 
intensities -931.8HU, 66.5HU, and 2592.0HU, respectively. (C) Distribution of intensities in the 
lung parenchyma (white) and soft tissue (gray) from one mouse in one scan with an adaptive 
threshold at -155HU. (D) Distribution of intensities of the same tissues as in (C) of the same 
mouse in a repeated scan six weeks later with an adaptive threshold at -190HU. All scans were 
acquired at 50µm with 720 projections. Variations in the intensity distribution of the phantoms 
and tissues were observed in repeated scans. 
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Table 3.5a. Descriptive statistics for the intensities of the histogram plots in Figure 3.8A and 
3.8B. 
 Air Water Bone 
Scan Mean 
(HU) 
SD 
(HU) 
Mean 
(HU) 
SD 
(HU) 
Mean 
(HU) 
SD 
(HU) 
Mouse 4 (Time 
point 2) 
-927.6 77.8 92.2 82.3 2612.6 120.6 
Mouse 4 (Time 
point 4) 
-931.8 108.7 66.5 107.0 2592.0 124.0 
 
a The standard deviation (SD) is a measure of the noise in the scan, with  higher values 
indicating more noise. 
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Next, we investigated whether changes in the nodule morphology could contribute to 
variations of the measurements. We suspected that the slight variability in the position of the 
mouse during each scan might affect the shape of the lung, which in turn could affect the lung 
volume and tumor morphology. In addition, as lung tumor burden increased over time, mice at 
later time points sometimes had breathing problems due to disease progression. This resulted in 
incomplete expansion of the lung tissue during inhalation and could affect measured lung and 
tumor volumes. To measure whether there were changes in lung volume from scan to scan, we 
applied the threshold found during the adaptive thresholding step of the algorithm to the lung 
total area and performed morphological filtering and connected component analysis to isolate the 
lungs. We measured the lung volume in each scan for all the mice and found that the change 
from the maximum lung volume to the minimum lung volume for a mouse ranged from 28% to 
61%. This suggests that changes in the lung volume and nodule morphology due to changes in 
mouse positions and disease burden are factors that could contribute to variations in tumor 
volume measurements.  
Deviation from a perfect exponential growth model also could be due to inaccurate 
measurements by the automated algorithm, such as when it fails to separate the boundary 
between the nodule and its attached structures. In order to address this, we compared the tumor 
volumes measured by the automated algorithm with those measured manually by an observer. As 
shown in Figure 3.9 and Figure 3.10, even when there were differences between the absolute 
values measured, the two methods give very similar trends for tumor growth, indicating that the 
automated algorithm can separate the nodules well from attached structures and give accurate 
measurement of tumor volumes. 
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Figure 3.9. Comparison of lung tumor growth measured manually by an observer and by 
the automated algorithm. Growth curves were plotted for tumors from mouse 3 tumor A (left) 
and mouse 4 tumor A (right) based on measurements by an observer and by the automated 
algorithm. The slopes of the manual and automated measurements were compared by Student’s 
t-test and no statistically significant differences were observed between the two slopes (P=0.54 
for mouse 3 tumor A and P=0.32 for mouse 4 tumor A), indicating that there was good 
correlation between the measurements from the two methods. 
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Figure 3.10. Comparison of lung tumor volume values determined manually by an 
observer and by the automated algorithm. Four tumor-bearing mice were subjected to 
sequential micro-CT imaging, and tumor volume measurements were determined manually by an 
observer or by the automated algorithm. (A) mouse #1, (B) mouse #2, (C) mouse #3 tumor B and 
(D) mouse #4 tumor B. The slopes of the manual and automated measurements were compared 
by Student’s t-test and no statistically significant differences between the two slopes were 
observed for mouse 3 tumor B and mouse 4 tumor B (P=0.98 and P=0.83 respectively), 
indicating that there is good correlation between the measurements by the two methods. The 
slopes of the manual and automated measurements for mouse 1 and mouse 2 showed significant 
differences (P=0.024 and P=0.020 respectively). This may due to the different scan parameters 
used for mouse 1 (time point 3) and mouse 2 (time point 1) (see Table 3.3). In addition, for these 
early scans, the micro-CT machine was not calibrated for every the scan, which also may have 
contributed to measurement inaccuracies.  
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3.5 Discussion 
The development of micro-CT has provided an opportunity to monitor disease 
progression and therapeutic responses over time in mouse models of human diseases. To take 
advantage of this opportunity, we developed an automated method to measure tumor volume in a 
mouse model of lung cancer using micro-CT scans. Prior to developing the automated algorithm, 
parameters used for the micro-CT scans were optimized on scans of euthanized mice. There were 
several trade-offs when optimizing the parameters. To obtain the highest resolution and best 
image quality, long time scans were required. However, we were constrained by the radiation 
dose that could be given to the mouse and the amount of time the mouse could be kept under 
anesthesia. The optimal parameters chosen in this study has the lowest noise level given the 
constraints of live animal scans, though the noise was still higher than what is typically obtained 
using low-dose whole lung human CT scans for which the algorithm was originally designed. 
This is due to the scale at which micro-CT operates – the image noise is inversely proportional to 
the spacing between the voxels, if X-ray exposure is held constant (Holdsworth and Thornton 
2002). The micro-CT scans in this study were acquired with a voxel size of 0.05 mm x 0.05 mm 
x 0.05 mm compared to typical human CT scans of 0.6 mm x 0.6 mm x 1.0 mm. Table 3.1 shows 
the tested parameters in the study and the noise measurements. In general, higher voltage tended 
to produce less noise, and noise could be further reduced by the use of frame averaging and 
additional projections. Figure 3.11 shows a single snapshot of a typical low-dose human CT scan 
obtained from the Public Lung Database to Address Drug Response as well as a micro-CT scan 
obtained in this study. Visually, the micro-CT scan has a noisier appearance, as evidenced by the 
texture pattern of the lung parenchyma compared to that of the human CT scan (Figures 3.11C 
and 3.11D). The increase in noise is reflected in the histogram shown in Figure 3.11A, in which  
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Figure 3.11. Comparison of soft tissue and lung parenchyma intensities in a micro-CT scan 
and a human whole lung CT scan. Distribution of intensities in the lung parenchyma (white) 
and soft tissue (gray) in (A) a mouse micro-CT scan with adaptive threshold of -190 HU and (B) 
a human whole lung CT scan with no need for adaptive threshold. The mouse micro-CT scan 
was obtained at 50µm with 720 projections. The human whole lung CT scan was from the Weill 
Cornell Medical College Lung CT database. It was obtained using a GE LightSpeed Ultra 
scanner at 120kVp and 80mA, with 0.7 x 0.7 x 1.25mm resolution. The peaks in (A) were not as 
sharp as those in (B), indicating that the mouse micro-CT scans were noisier than human CT 
scans. Magnified regions of the lung from (C) a micro-CT scan (yellow circle indicates tumor) 
and (D) a whole-lung CT scan (red arrow points to tumor) were shown to visualize the difference 
in scan quality. No scaling was done to the images and each image was windowed for viewing. 
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the micro-CT scan has much wider distribution of intensities than the human CT scan shown in 
Figure 3.11B. The mean and standard deviation of the distributions are given in Table 3.6. 
Nevertheless, the automated algorithm developed in this study is able to cope with the noise level 
found in micro-CT scans, as shown by the successful segmentation of tumors in Figure 3.5D. 
The growth curves of the tumors followed an exponential pattern, which is consistent 
with modeling of tumor growth patterns for human lung cancer (Schwartz 1961; Spratt, Meyer et 
al. 1995). It is also consistent with a recent CT study that shows exponential growth in early 
stage pancreatic cancers (Haeno, Gonen et al. 2012). Therefore, the exponential growth model of 
lung tumors is validated for mice in vivo and can be used in tumor measurement algorithms to 
monitor disease progression and therapeutic responses. However, the growth curves obtained in 
this study showed deviations from an ideal exponential model, although it remains unknown 
whether this accurately reflects the actual growth behavior of the tumors. We showed that 
alterations in scanner calibration and changes in mouse lung volumes are factors that could 
contribute to this deviation, while inaccuracy of the automated algorithm appears to play less of a 
role.  
One characteristic of CT is that the scale is calibrated. Air has a density of -1000 HU and 
water has a density of 0 HU. Thus, materials of the same density should have a consistent 
intensity on a CT scan, both across time and instruments. This allows for the use of a fixed 
threshold to separate different tissue types, in this case for the lung parenchyma and soft tissue. 
However, in this study, we found up to a 26 HU difference in the mean intensity of the same 
phantom imaged at different times and up to a 30 HU difference in the standard deviation, 
indicating inconsistencies in calibration and noise characteristics for the scanner. As a result, 
instead of a fixed threshold, an adaptive threshold estimated from the local region of interest was  
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Table 3.6a. Descriptive statistics for the intensities of the histogram plots in Figure 3.11.     
 Parenchyma Soft tissue 
 Mean SD Mean SD 
Micro-CT -376.9 110.2 -1.6 109.4 
Human CT -883.8 79.0 57.9 82.3 
 
a The standard deviation (SD) is a measure of the noise in the scan, with  higher values 
indicating more noise. 
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used. These findings additionally suggest that the micro-CT scanner should be calibrated prior to 
each scan using density phantoms that expand the entire range of densities to be observed in the 
scan.  
We also observed changes in lung volume between scans for individual mice. The lung 
volume of the same mouse varied up to 60% from one scan to another. Slight differences in 
mouse positioning between scans could contribute to observed differences in lung volume. In 
addition, as lung disease progressed, the increased tumor burden resulted in reduced respiratory 
capacity, which might be another factor contributing to changes in observed lung volume. 
Furthermore, in order for the mouse to activate the pressure sensor used for respiratory gating 
during live scans, a small external force was applied on the back of the mouse, which could lead 
to slight compression of the lungs. An alternative method for respiratory gating is to use a 
ventilator to control the respiratory cycle of the mouse. This would eliminate the need for a 
pressure sensor and provide better control of the degree and rate of inspiration. 
To verify that measurement accuracy of the automated algorithm does not significantly 
contribute to deviations from the ideal exponential growth model, an observer performed manual 
uni-dimensional measurements for all the tumors from all scans. Although the absolute tumor 
volumes were likely to be different between the manual and automated methods, of greater 
importance was that the growth patterns determined by the two methods were very similar. As 
shown in Figures 3.9 and 3.10, a similar trend indicted that the measured exponential growth was 
the result of actual changes in nodule volume and not the inaccuracy of the measuring method. 
The manual measurements of the tumor volume tended to be larger than those of the automated 
measurements. This is because the manual measurements assume a spherical shape for the tumor 
and use the uni-dimensional measurement of the longest diameter to calculate tumor volume. For 
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non-spherical shapes, this tends to exaggerate the volume compared to the automated method 
that measures the volume directly. There were only two measurements where the manual uni-
dimensional volume was smaller than the volume measured by the algorithm. These nodules 
were both very small (0.5 mm and 1.2 mm in diameter) and may not be accurately measured 
manually. The automated algorithm does have one limitation in terms of segmenting tumors that 
have complicated morphology. One assumption made during the development of the algorithm 
was that the tumor would only touch the outer chest wall. As a result, tumors located in the lower 
lung near the diaphragm and touching both the chest wall and the diaphragm could not be 
successfully segmented (Figure 3.12).  
The neoplasms analyzed in this study were all adenomas. The growth index (GI) values 
for these tumors ranged from 17.51 to 105.7% per month, which is much greater than the GI of 
5.4% per month reported for human lung tumors (Yankelevitz, Reeves et al. 2000), indicating 
that the murine tumors grow faster. This likely is due to the fact that the tumors in mice were 
detected at an early stage when they experience preferential growth conditions relative to larger 
human tumors, including greater nutrient access, oxygenation and less spatial constraint. For the 
same reason, tumors with smaller initial volumes in this study tended to grow faster. In support 
of this, Haeno et al. (Haeno, Gonen et al. 2012) reported in their study that primary pancreatic 
tumors that were larger at diagnosis grew slower. The tumor in mouse 2 was an exception in our 
study, as it had a bigger initial volume and also grew faster than some of the smaller neoplasms. 
This may be because this tumor appeared to be at a more advanced stage, as evidenced 
histologically by the lack of a well-defined boundary (Figure 3.7B). Tumor volume doubling 
time (VDT) for the tumors analyzed in this study ranged from 29.25 to 130.8 days (Table 3.4) 
with an average of 70.8 days. Oliver et al. (Oliver, Mercer et al.) reported an average mouse lung  
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Figure 3.12. Representative micro-CT images showing a nodule that is attached to both the 
chest wall and diaphragm. Micro-CT images of a nodule from mouse #3 that abuts the chest 
wall and diaphragm are shown. This nodule could not be successfully segmented by the 
automated algorithm because it violates the assumption of the algorithm that the nodule can only 
have one major attachment. These images were windowed to enhance the contrast for viewing 
and representative segmentations that are seven slices apart are shown. This scan was acquired at 
50µm with 720 projections. 
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tumor VDT of 35 days (with high variation). Haines et al. (Haines, Bettano et al. 2009) and 
Fushiki et al. (Fushiki, Kanoh-Azuma et al. 2009) showed an average VDT for murine lung 
tumors of around 42 days. These values are within the range of our tumor VDT and are 
comparable to our average number. These studies all used the K-asLSL-G12D mouse model, where 
the activation of the oncogene K-ras is induced by Adeno-Cre virus infection (Jackson, Willis et 
al. 2001). In comparison, the mouse model used in this study develops lung tumors through a 
stochastic process associated with mutations in the K-ras oncogene. The different mouse models 
used may contribute to the observed difference in the average tumor VDT. Moreover, a recent 
study in human lung cancer patients revealed an average tumor VDT of 136 days for 111 lung 
cancer cases (Henschke, Yankelevitz et al. 2012). 110 of the 111 cases had lung tumors 
diagnosed at screening rather than by symptoms, suggesting that the average VDT of 136 days 
reflects tumor growth at an early stage and therefore is comparable to the average VDT of 70.8 
days in our mouse model.  
The automated pulmonary nodule segmentation algorithm for measuring murine tumors 
imaged by micro-CT reported here was capable of accurate measurements of tumor volumes and 
was used to monitor disease progression over time. Tumor volume measurements from micro-
CT have the potential to be used as an imaging biomarker in preclinical studies. With future 
improvements to handle nodules with more difficult morphology this automated algorithm holds 
promise for use in monitoring disease progression following treatment with candidate drugs and 
evaluation of therapeutic responses. 
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CHAPTER 4 Summary and Future Directions 
4.1 RNR deregulation, ROS imbalance and genome instability 
Ribonucleotide reductase (RNR) plays an essential role in organismal survival and 
genome maintenance by providing dNTPs for DNA synthesis. Deregulation of RNR has been 
shown to cause mutagenesis and tumorigenesis. A major focus of the mechanism of RNR-
induced mutagenesis is on how RNR deregulation affects the dNTP pool balance. As an enzyme 
that produces free radicals during its catalytic cycle, the effect of RNR deregulation on the redox 
homeostasis in cells is less well studied. The first part of this dissertation (chapter two) was 
aiming to elucidate the effect of RNR deregulation on cellular redox status.  
In order to do this, we generated 3T3 cells that overexpress Rrm1, Rrm2 and p53R2 and 
showed that expression of the small subunits Rrm2 and p53R2 lead to elevated reactive oxygen 
species (ROS) in cells. By generating a series of Rrm2 mutants, we demonstrated that the di-
nuclear iron center of Rrm2 contributes to increased ROS while the radical transfer pathway has 
no effect on ROS production. In addition, some of the Rrm2 mutants have dominant negative 
effects in cells, leading to mitochondrial DNA depletion and mitochondrial redox imbalance. 
These findings indicate the importance of RNR regulation in maintaining cellular ROS levels 
and suggest the possibility that R2-induced ROS may play a role in mutagenesis and 
tumorigenesis.  
With the panel of Rrm2 mutants generated in this study, we are able to investigate 
whether R2-induced ROS plays a direct role in mutagenesis (Figure 4.1). By comparing the 
mutation frequency in the three groups of Rrm2 proteins, if Rrm2-radical transfer mutants show 
increased mutation frequency while Rrm2-iron mutant does not, we can conclude that R2 can 
lead to mutagenesis through ROS production independent of RNR enzyme activity.  
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Figure 4.1 Rrm2 mutants in studying the role of ROS in mutagenesis. Cells overexpressing 
WT Rrm2 have increased mutation frequency, which could result from increased enzyme 
activity and/or free radical production. Comparing the mutation frequency in Rrm2-Fe6 and 
Rrm2-Y177F/Rrm2-Y370F can tell us whether ROS plays a direct role in Rrm2-induced 
mutagenesis.  
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One important question we want to address is the molecular mechanism of R2-induced 
mutagenesis and lung tumorigenesis in mice. In this study, we showed that Rrm2 overexpression 
in cells leads to increased RNR enzyme activity and elevated ROS production, both of which 
could be mutagenic. However, dNTP measurements using Rrm2 overexpressing lung and 3T3 
cells didn’t show significant change, suggesting that increased RNR enzyme activity may not 
cause dNTP alterations due to the multilayered regulation of RNR in vivo. Alternatively, it could 
be that the method used to measure dNTP is not sensitive enough to detect small overall or local 
changes. On the other hand, R2 overexpression in cells leads to increased ROS. It would be very 
interesting to look at whether this increased ROS leads to oxidative stress and mutagenesis in 
cells. Oxidative stress can be addressed by measuring the levels of 8-oxoG (a major DNA 
oxidation product) and mutation frequency can be studied by HPRT assay. It is important to keep 
in mind that these two different mutagenic mechanisms of RNR may not be mutually exclusive. 
Instead, both may contribute to mutation accumulation and lead to tumorigenesis (Figure 4.2).  
In this study, we provided some evidence on RNR deregulation and ROS imbalance. In 
fact, there are a lot more to explore in this direction. For example, we can measure ROS levels in 
lung tissues from R2 transgenic mice. ROS levels in tumor tissues (with different tumor stages) 
and adjacent normal lung tissues can be measured and compared. This would give us a more 
direct look at ROS in lung tumor initiation and progression. On the other hand, R2 
overexpressing cells and R2 transgenic mice can be treated with antioxidant such as N-Acetyl 
Cysteine (NAC) and see whether this brings down the ROS levels and decreases mutation 
frequency and lung tumor incidences. It is also worth investigating the antioxidant defense 
systems, including the levels and dynamics of superoxide dismutase, catalase and 
glutathione/glutathione peroxidase in R2 overexpressing cells and R2 transgenic mice.  
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Figure 4.2 Model of the molecular mechanism of RNR-induced lung tumorigenesis. 
Overexpression of Rrm2 can lead to increased enzyme activity and ROS production in cells, both 
of which could be mutagenic and contribute to mutagenesis and tumorigenesis.  
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Furthermore, since misincorporation of 8-oxoG into DNA is primarily repaired by the base 
excision repair pathway (Robertson, Klungland et al. 2009), R2 transgenic mice can be bred with 
mice that are defective for base excision repair and see whether this leads to synergistic 
acceleration of tumorigenesis.  
Another research area that worth looking into is RNR deregulation and mitochondrial 
function. p53R2 mutations have been identified in several human mitochondrial diseases and 
have been shown to cause mtDNA depletion ((Bourdon, Minai et al. 2007; Kollberg, Darin et al. 
2009; Shaibani, Shchelochkov et al. 2009). It would be interesting to obtain patient cell lines 
and/or make clones of these p53R2 mutants and study their effect on mitochondrial function. For 
example, we can examine whether mtDNA depletion in these cells leads to respiratory defects 
and mitochondrial ROS imbalance, and whether this increase in ROS further leads to oxidative 
damage in cells (a vicious cycle). We can introduce WT p53R2/Rrm2 back to these mutant cells 
and see whether mtDNA depletion and mitochondrial ROS imbalance can be rescued.  
Reactive oxygen species (ROS) are important cell signaling molecules and it is important 
to maintain their homeostasis. Increased ROS production and subsequent oxidative stress has 
been associated with many disease conditions, but their exact roles are still not clear. It remains 
puzzling whether ROS or disease comes first, whether ROS is required for disease initiation or it 
potentiates disease progression, and whether ROS can be exploited therapeutically. Recently, 
there is more discussion on targeting ROS and their downstream pathways in cancer cells 
(Trachootham, Alexandre et al. 2009; Raj, Ide et al. 2011). However, the study of ROS is 
difficult due to their numerous roles in cellular processes and their labile nature. Advances in 
understanding ROS biology require methodology that can accurately monitor cellular ROS 
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concentrations. With the development of biological assays, we hope to further elucidate the 
relationship between ROS and diseases.  
4.2 RNR mouse model of lung cancer and translational imaging studies 
R2 transgenic mice develop lung tumors that histopathologically resemble human 
papillary adenocarcinomas (Xu, Page et al. 2008) and therefore can be used as an authentic lung 
tumor model in translational studies. Lung caner has high mortality rate and this is largely due to 
the fact that the tumors are often detected at late and advanced stages where treatments are rarely 
effective. Therefore, early detection of lung cancer is critical for improving survival of this 
disease. The second part of this dissertation (chapter 3) was aiming to improve early lung tumor 
detection and study lung tumor growth rate by micro-computed tomography (micro-CT) using 
R2 transgenic mice as a model.  
In order to do this, we adapted an automated algorithm from tools for the measurement of 
pulmonary nodules on human chest CT scans and used it to measure mouse lung tumors. 
Euthanized mice were first imaged to optimize scan parameters and refine computational 
algorithms for tumor volume measurement. Four live lung tumor-bearing mice were then 
scanned sequentially for tumor growth rate determination. Findings from this study establish 
automated algorithms to measure early stage lung tumor and confirm the exponential lung tumor 
growth model in humans.  
As a good lung tumor model in imaging studies, R2 transgenic mice can be used to 
explore more imaging options. Positron emission tomography (PET) is a noninvasive, three-
dimensional imaging technique that depicts physiologic processes. Recently, PET and CT have 
been combined (PET/CT) in a single scanner where metabolic and anatomic information can be 
revealed simultaneously (Bybel, Brunken et al. 2006). Different PET tracers can be used to 
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depict specific physiologic processes. Since tumor cells metabolize glucose at a high rate 
(Warburg 1956), a glucose analogue [18F] fluorodeoxyglucose (FDG) has been used in PET/CT 
to diagnose and stage neoplasms such as lung cancers (Bruzzi and Munden 2006). Besides [18F] 
FDG, other tracers have been proposed to monitor different physiologic processes in tumor 
development such as [18F] Fluorothymidine in cell proliferation, [18F] Fluoromisonidazole in 
tumor hypoxia and [18F] Arginine glycine aspartic acid in angiogenesis (Bybel, Brunken et al. 
2006). Studies in small animal models would be extremely helpful to test these tracers and 
establish working protocols that can be applied to humans. In this context, our R2 mice can serve 
as a great model to study non-small cell lung cancer (NSCLC) in PET/CT imaging. In addition to 
tumor diagnosis and staging, PET/CT can also be used to test drug efficacy. For instance, R2 
mice can be treated with anticancer drugs and tumor sizes and metabolism can be monitored by 
PET/CT scanning on a regular basis. A reduction in tumor size and metabolic activity would be 
an indication of effective treatment and better survival.  
  The use of PET/CT imaging brings both refinements and greater complexity in tumor 
imaging. Interpretation of PET/CT images requires multidisciplinary collaboration between 
oncologists, basic researchers, radiologists and engineers. By using R2 mice as a model of 
NSCLC for imaging, we can help improve tumor diagnosis and staging, as well as protocols and 
algorithms used in tumor measurements and quantifications.    
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APPENDIX 1 The Physiological Effect of Disrupting Two Primary Regulatory 
Mechanisms of Mouse Ribonucleotide Reductase  
Introduction 
Mammalian Ribonucleotide Reductase (RNR) is regulated by two primary regulatory 
mechanisms: one is the cell cycle regulation of the R2 protein level and the other is the feedback 
inhibition of RNR activity through the activity site of the R1 subunit (Nordlund and Reichard 
2006). During the cell cycle, the R1 protein level is constant while the R2 protein level 
fluctuates. R2 protein peaks during S phase and is undetectable outside of S phase (Engstrom, 
Eriksson et al. 1985). As a result, the R2 protein level acts as a limiting factor for RNR enzyme 
activity. It has previously been shown that disruption of the cell cycle regulation of R2 by 
overexpressing this subunit in mice leads to lung tumorigenesis through a mutagenic mechanism 
(Xu, Page et al. 2008). RNR activity is also regulated through the activity site of R1. This site 
senses the ratio of dATP and ATP in cells. dATP binding at the activity site of R1 inhibits RNR 
enzyme activity while ATP binding stimulates enzyme activity (Kolberg, Strand et al. 2004). 
Disruption of the activity site in R1 by the D57N (aspartic acid to asparagine) point mutation 
results in an enzyme that cannot be inhibited by dATP binding and leads to perturbations in 
dNTP pools and increased mutation rate in cells (Weinberg, Ullman et al. 1981; Caras and 
Martin 1988). Mice that are heterozygous for the D57N mutation (Rrm1+/D57N) were grossly 
normal while mice that are homozygous for the mutation (Rrm1D57N/D57N) were embryonic lethal 
(Page, JL and Weiss, RS, unpublished data).  
We are interested in the physiological consequences of simultaneous disruption of both 
the regulatory mechanisms of RNR. We hypothesized that this interruption would result in 
significant dNTP pool disturbances and mutagenesis. In order to do this, I crossed Rrm1+/D57N 
 160 
heterozygous mice with Rrm2Tg/p53R2Tg mice and aged the desired Rrm2TgRrm1+/D57N and 
p53R2TgRrm1+/D57N experimental mice till 15-months old. These mice were born at expected 
frequency and had limited phenotypes.  
Materials and Methods 
Mice 
Rrm2Tg and p53R2Tg transgenic mice and Rrm1D57N knock in (KI) mice were generated 
previously (Xu, Page et al. 2008) (Page, JL and Weiss, RS, unpublished data). Rrm2Tg and 
p53R2Tg mice were interbred with Rrm1+/D57N mice to generate Rrm2TgRrm1+/D57N and 
p53R2TgRrm1+/D57N experimental mice. All mice were maintained identically and aged till 
moribund for 15-month old.  
Pathological assessment 
Mice terminated according to schedule were euthanized by asphyxiation using carbon 
dioxide and necropsied. The weight of the whole mouse and tissues including kidney, testis, 
heart, and skeletal muscle (right quadriceps) were measured at necropsy. Lung, spleen, thymus, 
kidney, testis, ovary, uterus, heart, diaphragm, liver and skeletal muscle (right quadriceps) tissues 
were fixed with 10% neutral-buffered formalin, embedded in paraffin and 5µm thick sections 
were stained with hematoxylin and eosin.  
Results 
Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice were born at expected frequency 
Rrm2Tg and p53R2Tg mice were intercrossed with Rrm1+/D57N. Offspring were genotyped 
at weaning by PCR. The total numbers of mice of each genotype observed are listed in Table 1 
and Table 2. χ2 test indicated that there is no difference among the four different genotypes.   
 161 
 
 
 
 
 
 
 
Table 1 Number of offspring obtained from Rrm2Tg and Rrm1+/D57N intercrosses.  
Genotype # Expected # Observed 
Wild type 29.25 34 
Rrm1+/D57N 29.25 21 
Rrm2Tg 29.25 32 
Rrm2TgRrm1+/D57N 29.25 30 
Total  117 (P=0.61a) 
a χ2 test is done among the four different genotypes and no statistical significance is observed.  
 
 
 
 
 
 
 
 
 162 
 
 
 
 
 
Table 2 Number of offspring obtained from p53R2Tg and Rrm1+/D57N intercrosses.  
Genotype # Expected # Observed 
Wild type 26 42 
Rrm1+/D57N 26 29 
p53R2Tg 26 19 
p53R2TgRrm1+/D57N 26 15 
Total  104 (P1=0.047a; P2=0.66b) 
a χ2 test is done among the four different genotypes and statistical significance is observed. 
However, this is due to the fact that p53R2Tg single mutant mice were underrepresented (Xu, X, 
Page, JL, Li, M and Weiss, RS, unpublished data). 
 
b χ2 test is done between p53R2Tg and p53R2TgRrm1+/D57N mice and this time no statistical 
significance is observed. 
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Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice were grossly normal 
A cohort of Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice were maintained and 
monitored till 15-month old. All mice survived the 15-month period and were grossly normal. 
Since Rrm2Tg and p53R2Tg mice develop lung tumors and Rrm1+/D57N heterozygous mice were 
grossly normal (with slight increase in lung tumorigenesis), we were interested in whether 
Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice have synergistic increase in lung tumorigenesis 
and whether they develop new pathological phenotypes. However, as summarized in Table 3, 
Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice have limited phenotypes. 
Discussion 
It is somewhat surprising that Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N mice were 
grossly normal and didn’t have synergistic phenotypes even if they have disruptions in the two 
primary RNR regulatory pathways. Besides the Rrm1+/D57N and Rrm1D57N/D57N KI mice, the 
Weiss lab also generated Rrm1-D57NTg transgenic mice that overexpress the Rrm1-D57N 
mutant protein. The Rrm1-D57NTg mice were also grossly normal and had no significant 
increased in total cellular dNTP pools (Page, JL and Weiss, RS, unpublished data). When Rrm1-
D57NTg mice were intercrossed with Rrm2Tg and p53R2Tg mice, the resulting bitransgenic Rrm1-
D57NTgRrm2Tg and Rrm1-D57NTgp53R2Tg mice showed embryonic and neonatal lethality, as 
well as huge increases in cellular dNTP pools (Page, JL and Weiss, RS, unpublished data). 
Several recent studies indicate that when RNR activity is inhibited by allosteric effector binding 
at the activity site, the large R1 subunit is converted into persistent inactive hexamers (Aye and 
Stubbe 2011; Fairman, Wijerathna et al. 2011; Aye, Brignole et al. 2012). Based on this 
information, we propose the following model to explain the observations with Rrm1-D57NTg,  
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Table 3 Pathological analyses of 15-month old Rrm2TgRrm1+/D57N and p53R2TgRrm1+/D57N 
mice 
Genotype Sex Weight 
(g) 
Lung Lymph 
node (near 
thymus) 
Heart 
(mg) 
Uterine or 
testis (mg) 
Kidney 
(mg) 
Skeletal 
muscle 
(mg) 
p53R2Tg 
Rrm1+/D57N 
M 40.12 Tumor  156 93 317 118 
p53R2Tg 
Rrm1+/D57N 
M 34.79 Tumor Enlarged 183 94 (moderate 
degeneration) 
306 175 
p53R2Tg 
Rrm1+/D57N 
M 37.65 Tumor  214 116 360 194 
Rrm1+/D57N M 37.62   192 128 341 212 
p53R2Tg M 42.36  Enlarged 209 127 362 112 
Wild type M 37.57   197 121 (moderate 
degeneration) 
364 190 
 
Rrm2Tg 
Rrm1+/D57N 
F 41.34 Tumor  175  260 179 
Rrm2Tg 
Rrm1+/D57N 
F 31.86 Tumor Enlarged 146  218 181 
Rrm2Tg 
Rrm1+/D57N 
F 42.94 Tumor  158 Dilated lumen 189 132 
Rrm2Tg 
Rrm1+/D57N 
F 35.03 Tumor  163  214 163 
p53R2Tg 
Rrm1+/D57N 
F 41.31   153  213 135 
Rrm2Tg F 41.59 Tumor  180  242 183 
Wild type F 49.73   162  235 179 
Wild type F 44.33   148 Dilated lumen 241 179 
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Rrm1+/D57N, Rrm1D57N/D57N, Rrm1-D57NTgRrm2Tg, Rrm1-D57NTgp53R2Tg, Rrm2TgRrm1+/D57N 
and p53R2TgRrm1+/D57N mice (Figure 1).  
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Figure 1 Hypothetical model of RNR deregulation in various RNR mouse models. (A) In 
wide type mice, dATP binding to Rrm1 locks Rrm1 subunits in homohexamer confirmation and 
inhibits RNR activity to maintain balanced dNTP pools in cells. (B) In Rrm1-D57NTg and 
Rrm1+/D57N mice, there are Rrm1 WT and Rrm1-D57N mutant proteins. There could be two 
scenarios: (i) there could be heterohexamer formation of Rrm1 WT and Rrm1-D57N upon dATP 
inhibition. Even if Rrm1-D57N cannot respond to dATP inhibition, Rrm1 WT in the 
heterohexamer can respond and lead to inactive RNR complex; (ii) R2 subunit is the limiting 
factor for RNR enzyme activity. Even if there is Rrm1-D57N present, there is no excess R2 
subunit to form a functional RNR complex. As a result, these mice are grossly normal and have 
limited phenotypes. (C) In Rrm1D57N/D57N mice, there is no Rrm1 WT protein, all Rrm1-D57N 
proteins complex with R2 and form RNR enzymes that cannot respond to dATP inhibition any 
more, leading to increased dNTP pools and embryonic lethality in mice. (D) In 
Rrm1+/D57NRrm2Tg and Rrm1+/D57Np53R2Tg mice, half of the R1 protein is WT and half is Rrm1-
D57N. Even if the R2 subunit is overexpressed, there is a big chance that Rrm1-D57N is locked 
in the heterohexamer with Rrm1 WT. Since Rrm1 WT can respond to dATP inhibition, these 
mice have inactive RNR complexes and limited phenotypes. In Rrm1-D57NTgRrm2Tg and Rrm1-
D57NTgp53R2Tg mice, majority of the R1 protein is Rrm1-D57N. These Rrm1-D57N mutants 
can complex with R2 and form active RNR proteins that do not respond to dATP inhibition, 
resulting in increased dNTP pools and embryonic and neonatal lethality in mice.  
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Regulatory Mechanisms that Prevent Lethal Alterations in Nucleotide Levels 
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measurements in Figure 4.  
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SUMMARY (250 words max) 
Background: Regulation of RNR is accomplished through multiple mechanisms which include 
control of R2 subunit protein levels and negative feedback regulation through the activity site 
within the R1 subunit. The D57N mutation within the activity site disables feedback inhibition 
and results in a mutator phenotype in cultured cells. 
Results: We generated a mouse model featuring a hyperactive mutant form of the enzyme. We 
crossed mice overexpressing the Rrm1-D57NTg mutant to Rrm2- or p53R2-overexpressing mice. 
Combining overexpression of the mutant form of the large subunit, but not the wild type large 
subunit, with either small subunit caused synthetic lethality. The extent of Rrm1D57N 
overexpression affected the dNTP output in tissues expressing the RNR transgenes most highly, 
with higher RNR expression correlating with elevated and unbalanced nucleotide pools. 
Moreover, the dNTP pool alterations correlated with the onset of phenotypes in the mice. Mice 
that survived to adulthood were underrepresented and displayed severe skeletal muscle 
degeneration and premature aging phenotypes. 
Conclusions: We propose a mechanism in which simultaneously overriding two primary RNR 
regulatory mechanisms results in greatly elevated RNR activity, producing abnormal dNTP pools 
that interfere with genome maintenance and function. These experiments provide insights into 
how the control of nucleotide levels through regulation of RNR catalytic activity impacts 
genomic stability and survival in mammals. 
HIGHLIGHTS (85 characters each) 
• Disabling both main regulatory mechanisms of RNR causes synthetic lethality 
• Increased RNR activity correlates to increased dNTPs and to timing of lethality 
• Deregulating RNR leads to premature aging phenotypes and degeneration of multiple tissues 
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INTRODUCTION 
Proper genome maintenance is critical for survival. In addition to the nuclear genome, 
which is comprised of approximately 3.4 gigabases of DNA and encoding roughly 28,000 genes 
in mice, eukaryotic cells maintain a mitochondrial genome, which is multicopy, comprised of 
16,569 bp of DNA and only encodes 37 genes. One of the key determinants in the maintenance 
of these genomes is the availability of dNTPs for DNA synthesis. Efficient and faithful 
replication by the three main replicative polymerases, the nuclear DNA polymerases d and e, and 
the mitochondrial DNA Pol g, relies on adequate and balanced nucleotide pools. All three 
polymerases contain exonucleolytic proofreading domains that prevent DNA mismatches under 
ideal conditions, but all three make increased replication errors in perturbed nucleotide pools (1-
4). In particular, elevated nucleotide pools increase the error rate of all three polymerases and 
result in increased mutation rates(5). Conversely, elevated nucleotide pools have also been 
shown to aid survival following DNA damage, by promoting lesion by-pass(6). This suppresses 
potentially deleterious repair mechanisms such as sister chromatid exchange and 
hyperrecombination, stabilizing the genome at the cost of potentially increased point 
mutations(7). 
Non-elevated but unbalanced nucleotide pools are also highly mutagenic(8, 9). During 
DNA synthesis, excessive amounts of an incorrect nucleotide at the site of elongation can 
dramatically increase mismatches(1), and also can promote frame-shift errors by yeast Pol a and 
in HeLa cell extracts(10). At the most extreme, severely unbalanced dNTP pools, particularly 
those that deplete one or more specific nucleotides, can trigger activation of the S-phase check 
point(9).  
Another significant effect of unbalanced nucleotide pools is instability of mitochondrial 
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DNA, which can manifest as mtDNA depletion, large scale deletions, or point mutations in 
mtDNA. Mitochondrial DNA maintenance  syndromes are a set of heterogeneous disorders that 
can present in almost any tissue at any age (Reviewed in (12), (13)). Homozygous or compound 
heterozygous mutations in the ribonucleotide reductase small subunit p53R2 are important 
causes of mtDNA depletion syndrome(15-17), mimicking the phenotypes of inactivating 
mutations in thymidine kinase and deoxyguanosine kinase (18-21).  In contrast, a dominant 
truncating mutation in the p53R2 gene causes multiple mtDNA deletions in their skeletal muscle 
but normal mtDNA copy number(22). Therefore, perturbed nucleotide pools are known to cause 
diverse forms of mtDNA instability.  
Control over nucleotide abundance and pool balance is accomplished in part through the 
cytosolic enzyme ribonucleotide reductase (RNR)(26). RNR catalyzes the rate-limiting step in de 
novo dNTP biosynthesis(27). The mammalian enzyme is composed of two subunits, a large R1 
subunit encoded by a single gene, Rrm1, and a small R2 subunit, encoded by either Rrm2 or 
Rrm2b (a.k.a. p53R2)(28). Control of RNR activity in mammals is primarily accomplished 
through two main partially redundant mechanisms; limitation of small subunit availability and 
allosteric feedback control. 
The S-phase R2 gene, Rrm2, is not expressed in mammalian cells during quiescent stages 
of the cell cycle(30), but is strongly induced in S-phase to complex with Rrm1 and synthesize 
dNTPs for DNA synthesis(31). The Rrm2 protein is targeted for proteolytic degradation at the 
G2/M transition by the APCCdh1 complex(32), limiting the bulk of RNR activity to S-phase. The 
p53R2 protein is expressed at low levels throughout the cell cycle and a complex of Rrm1 and 
p53R2 is continually active(30).  
We previously described the generation of mice which overexpress individual RNR 
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subunits(33). Modest dNTP pool alterations were observed in the skeletal muscle of mice 
expressing individual RNR transgenes(34), suggesting that overexpression of single RNR 
subunits caused limited net increases in enzyme activity. We also generated mice that feature 
simultaneous overexpression of Rrm1 and either small RNR subunit. Combined overexpression 
of both wild-type RNR subunits caused even greater increases in nucleotide pools and age-
dependent mtDNA depletion(34). 
In addition to control of RNR protein levels, a second regulatory mechanism governing 
RNR activity is allosteric feedback control. The Rrm1D57N mutation disables allosteric feedback 
control and was shown in yeast and in mammalian cell culture models to be mutagenic(6, 37). 
Further experiments in yeast which involved overexpression of rnr1-D57N simultaneously 
disrupted both main regulatory mechanisms controlling RNR activity. This more thorough 
deregulation resulted in constitutively elevated dNTP pools that were able to inhibit origin firing 
in S-phase and cause a slow-growth phenotype. To date, no studies have been performed to test 
the physiological effect of the Rrm1D57N mutation in an in vivo animal model. We therefore 
generated transgenic mice that broadly overexpress the Rrm1D57N mutant to a high degree. 
Here we report on the first model of loss of allosteric feedback control of RNR in mice, 
as well as the effect of simultaneous disruption of multiple regulatory modes of RNR. Whereas 
mice that overexpressed Rrm1-D57N alone were grossly normal, combined overexpression of 
Rrm1-D57N with either small subunit caused synthetic lethality. We show that simultaneous 
overexpression of Rrm1-D57N and either small subunit leads to both increased and unbalanced 
dNTP pools, and the extent of the dNTP pool perturbation correlates with the onset of lethality. 
These manipulations will allow us to study the effects of various degrees of RNR deregulation in 
mice, and more completely understand the complex control of this critical enzyme.  
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MATERIALS AND METHODS 
Plasmids. An expression plasmid encoding mouse Rrm1 was constructed in the pCaggs 
expression vector as described previously (Xu, et al.). Relative to the previously reported Rrm1 
transgene construct, UTR sequences were removed in order to improve expression. The Rrm1 
open reading frame (ORF) was amplified from pCaggs-Rrm1 with primers:  
F: 5’-CTCGTCGACATGCATGTGATCAAGCGAGATGGC-3’  
R: 5’-TCAGGATCCACACATCAGGCACTC-3’ 
The PCR product was cloned into pCR2.1 with the Topo-TA cloning kit (Strategene). Following 
sequencing analysis of the insertion fragment ends to confirm the absence of PCR-induced 
mutations, the PCR-amplified Rrm1 sequence was digested out with StuI and replaced by the 
non-amplified StuI fragment from pCaggs-Rrm1. Fragment orientation was confirmed by SphI 
and EcoRI digestion. The Rrm1 ORF was then excised from pCR2.1 with SalI/XhoI and ligated 
into XhoI-linearized pCaggs.  Fragment orientation was confirmed by BamHI and SalI/XhoI 
digests. The Rrm1-D57N mutation was inserted by site-directed mutagenesis. Briefly, primers 
D57N (5’-CCACAGTGGAACTGAACACCCTGGCTGCT-3’)  
D57N-AS (5’-AGCAGCCAGGGTCAGTTCCACTGTGG-3’)  
were used to amplify the entire pCaggs-Rrm1 plasmid. Following DpnI digestion, products were 
transformed into DH5a and cultured on NZY+ medium. The presence of the mutation was 
confirmed by XcmI digest, as the D57N mutation destroys an XcmI site. The pCaggs-Rrm1-
D57N clone was confirmed to be free of other mutations by sequencing. 
Transgenic mice. Transgenic mice were generated by microinjection of linear plasmid DNA 
into the male pronucleus of FVB/N zygotes. The pCaggs-Rrm1-D57N plasmid was linearized by 
SalI digestion. Transgenic founder mice were identified by Southern blot analysis. Transgenic 
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mice were maintained as hemizygotes on the FVB/N inbred background strain. Genotyping of 
mice expected to carry a single RNR transgene was performed as previously described (33). In 
crosses between Rrm1 or Rrm1-D57N and Rrm2 or p53R2, mice were genotyped by Southern 
blot as described below. 
Southern blot analysis. DNA extracted from tails of adult mice or yolk sacs of embryos was 
subjected overnight to transgene-specific restriction digest and separated on 0.8% agarose gel. 
The Rrm1 and Rrm1-D57N transgenes were detected by digestion with BamHI (Fermentas) and 
the p53R2 transgene was detected by digestion with EcoRV (Fermentas). Following alkaline 
transfer to a nylon membrane (GeneScreen Plus, Perkin Elmer), the presence of transgene DNA 
was detected with a transgene-specific radiolabeled probe.  
Northern blot analysis. Total RNA was extracted from mouse cells with RNAStat-60 (TelTech, 
Inc) and separated on agarose/formaldehyde gel. RNA was transferred to a nylon membrane 
(GeneScreen, Perkin Elmer) and detected with Rrm1- or Gapdh-specific radiolabeled probe. 
Immunoblot analysis. Tissue extracts were prepared by lysis in RIPA buffer (150mM NaCl, 
50mM NaF, 1% NP-40, 0.8% DOC, 0.1% SDS, 50 mM Tris pH 8.0, and 50 mM EDTA) 
supplemented with protease inhibitors (apropinin, 2mg/mL; leupeptin 2mg/mL, and PMSF, 20 
mg/mL) and sodium orthovanadate (400 mM) as a phosphatase inhibitor. Extracts were 
separated on 10% polyacrylamide gel and transferred to PVDF membrane (Perkin Elmer). R1 
protein was detected by AD203, mouse monoclonal anti-R1 (InRo Biomedtek), and loading was 
assessed by detection of a-tubulin with mouse monoclonal anti-a-tubulin (Sigma). To quantify 
overexpression in Rrm1-D57N transgenic mice, serial dilutions were prepared in RIPA buffer. 
The same sample volume necessary for 25 mg of total protein from undiluted lysate was used for 
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the dilution samples. Chemiluminescent signal was detected on a VersaDoc Imaging system and 
quantified using Quantity One software (Bio-Rad Laboratories). Band intensity was determined 
for each dilution series sample and plotted following subtraction of background signal. The 
measured intensity for each undiluted wild-type band was fitted to the generated line for the 
corresponding Rrm1-D57NTg dilution series. Fold overexpression values were corrected for 
loading by standardization based on α-tubulin signal. 
Histology. Adult mice were euthanized by overdose with carbon dioxide. Neonates (mice ages 
P10 and younger) were euthanized by decapitation. Tissues for histological analysis were 
excised and fixed overnight at room temperature in 10% buffered formalin. Tissues were 
sectioned at 5mm thickness prior to staining with hematoxylin and eosin (H&E), Masson’s 
trichrome stain (MT), or Periodic Acid Schiff’s stain (PAS). Adult and neonate sample 
dehydration, embedding, sectioning, and staining were conducted by the Core Histology Lab in 
the College of Veterinary Medicine at Cornell University. Embryos were fixed overnight in 4% 
paraformaldehyde at 4°C, after which time they were transferred to 70% ethanol and kept at 4°C 
during genotyping of yolk sacs. Processed and embedded embryos were sectioned at 5mm 
thickness and were stained with H&E, or Feulgen-Schiff’s. 
Neonate survival assays. Rrm1-D57N(low)Tg female mice were set up in timed matings with 
Rrm2Tg or p53R2Tg males. Females were monitored until pups were born, at which time the pups 
were counted and weighed. Mice were counted and weighed daily until P21. Pups were 
genotyped by Southern blot at weaning or when found dead. Only litters in which the fate of all 
pups was known and in which all control littermates survived the full 21 days or died naturally 
were used in this analysis. Survival plots were generated with SPSS software. 
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Southern blotting for mtDNA copy number determination. 
Total DNA was isolated from tissues by proteinase K digestion and standard phenol-chloroform 
extraction. Southern blotting was performed essentially as described (39). Briefly, three 
micrograms total DNA was digested with SacI overnight at 37◦C, samples were then separated 
by electrophoresis in an agarose gel and blotted by alkaline transfer onto a Hybond N+ 
membrane (Amersham Biosciences). The membrane was hybridized overnight at 68◦C in a roller 
hybridizer using 5 µCi/ml 32P-dCTP labeled (PCR-generated) mouse mtDNA probe, and 18S 
rDNA probe in pBR322 plasmid. Phosphoimager analysis was done with Typhoon 9400 
(Amersham Biosciences) and mtDNA was quantified against the 18S rDNA signal using 
ImageQuant v5.0 software (Amersham Biosciences). 
Real time PCR. 
For mtDNA quantification, the quantitative real-time (Q)PCR reactions were done with 25 ng 
total DNA used as template and normalizing the mt-Cytb gene amplification level (primer 
sequences: 5'-GCTTTCCACTTCATCTTACCATTTA-3' and 5'-TGTTGGGTTGTTTGATCCTG-3') 
against the amplification level of Rbm15, which was used as a nuclear DNA control (primer 
sequences:5’- GGACACTTTTCTTGGGCAAC -3’ and 5’-AGTTTGGCCCTGTGAGACAT-
3’). Samples were run on an Abi Prism SDS 7000 machine (Applied Biosystem). Amplification 
conditions were: 95◦C for 7 minutes followed by 35 cycles of 95◦C for 10 seconds and 60◦C for 
30 seconds. Dissociation curves were checked to ensure the existence of a single PCR product. 
Each sample was run in duplicate, and samples with significant variation between duplicates 
were excluded. QPCR data were analyzed using 7000 System Sequence Detection Software 
version 1.2.3 (Applied Biosystems).  
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Long PCR. 
Long PCR to amplify the entire mitochondrial genome or selectively deleted mtDNA molecules 
was done using the Expand Long Template PCR System (Roche). 25 ng total DNA was used as 
template. Cycling conditions were: 92◦C for 2 minutes followed by 30 cycles of 92◦C for 10 
seconds and 68◦C for 12 minutes. PCR products were separated by electrophoresis on 1% 
agarose gels and visualized with a Typhoon 9400 scanner (Amersham Biosciences). Primers 
hybridized to the control region of mtDNA located at nucleotide positions 1953-1924 and 2473-
2505 (primer sequences 5'- GAG GTG ATG TTT TTG GTA AAC AGG CGG GGT -3' and 5'- 
GGT TCG TTT GTT CAA CGA TTA AAG TCC TAC GTG -3'). 
Extraction of nucleotides from neonate skeletal muscle and embryos. 
Total nucleotides were extracted from neonatal skeletal muscle using the method described in 
(34) with the following modifications: Neonates were euthanized by decapitation and 
immediately dissected in order to prevent nucleotide degradation. Skeletal muscle harvested 
from all four limbs was pooled together and immediately chilled on dry ice. The sample was 
weighed and snap-frozen in liquid nitrogen. Samples were stored at -80°C until nucleotides were 
extracted. Samples were homogenized in cold 10% trichloroacetic acid+15mM MgCl2 for 1 
minute in a Qiagen TissueLyser. Halfway through, samples were incubated on ice for 30 sec.  
Embryos at e10.5 were removed from the uterus and yolk sac in cold 1x PBS and immediately 
ground in 100mL of cold 0.4N perchloric acid using a microcentrifuge tube-fitting pestle. 
Following homogenization, samples were incubated on ice for 20 minutes. The rest of the 
extraction was performed as previously described(34). 
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RESULTS 
Generation of Rrm1-D57N transgenic mice and expression analyses 
We previously showed(33) that mice overexpressing either small RNR subunit, Rrm2 or 
p53R2, develop lung neoplasms at a high frequency, but the effect of hyperactive RNR in 
mammals has not been addressed. To assess the effect of loss of RNR allosteric feedback 
control, we generated mice that overexpress a mutant form of the large subunit. The previously 
identified Rrm1D57N mutant harbors a point mutation in the activity site of the large subunit that 
disables feedback control(37). The Rrm1D57N mutation was shown in both yeast and in a 
mammalian cell culture model to be mutagenic(6, 37), but the effect of loss of allosteric 
feedback control in an in vivo mammalian model has yet to be determined. To generate 
transgenic mice overexpressing Rrm1-D57N, we modified the previously-generated pCaggs-
Rrm1 construct. Two independent transgenic founder animals were obtained (Fig 1A, lanes 6 and 
12). The founder animal in lane 12 showed greater transgene signal and the presence of two 
different transgene bands whereas the founder in lane 6 showed a single band of lower relative 
intensity; the resulting strains are referred to hereafter as Rrm1-D57N(low)Tg (lane 6) and Rrm1-
D57N(high)Tg (lane 12). The strains were maintained on a pure FVB/N background.  
Endogenous and transgenic expression was assessed in a variety of tissues in Rrm1-
D57N(high)Tg and wild-type FVB mice by Northern blot analysis (Fig 1B). In wild type FVB 
mice, Rrm1 was detected most strongly in the most proliferative tissues, the testis and thymus 
(Fig 1B, left). Northern blot analysis of Rrm1-D57N(high)Tg mice revealed two bands 
corresponding to Rrm1 transcript, the upper band from the endogenous locus was the 
predominant band in the spleen and thymus, while the lower band from the transgene 
predominated in lung, liver, kidney, and skeletal muscle.  
 179 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Generation of Rrm1-D57N overexpressing mice. A. Southern blot analysis of DNA 
from potential Rrm1-D57NTg founder animals. Tail DNA from potential founder animals was 
subjected to hybridization with Rrm1-specific radiolabeled probe. Arrows indicate bands 
corresponding to endogenous Rrm1 gene and Rrm1-D57N transgene. Asterisks denote founder 
DNA showing presence of Rrm1-D57N transgene. Note that the founder in lane 12 [referred to 
as Rrm1-D57N(high)] shows an additional transgene band, indicating integration of a greater 
amount of the transgene DNA than the founder in lane 6 [Rrm1-D57N(low)]. B. Northern blot 
analysis of Rrm1 expression in wild type and Rrm1-D57N(high) mice. Total RNA was extracted 
from the indicated tissues of wild type FVB (left panel) and Rrm1-D57N(high) transgenic mice 
(right panel) and subjected to Northern blot analysis with a radiolabeled Rrm1-specific probe. 
Positions of endogenous- and Rrm1-D57N-derived transcripts are indicated. Total RNA is shown 
as a loading control. Note that skeletal muscle lane in right panel was intentionally underloaded. 
Wild type FVB panel is reprinted from Xu et al.(33) C. Immunoblot analysis of Rrm1 protein 
expression in the indicated tissues of wild type (wt), Rrm1-D57N(low)Tg (L), and Rrm1-
D57N(high)Tg (H) transgenic mice. Total protein from the indicated tissues was detected with 
R1-specific antibody. The same membrane was probed with an antibody specific to a-tubulin as 
a loading control. D. Measurement of dNTP pools in the skeletal muscle of adult wild type, 
Rrm1Tg and Rrm1-D57N(high)Tg mice. Total nucleotides were extracted from the skeletal muscle 
of mice of the indicated genotypes and were assayed using the indirect enzymatic method of 
Sherman and Fyfe, with modifications by Ferraro, et al.  
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The expression results obtained by Northern blot analysis were confirmed by immunoblot 
(Fig 1C). We assessed total R1 protein levels in tissues obtained from wild type FVB mice (wt), 
Rrm1-D57N(low)Tg mice (L), and Rrm1-D57N(high)Tg (H) mice. In agreement with the Southern 
blot in Fig 1A, Rrm1-D57N(high)Tg mice showed higher R1 protein levels than Rrm1-
D57N(low)Tg mice, which were intermediate between wild type and Rrm1-D57N(high)Tg levels. 
To obtain a more precise value for Rrm1-D57N overexpression in tissues from transgenic mice, 
we utilized the serial dilution method reported previously(34). Because pCaggs drives the 
greatest expression in skeletal and cardiac muscle, we assessed the level of D57N overexpression 
in these two tissues (Supplementary Figure 1). We found that the D57N(low)Tg was expressed 
roughly 94-fold (93.99x) in the skeletal muscle while the D57N(high)Tg was expressed over 600-
fold (608.41x).  
We next wanted to address whether overexpression of Rrm1-D57N in mice would cause 
changes to the dNTP pools. We previously reported that mice that overexpress either of the small 
RNR subunits, Rrm2 or p53R2, show elevated and unbalanced dNTP pools in the skeletal 
muscle, the tissue with the highest level of overexpression. We therefore measured dNTPs from 
the skeletal muscle of wild type, Rrm1Tg, and Rrm1-D57N(high)Tg aged 3-6 months (Figure 1D). 
We found no dNTP pool elevations in the Rrm1Tg mice compared to wild type mice, consistent 
with our findings from a previous study(34). We found modest elevations in the skeletal muscle 
from Rrm1-D57N(high)Tg (2.4-fold over wild type), but these were not statistically significant 
when compared to either wild type or Rrm1Tg mice.  
Even with the high levels of Rrm1-D57N overexpression, mice harboring the transgenes 
appeared grossly normal and were obtained at expected frequencies (Table 1). In crosses 
between wild type FVB mice and Rrm1-D57N(low)Tg mice, 256 wild type and 231 transgenic  
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Table 1: Rrm1-D57N transgenic mice are obtained at expected frequencies.a 
 
 
 
 
 
a Mice harboring Rrm1-D57N(low)Tg or Rrm1-D57N(high)Tg were crossed to wild type FVB 
mice. Progeny were genotyped at weaning by PCR. Observed numbers of animals of each 
genotype are indicated with expected number in parentheses. 
 
 
 
 
 
 
 
 
cross genotype # offspring 
wt FVB x Rrm1-
D57N(low)Tg 
wild type 256 (243.5) 
R1Tg 231 (243.5) 
   
wt FVB x Rrm1-
D57N(high)Tg 
wild type 275 (260.5) 
R1Tg 246 (260.5) 
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mice were obtained (p=0.26, c2). Likewise, crosses between wild type FVB and Rrm1-
D57N(high)Tg mice yielded 275 wild type and 246 transgenic mice (p=0.20, c2). In order to 
assess the phenotypic effects of loss of RNR allosteric regulatory control in mice, we generated a 
cohort of Rrm1-D57N(low)Tg, Rrm1-D57N(high)Tg, and transgene-negative control mice and 
aged them to a maximum age of 18 months. Necropsy of these mice revealed that mice harboring 
either D57N transgene were grossly normal relative to wild type control animals. We found a 
modest increase in the lung tumor incidence in both Rrm1-D57N(low)Tg (36.73%, n=49) and 
Rrm1-D57N(high)Tg (34.62%, n=26) mice compared to wild type mice (27.27%, n=44). Mean 
tumor size, tumor multiplicity, and histopathological grade were not altered by overexpression of 
Rrm1-D57N.  
The Rrm1-D57N mutation has been previously reported to be mutagenic in both yeast(6) 
and mammalian cells(37). To assess the mutagenic potential of Rrm1-D57N overexpression, we 
used the Big Blue mutation detection system to measure the mutant frequency in the lungs of 
Rrm1-D57N(low)Tg and Rrm1-D57N(high)Tg mice, and also combined overexpression of Rrm1-
D57NTg with a mismatch repair deficiency caused by loss of Msh6. We found no difference in 
the mutation frequency in either Rrm1-D57NTg strain compared to wild type mice. Rrm1-D57N 
overexpression also failed to synergize with mismatch repair deficiency to significantly shorten 
lifespan or accelerate tumor development. These results suggest that overexpression of an RNR 
mutant defective for allosteric feedback control has limited effects in mice. 
Simultaneous overexpression of Rrm1-D57N and either small RNR subunit causes synthetic 
lethality 
We previously reported (34) that combined overexpression of Rrm1 and either small 
RNR subunit resulted in viable mice which developed late-onset mitochondrial DNA (mtDNA) 
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depletion. In crosses between Rrm1Tg and Rrm2Tg, roughly 49 bitransgenic mice were expected 
and 46 were observed; similarly, in crosses between Rrm1Tg and p53R2Tg, 33 bitransgenic mice 
were observed of about 38 expected. However, those mice only exhibited disruption of one RNR 
regulatory mechanism, control of RNR activity through limitation of small subunit protein levels. 
As previously stated, mice overexpressing Rrm1-D57N alone were also obtained at expected 
frequencies and were grossly normal. In order to assess the effect of simultaneous disruption of 
multiple RNR regulatory modes, we crossed mice overexpressing either small RNR subunit with 
mice overexpressing Rrm1-D57N. We used each Rrm1-D57N strain individually in these 
crosses, resulting in four possible overexpression combinations. We found that mice with either 
level of Rrm1-D57N overexpression and either small RNR subunit were not viable (Table 2). 
Specifically, of an expected 30 Rrm1-D57N(high)Tg + p53R2Tg bitransgenic mice, 0 were 
obtained. Likewise, 51.25 Rrm1-D57N(low)Tg + p53R2Tg bitransgenic mice were expected and 0 
were observed, and 26.5 Rrm1-D57N(high)Tg + Rrm2Tg bitransgenic mice were expected and 0 
were obtained. Interestingly, of 69.75 expected Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice 
expected, 5 were obtained that survived to adulthood. Of the five surviving bitransgenic adults, 
two survived only 21 days and one only 25 days. The last two mice were littermates, one female 
surviving 90 days and one male surviving 102 days. These results suggest that simultaneous 
disruption of multiple regulatory mechanisms of RNR is incompatible with survival in mice. 
Lethality manifests at different stages depending on cross 
 While rare surviving adult Rrm1-D57N(low)Tg + Rrm2Tg mice were obtained, no other 
cross produced any surviving offspring. To determine the exact stage of lethality, we dissected 
embryos from Rrm1-D57N(high)Tg x p53R2Tg mice (Fig 2A). Through embryonic day 10.5 
(e10.5), bitransgenic embryos were observed at the expected frequencies, and most were grossly  
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Table 2. Synthetic lethality upon simultaneous overexpression of Rrm1-D57N and either 
small RNR subunit. 
 
Note: Mice harboring Rrm1Tg, Rrm1-D57N(low)Tg , or Rrm1-D57N(high)Tg were crossed to mice 
carrying either the Rrm2 or p53R2 transgene. Progeny were genotyped at weaning by Southern 
blot. Observed numbers of animals of each genotype are indicated with expected number in 
parentheses. 
a p<0.05, c2 test. 
 
 
 
 
 
 
 
cross genotype Rrm1Tg (wt) Rrm1-
D57N(low)Tg 
Rrm1-
D57N(high)Tg 
R1Tg x Rrm2Tg wild type 57 (48.75) 96 (69.75) 33 (26.5) 
 R1Tg 54 (48.75) 93 (69.75) 35 (26.5) 
 Rrm2Tg 38 (48.75) 85 (69.75) 38 (26.5) 
 R1Tg + Rrm2Tg 46 (48.75) 5 (69.75)a 0 (26.5)a 
     
R1Tg x p53R2Tg wild type 29 (37.25) 77 (51.25) 51 (30) 
 R1Tg 52 (37.25) 68 (51.25) 40 (30) 
 p53R2Tg 35 (37.25) 60 (51.25) 29 (30) 
 R1Tg + p53R2Tg 33 (37.25) 0 (51.25)a 0 (30)a 
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Figure 2. Gross morphology of Rrm1-D57N(high)Tg + Rrm2Tg or p53R2Tg bitransgenic 
embryos. A. Rrm1-D57N(high)Tg + p53R2Tg bitransgenic embryos. Bitransgenics are grossly 
normal through 11.5 dpc. At 12.5 dpc, dead bitransgenic embryos were observed. B. Rrm1-
D57N(high)Tg + Rrm2Tg bitransgenic embryos and controls. Bitransgenics are found dead as 
early as 13.5 dpc. Some normal embryos are observed at e14.5.  
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normal. After e12.5, only dead bitransgenic embryos were observed, and were fewer than 
expected. These embryos lacked blood within the vessels of the yolk sac (data not shown). The 
frequency of resorbed embryos increased over the time frame analyzed, with few resorptions 
being observed before e10.5, but 8, 19 and 9 resorptions at e10.5, e11.5 and e12.5, respectively. 
Life span of Rrm1-D57N(high)Tg + p53R2Tg mice was summarized in Table 2. 
Bitransgenic embryos derived from crosses between Rrm1-D57N(high)Tg and Rrm2Tg 
mice displayed great variability in lifespan. As early as e10.5, abnormal bitransgenic embryos 
were observed. Normal bitransgenic embryos were observed through e17.5 but at lower than 
expected frequencies, and two bitransgenic mice were observed that had survived gestation but 
died immediately after birth. Life span of Rrm1-D57N(high)Tg + Rrm2Tg mice was summarized 
in Table 3.  
The lifespan of Rrm1-D57N(low)Tg + p53R2Tg bitransgenic mice was intermediate 
between that of Rrm1-D57N(high)Tg + Rrm2Tg mice and Rrm1-D57N(low)Tg + Rrm2Tg mice 
(Figure 3). Rrm1-D57N(low)Tg + p53R2Tg bitransgenic mice survived birth and developed 
normally through approximately 4 days. However, survival of these bitransgenics decreased 
rapidly at P5, with all bitransgenics observed dying between P5 and P8 (Fig 3D). The frequency 
of Rrm1-D57NTg + p53R2Tg and Rrm1-D57NTg + Rrm2Tg mice at weaning age is summarized in 
Table 2. Overall, higher levels of expression of Rrm1-D57N cause a shorter lifespan, while 
overexpression of p53R2 has more severe effects when combined with Rrm1-D57N than does 
overexpression of Rrm2. 
Altered dNTP pools in the skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
mice 
 We hypothesized that simultaneously removing both main regulatory mechanisms  
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Table 3. Lifespan of Rrm1-D57N(high)Tg + p53R2Tg bitransgenic embryos.a 
 
a Females harboring the Rrm1-D57N(high) transgene were mated to males harboring the p53R2 
transgene. At the indicated time points (in days post coitus or dpc) females were euthanized by 
CO2 asphyxiation and the embryos analyzed. DNA isolated from the yolk sacs was genotyped by 
Southern blot analysis. Total numbers of embryos of each genotype observed are indicated with 
expected numbers. Numbers in parentheses indicate dead and abnormal embryos. 
 
 
 
 
 
 
 
 Rrm1-D57N(high)Tg x p53R2Tg 
! wild type Rrm1-D57NTg p53R2Tg bitransgenic  
stage # obs (#exp) # obs (#exp) # obs (#exp) # obs (#exp) resorptions 
9.5 5 4.5 6 4.5 3 4.5 4(1) 4.5 2 
10.5 37(3) 26.75 24 26.75 14 26.75 32(1) 26.75 8 
11.5 54 30.5 29 30.5 36 30.5 13(3) 30.5 19 
12.5 25 16.5 14 16.5 16 16.5 11(11) 16.5 9 
13.5 12 10.25 17(2) 10.25 10(1) 10.25 2(2) 10.25 1 
14.5 7 4 5 4 4 4 0 4 0 
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Table 4. Lifespan of Rrm1-D57N(high)Tg + Rrm2Tg bitransgenic embryos.a 
 
a Females harboring the Rrm1-D57N(high) transgene were mated to males harboring the Rrm2 
transgene. At the indicated time points (in days post coitus or dpc) females were euthanized by 
CO2 asphyxiation and the embryos analyzed. DNA isolated from the yolk sacs was genotyped by 
Southern blot analysis. Total numbers of embryos of each genotype observed are indicated with 
expected numbers. Numbers in parentheses indicate dead and abnormal embryos. 
 
 
 
 
 
 
 Rrm1-D57N(high)Tg x Rrm2Tg 
 wild type Rrm1-D57NTg Rrm2Tg bitransgenic  
stage # obs (#exp) # obs (#exp) # obs (#exp) # obs (#exp) resorptions 
9.5 3 4 5 4 3 4 5 4 0 
10.5 7 7.25 3 7.25 11 7.25 8(1) 7.25 3 
11.5 6 6 6 6 7 6 5 6 9 
12.5 8 10 7(1) 10 16 10 9(1) 10 2 
13.5 2 8.25 7 8.25 13(1) 8.25 11(6) 8.25 1 
14.5 2 4 2 4 7 4 5(3) 4 1 
15.5 7 9.25 9(1) 9.25 11(1) 9.25 10(7) 9.25 1 
16.5 1 4 3 4 7 4 5(1)% 4 0 
17.5 7 7 6 7 12(1) 7 4(3) 7 0 
18.5 11(1) 8.75 7 8.75 17 8.75 0 8.75 7 
19.5 4 2.75 4(1) 2.75 3 2.75 0 2.75 0 
P0 9 4.5 3 4.5 4 4.5 2(2) 4.5 0 
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Figure 3. Reduced survival of bitransgenic mice. A. Gross morphology of Rrm1-D57N(low)Tg 
+ p53R2Tg bitransgenic mice. B. Reduced survival of bitransgenic mice derived from Rrm1-
D57N(low)Tg x p53R2Tg cross. Pups were counted on P0 (day of birth) and monitored daily. Pups 
were genotyped by Southern blot analysis of tail DNA at 21 days of age or when found dead. 
Bitransgenic mice (purple line) have a 50% survival rate of 5 days. C. Gross morphology of 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice. Bitransgenic mice are runted and show alopecia 
and decreased activity. A bitransgenic mouse (right) is pictured at P15 with a wild type littermate 
(left). D. Survival of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice. Pups were genotyped by 
Southern blot analysis of tail DNA at 21 days of age or when found dead. Bitransgenics 
surviving past 21 days of age were housed with sex-matched littermates and monitored 
frequently, and euthanized when moribund.  
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governing RNR activity would lead to elevated and/or unbalanced nucleotide pools, which may  
have consequences for genomic stability and survival. We next wanted to test whether RNR 
deregulation in mice caused lethality through alterations to dNTP pools. In order to test this, we 
extracted total nucleotides from the skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic neonates at P5. The total amount of each dNTP was measured using the indirect 
enzymatic assay described by Sherman and Fyfe with modifications(34, 40, 41). Remarkably, the 
level of dATP in Rrm1-D57N(low)Tg + Rrm2Tg  bitransgenic muscle tissue was increased over 
300-fold over wild type (Figure 4A). This increase in dATP actually interfered with the assays to 
measure dGTP, dCTP, and dTTP by competing with the radiolabeled dATP for incorporation 
into the DNA product. We therefore measured dNTPs in the bitransgenics by preparing 10- or 
100-fold dilutions and compared the dNTP level to undiluted control samples. Levels of each 
nucleotide were increased in the bitransgenics relative to wild type mice; dATP was increased 
335-fold, dGTP was increased 2.55-fold, dCTP was increased 8.78-fold, and dTTP was 
increased 12.57-fold. The data are summarized in Figure 4A. These results suggest that 
simultaneous disruption of multiple regulatory modes of RNR dramatically elevates RNR 
activity and leads to significant increases in dNTP levels.  
Of the four RNR transgene combinations that result in synthetic lethality, the Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice display the least severe phenotype and the longest 
lifespan, yet show dramatic dNTP pool alterations within the skeletal muscle. We therefore 
hypothesized that the combination which produces the most severe phenotype, Rrm1-
D57N(high)Tg x p53R2Tg, would show a more dramatic increase in dNTPs, which would 
correlate with the early lethality. We tested this hypothesis by extracting nucleotides from the 
skeletal muscle from Rrm1-D57N(low)Tg + p53R2Tg neonates (Figure 4B) and from whole  
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Figure 4. dNTP pool alterations in bitransgenic embryos and neonates. A. dNTP pools in 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic neonates. Total nucleotides were extracted from the 
skeletal muscle of bitransgenic and control littermates at P5. Each dNTP was measured by an 
indirect enzymatic assay. Results are normalized for total amount of tissue used. B. dNTP pools 
in Rrm1-D57N(low)Tg + p53R2Tg bitransgenic neonates at P3 or P5. C. dNTP pools from whole 
embryos derived from the Rrm1-D57N(high)Tg x p53R2Tg cross at e10.5. D. dNTP pools from 
whole embryos derived from the Rrm1-D57N(low)Tg x Rrm2Tg cross at e10.5. E. NDP precursor 
pools in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic neonate skeletal muscle. Nucleotides are 
measured by HPLC and compared to standard curves. 
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embryos derived from the Rrm1-D57N(high)Tg x p53R2Tg cross at e10.5 (Figure 4C).  
While dNTP pools were again elevated and unbalanced in the Rrm1-D57N(low)Tg + 
p53R2Tg neonatal skeletal muscle, they were not perturbed to the same extent as in Rrm1-
D57N(low)Tg + Rrm2Tg neonates.  
We were surprised to find that dNTP pools were only moderately altered in Rrm1-
D57N(high)Tg + p53R2Tg bitransgenic embryos relative to wild type embryos. dATP showed a 
3.99-fold increase, while dGTP was increased 3.91-fold, dCTP was increased 1.26-fold, and 
dTTP was increased 1.94-fold. The increases in dATP and dGTP are statistically significant 
(p=0.02 and p=0.01, respectively, Student’s t-test), while the changes in dCTP and dTTP are not. 
However, these results suggest the simultaneous overexpression of Rrm1-D57N(high)Tg and 
p53R2Tg generate altered dNTP pools in developing embryos. 
These results suggested that the timing of lethality is dictated in part by dNTP pool 
alterations during embryonic development. We hypothesized that if Rrm1-D57N(high)Tg + 
p53R2Tg bitransgenic embryos show only minor dNTP pool changes yet die during mid-
gestation, then perhaps embryos carrying the Rrm1-D57N(low) transgene are able to survive 
gestation because they exhibit no dNTP pool changes as embryos, and show dramatic increases 
in dNTP pools later as the transgenes become highly expressed within the skeletal muscle. We 
tested this hypothesis by extracting and measuring dNTPs in whole embryos derived from the 
Rrm1-D57N(low)Tg + Rrm2Tg cross at e10.5. We found no difference in any of the dNTPs 
between the genotypes, supporting our hypothesis. The data are summarized in Figure 4D. 
Extreme RNR hyperactivity could not only elevate dNTP pools to toxic levels, but could 
conceivably also deplete the pools of precursors. In order to test whether this was occurring in 
our bitransgenic neonates, we measured the levels of the NDPs (CDP, UDP, GDP, and ADP) by 
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HPLC (Figure 4E). We again found no differences between genotypes. These data suggest that 
elevated RNR activity causes increased and unbalanced dNTP pools, but not depleted precursor 
pools. 
Mitochondrial genome instability does not cause synthetic lethality in the bitransgenics 
We previously reported age-dependent mtDNA depletion in wild-type Rrm1Tg + Rrm2Tg 
or p53R2Tg mice, to levels of approximately 40% compared to wild-type (42). Furthermore, 
mtDNA depletion to <1-10 % in mice is known to be lethal during embryonic development (43) 
and after birth (15). Therefore, we asked if the synthetic lethality of Rrm1-D57NTg + Rrm2Tg or 
p53R2Tg bitransgenic mice was caused by mtDNA instability. We measured mtDNA copy 
number in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice at juvenile (P4 and P8), young adult 
(P19 and P25), and aged adult (P90 and P102) mice (Figure 5A). We found that the bitransgenic 
mice had normal mtDNA copy numbers in the skeletal muscle at P4 and P8. However, while 
mtDNA copy number in skeletal muscle of control mice increased with age, mtDNA copy 
number in the skeletal muscle of bitransgenic mice failed to expand to the same level throughout 
development. At P19, mtDNA copy number in bitransgenic mice was ~50% of the wild type 
level. In the two mice that survived to 90 and 102 days, mtDNA copy numbers in skeletal muscle 
were 30 % and 62 % of the wild-type levels, respectively. Therefore, as the mice aged beyond 
P19, the mtDNA levels remained lower in the Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice 
than in wild-type mice, but the depletion did not appear to progress below the levels present at 
P19. The data are summarized in Figure 5A. 
We measured mtDNA copy numbers also in other tissues of the Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice. In heart, the mtDNA level remained similar to wild-type both at P8 
and P25.  In liver and kidney, the mtDNA copy numbers were normal at P8, and showed a  
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Figure 5. mtDNA integrity in bitransgenic mice. A. mtDNA copy number in bitransgenic mice 
from the Rrm1-D57N(low)Tg x Rrm2Tg cross. Total DNA was extracted from skeletal muscle of 
bitransgenic and control mice at different stages of development: juvenile=P4, P8; young adult= 
P19, P25; aged adult=P90, P102.mtDNA is quantified by qPCR and normalized to the nuclear 
18S rRNA. B. Long PCR on mtDNA from skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic and wild type littermate at P25. Only the full 16 kb mtDNA is detected. C. Activity 
of respiratory chain complexes in skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
and wild type littermate at P25. Tissues are stained for activity of the mtDNA-encoded complex 
IV (COX, brown), the nDNA-encoded complex II (SDH, blue), or both. 
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tendency to decrease at P19 and P25 but this difference was not statistically significant (data not 
shown). These results suggest that simultaneous overexpression of Rrm1-D57N(low)Tg and 
Rrm2Tg delays  the developmental amplification of mtDNA, but the residual mtDNA is higher 
than the minimum threshold reported to escape pathogenic mtDNA depletion in mice.  
In addition to quantitative mtDNA defects, alterations to dNTP pools have been 
suggested to cause mtDNA point mutations and large scale mtDNA deletions in humans 
(Tyynismaa et al. Am J Hum Genet. 2009 Aug;85(2):290-5, Nishino et al. Science. 1999 Jan 
29;283(5402):689-92,, Nishigaki et al. J Clin Invest. 2003 Jun;111(12):1913-21.). We sequenced 
mtDNA in the hypervariable control region and the cytochrome b gene regions but found no 
increase in mtDNA point mutations in skeletal muscle of D57N(low)Tg + Rrm2Tg bitransgenic 
mice at P25 (data not shown). To determine whether mtDNA deletions were present, we 
performed long PCR to assess the total size of the mtDNA in P25 bitransgenic mice. In both wild 
type and Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, we detected only the full-length 
mtDNA (16kb) in skeletal muscle (Figure 5B), kidney and heart (data not shown), indicating that 
no deletions were formed in the mtDNA of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice. 
 A clinically significant defect of mtDNA maintenance leads to dysfunction of respiratory 
chain complex IV (cytochrome c oxidase, COX) that is partially encoded by mtDNA.  
Compensatory hyperproliferation of mitochondria, which can be observed as increased activity 
of the nuclear encoded complex II (succinate dehydrogenase, SDH), is also frequently observed. 
We performed the COX/SDH assay on frozen skeletal muscle from the P25 bitransgenic, which 
displayed ~50% mtDNA, and a wild type littermate (Figure 5C). We found normal COX activity 
in the muscle of the bitransgenic mouse, and no increase in SDH signal.  
 Taken together, these results showed that extreme upregulation of dNTP pools in 
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bitransgenic D57N(low)Tg + Rrm2Tg mice caused age-dependent mtDNA depletion in skeletal 
muscle, but no point mutations or deletions. The mice were born with normal mtDNA copy 
numbers, suggesting that mtDNA maintenance was not impaired during embryonic development. 
Finally, the mtDNA depletion was not deep enough to impair respiratory chain function, as 
determined by the COX/SDH activity assay. 
Bitransgenic neonates display pleural effusion, hepatocellular swelling, and kidney 
degeneration. 
The aforementioned muscle defects were only observed in Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice that survived to adulthood, but do not account for the earlier lethality observed 
in this and the other synthetic lethal crosses. We therefore sought to determine the defects that 
arise in the more severely-affected mice via histological staining of a wide range of tissues at 
earlier time points. Mice were monitored and weighed daily from birth in order to be able to 
predict when the bitransgenics might expire; at that time the entire litter was culled for 
histological analysis. Liver, kidneys, and muscle tissues were all examined by H&E staining for 
changes in morphology.  
We first noticed upon necropsy that Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, but 
not control mice, showed pleural effusion. Fluid accumulation affected the entire pleural cavity, 
and in mice surviving 8 days or later, was also observed within the abdomen. Pleural effusion 
was observed in roughly 50% of all Rrm1-D57N(low)Tg + Rrm2Tg neonates as early as P4. At P5 
and later, all bitransgenic neonates displayed the fluid accumulation. However, effusion was not 
observed in the mice surviving 19 days or longer. In order to determine the type of the pleural 
effusion, we collected the fluid and analyzed the constituents. Total fluid albumin content among 
three bitransgenic neonates averaged 1.1 g/dL; the total fluid protein content averaged 1.67 g/dL. 
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Pleural effusions with less than 1.6g/dL albumin and less than 2.0 g/dL total protein are 
considered transudative. 
In order to determine the cause of the pleural effusions, we analyzed liver, intestine, 
spleen, kidney, heart, lung, skeletal muscle, and brain via H&E staining. Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice surviving to 9 or 11 days of age showed kidney degeneration. Kidneys 
exhibited degeneration of renal tubules, edema, dilated tubules, and fibrosis (Figure 6A). This 
phenotype was not observed in the kidneys of 3-month-old bitransgenic mice.  
We also found that bitransgenic neonates displayed hepatocellular swelling at p6 (n=4), 
p7 (n=5), p8 (n=2), p9 (n=1), and p11 (n=1) (Figure 6C and data not shown). Examination of the 
liver isolated from bitransgenic mice surviving 3 months of age did not show the same 
phenotype (DNS). Hepatocytes can accumulate either glycogen or lipid to show the swollen 
phenotype. To distinguish between these two possibilities, we performed periodic acid Schiff’s 
(PAS) staining on liver samples from selected bitransgenics and control animals. Liver from a 
bitransgenic neonate at P11 showed a lack of red staining, indicating lipid accumulation in those 
cells (DNS). However, a bitransgenic neonate aged P9 showed hepatocytes with lipid 
accumulation as well as hepatocytes with glycogen (Figure 6D).  
Severe muscle degeneration in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice 
Of approximately 70 Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic adults expected, only 5 
were observed. The few surviving Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice were runted 
compared to littermates. Throughout life, bitransgenic mice were hunched, inactive, and 
displayed small muscles and alopecia. All bitransgenic mice showed a significant loss of body 
weight prior to death. Upon necropsy, we found that bitransgenic mice which survived 90 days 
or longer exhibited severe skeletal and cardiac muscle degeneration. H&E staining of  
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Figure 6. Spectrum of phenotypes in Rrm1-D57NTg + Rrm2Tg bitransgenic neonates. A. 
Kidney degeneration in bitransgenic animals. Tissues were harvested from bitransgenic and 
control littermates at P11 and fixed overnight in 10% formalin. Sections were stained with H&E. 
The bitransgenic shows degeneration of cortical tubules (arrows), dilated tubules in the medulla 
(arrowheads), and fibrosis (thick arrows). B. Hepatocellular swelling in bitransgenic liver. 
Tissues were harvested from bitransgenic and control littermates at P9 and fixed, sectioned, and 
H&E stained as previously. Arrow indicates focus of hepatocytes with abnormal accumulations 
of lipid or glycogen, leading to swollen appearance. C. Periodic acid Schiff’s stain of neonate 
livers from (B). Hepatocytes with glycogen accumulation stain fuschia, while hepatocytes with 
lipid accumulation remain mostly white. Glycogen is abundant in the wild type liver but does not 
accumulate within hepatocytes. 
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bitransgenic and control skeletal muscle samples reveals disorganized fibers and large, open 
nuclei, in the bitransgenic (Fig 7A). To further investigate the degree of muscle degeneration, we 
performed Masson’s trichrome staining on duplicate sections of the same samples. Staining with 
Masson’s trichrome stain also revealed severe degeneration in the bitransgenic, as demonstrated 
by vacuoles appearing within the skeletal muscle fibers and extensive fibrosis developing 
between muscle fibers (Fig 7A). Histological analysis of cardiac muscle tissue also revealed 
severe degeneration (Fig 7B). Analysis of a wider range of tissues did not reveal marked 
degenerative changes, suggesting that degeneration was limited to skeletal and cardiac muscle 
tissues. Taken together, these results suggest that high-level overexpression and deregulation of 
RNR leads to elevated dNTP pools that correlate with overexpression levels and cause tissue-
specific degeneration. 
DISCUSSION 
Previously works have analyzed the results of disabling RNR via small subunit 
overexpression or by mutation of the allosteric activity site. Because deregulating RNR by 
disabling allosteric feedback control had limited phenotypes, we sought to further deregulate the 
enzyme by simultaneously disrupting both main regulatory modes. In yeast, simultaneous 
disruption of the two main regulatory mechanisms caused constitutively elevated dNTP pools, 
which resulted in proliferation defects(38). In order to determine if mice would have a similar 
phenotype, we crossed mice overexpressing either Rrm1-D57N transgene to mice overexpressing 
either small RNR subunit. In mice, cell proliferation defects would be expected to lead to 
embryonic lethality, as cell division is required for embryogenesis. Our first observation was that 
the combination of Rrm1-D57N and either small RNR subunit causes synthetic lethality in mice, 
which would be predicted by the previous model. We next found that the timing of the lethality  
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Figure 7. Muscle degeneration in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic adult mice. 
Degeneration of skeletal muscle (A.) and cardiac muscle (B.) in bitransgenic adults. Tissues from 
90-day old mice were fixed overnight in formalin at room temperature prior to embedding and 
sectioning. Tissues were stained with H&E (i-iv) or Masson’s trichrome (v-viii). Both skeletal 
and cardiac muscle from bitransgenic mice (A: iv, viii, B: iv, viii) display irregular fiber size and 
shape, large internal nuclei (white arrows), interstitial replacement fibrosis (white arrowheads), 
and vacuoles within muscle fibers (black arrowheads).  
 
 
 
 
 
 
 206 
was determined by which specific transgenic combination was expressed. Combination of Rrm1-
D57N(high)Tg with either small subunit caused embryonic lethality. The Rrm1-D57N(low)Tg 
strain, when paired with Rrm2Tg or p53R2Tg, was able ,to survive longer, through gestation, but 
the lifespan is still significantly shortened and lasts a matter of days. In both cases the presence 
of the p53R2Tg makes the phenotype more severe than having Rrm2Tg. This may be due to the 
differential patterns of expression of Rrm2 and p53R2. p53R2 is expressed at very low levels 
throughout the cell cycle, while during S-phase, Rrm2 is expressed very highly. High-level 
overexpression of p53R2 would then be expected to cause a more significant deregulation of 
RNR than overexpression of Rrm2.  That some bitransgenic mice are able to survive through 
gestation contradicted our hypothesis. These findings indicate that while RNR is deregulated to a 
lethal extent in these mice, it is not sufficiently altered to cause cellular defects.  
In order to explain the lethality caused by simultaneous disruption of both main 
regulatory modes of RNR, it was necessary to determine whether nucleotide pools were altered 
in bitransgenic mice, and to what extent. We hypothesized that if the least-severe combination 
resulted in altered nucleotide pools, then the other three combinations must also alter nucleotide 
pools, and may provide for a mechanism by which severe RNR deregulation results in lethality. 
We therefore measured nucleotides from the skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice and control littermates at P5 and P6. We found that dNTP pools were 
dramatically elevated and unbalanced, resulting in a greater than 300-fold increase in dATP, 
while dCTP and dTTP were increased about 10-fold, and dGTP was increased 50%. This was 
consistent with our previous findings that both the Rrm1-D57N(low)Tg and Rrm2Tg transgenes 
are highly overexpressed within the skeletal muscle. These significant changes support a role for 
RNR hyperactivity in causing synthetic lethality. 
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We also found support for the hypothesis that the extent of dNTP pool alteration 
determines lifespan. We found that dNTP pools were significantly altered in the Rrm1-
D57N(high)Tg + p53R2Tg bitransgenic embryos, which die around e12.5, but not in the Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic embryos, which survive gestation and die about 1 week 
after birth. This indicates that any dNTP pool alteration has severe consequences for developing 
embryos, while a tissue-specific increase in dNTPs can be tolerated for a short time. 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, the least severe combination, were 
severely underrepresented in adulthood, most having succumbed to illness within the first 2 
weeks of life. Rare surviving bitransgenic adults displayed severe skeletal and cardiac muscle 
degeneration. In addition to muscle degeneration, they also displayed a general wasting 
phenotype, kyphosis, and alopecia. Taken together, these phenotypes are consistent with 
premature aging. Mice harboring a proofreading-deficient DNA Pol g with an increased rate of 
mtDNA point mutations  also display premature aging (48), suggesting that destabilization of 
the mitochondrial genome may play a role in this synthetic lethality. Indeed, altered dNTP pools 
are thought to underlie mtDNA instability in several mitochondrial disorders in humans, and in 
mouse models. For instance, knock-out mice lacking p53R2 developed post-natal mtDNA 
depletion leading to early death{Bourdon, 2007 #166},{Kimura, 2003 #165}. We also 
previously noted that mice  overexpressing Rrm1Tg and Rrm2Tg or p53R2Tg displayed age-
dependent mtDNA depletion, which was associated with altered dNTP pools in the skeletal 
muscle (34, 42). These results showed that mtDNA maintenance in mice is dependent on dNTP 
balance. Therefore, we hypothesized that synthetic lethality and premature aging in Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice may be mediated through mitochondrial genome 
instability. However, our analyses of Rrm1-D57N(low)Tg + Rrm2Tg mice showed that mtDNA 
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was surprisingly intact, despite the highly disordered dNTP pool. We did observe age-related 
mtDNA depletion, but found no signs of increased rate of mtDNA point mutations or deletions. 
The mtDNA depletion is unlikely to account for the lethal phenotype for the following reasons: 
First, the earliest age at which mtDNA depletion in skeletal muscle was observed was P19, 
although the other phenotypes developed much earlier. Second, the residual level of mtDNA was 
similar to that of other mouse models that have mtDNA depletion but no overt muscle 
degeneration ({Akman, 2008 #143}., {Zhou, 2008 #145}. Furthermore, it must be noted that 
severe muscle degeneration and deposition of connective tissue could cause the measured 
mtDNA level to be lower than the actual mtDNA level within the muscle fibers. The normal 
result from the COX/SDH activity assay confirmed that mitochondrial dysfunction is not a cause 
of muscle degeneration in these mice. Therefore, while the mtDNA depletion in bitransgenic 
mice supports the notion that mtDNA replication is sensitive to the dNTP balance, it does not 
explain the early lethality of these animals. 
A hypothesis to explain the particular phenotypes observed in the Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice links cellular control of nucleotide levels and hypertension. A cellular 
defense against unbalanced nucleotide pools is through nucleotide degradation, in which dNTPs 
are cleaved by deaminases and nucleoside phosphorylases and either returned to the substrate 
cycles or excreted(49). For purines especially, elevated degradation products in the bloodstream 
of mice or humans can have adverse effects. The products of purine nucleotide degradation, 
xanthine, hypoxanthine, and uric acid, are elevated in the blood of hypertensive patients(50) and 
elevating uric acid causes hypertension in rats(51). Among other phenotypes, hypertension 
causes pleural effusion(52) and glaucoma(53), which are either observed in Rrm1-D57N(low)Tg 
+ Rrm2Tg bitransgenic mice or are similar to phenotypes observed in these mice. Therefore, we 
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hypothesize that simultaneous disruption of both main RNR regulatory pathways in Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice elevates nucleotide pools, which are rapidly degraded 
in an attempt to keep levels balanced. The increase in nucleotide degradation products in the 
blood triggers hypertension, which results in pleural effusion and eventually suffocates the 
bitransgenic mice at a young age. Further work is necessary in order to link elevated nucleotide 
pools with the observed phenotypes. 
 Deregulation of RNR in mice by small subunit overexpression causes lung tumorigenesis 
and moderately elevated dNTP pools, while overexpression of the feedback-resistant mutant 
Rrm1-D57N had limited phenotypes. Only when these two regulatory modes were 
simultaneously disabled were phenotypes observed, suggesting that these two mechanisms are 
partially redundant. The timing of the lethality is dependent on the degree of RNR deregulation, 
with higher-level overexpression of Rrm1-D57NTg or either small subunit resulting in more 
severe defects and earlier lethality. In yeast, simultaneous loss of both regulatory modes caused 
proliferation defects, while the cells were able to survive. All together, we conclude that severe 
deregulation of RNR in multicellular organisms has hazardous consequences, and further work 
will allow us to explore the ability of cells to maintain their genomes in the presence of 
deregulated RNR. 
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